OA17485A

OA17485A - 4-Amino-6-(heterocycIic) picolinates and 6amino-2 (heterocyclic) pyrimidine-4-carboxylates and their use as herbicides.

Info

Publication number: OA17485A
Application number: OA1201500371
Authority: OA
Inventors: Joseph D Eckelbarger; Jeffrey B. EPP; Stephen Craig Fields; Lindsey G Fischer; Natalie C. GIAMPIETRO; Katherine A Guenthenspberger; Christian T. LOWE; Jef PETKUS; Joshua Roth; Norbert M. Satchivi; Paul Richard Schmitzer; Thomas L. Siddall; Nick X. WANG
Original assignee: Dow Agrosciences Llc
Priority date: 2013-03-15
Filing date: 2014-03-12
Publication date: 2016-12-30

Abstract

4-Amino-6-(heterocyclic)picolinic acids, 6amino-2-(heterocyclic)pyrimidine-4-carboxylates, and derivatives thereof are provided. Also provided are herbicidal compositions including these compounds, as well as methods of using thereof as herbicides.

Description

4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES

Cross Reference to Related Applications

This application daims benefit of U.S. Application No. 13/839,000 filed March 15, 2013, the disclosure of which is expressly incorporated herein by reference.

Field

The invention relates to herbicidal compounds and compositions and to methods for controlling undesirable végétation.

Background

The occurrence of undesirable végétation, e.g., weeds, is a constant problem facing famers in crops, pasture, and other settings. Weeds compete with crops and negatively impact crop yield. The use of chemical herbicides is an important tool in controlling undesirable végétation.

There remains a need for new chemical herbicides that offer a broader spectrum of weed control, selectivity, minimal crop damage, storage stability, ease of handling, higher activity against weeds, and/or a means to address herbicide-tolerance that develops with respect to herbicides currently in use.

Summary of the Invention

Provided herein are compounds of Formula (I):

wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cs alkyl, or C7-C10 arylalkyl, and R¹and R are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

•y

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸

-117485 is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³’(R⁴ ), wherein R³' and R⁴ are independently hydrogen, Ci-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, Ci-C₆ alkoxy or Ci-C₆ alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is one of groups Al to A36

r₆

Ry

A4

A12

-217485

A20

	A17 Re	A18 Re	A19 Re
Re'x	yKY	Re'-	rïr	<	r₆'^	YiT^

Re'	\#-^R7'	r₆-		'0	Re	/^^r ₇'
	⁰ \			(		^s \
	r₇		r₇	r₇		r₇
	A21		A22			A23

Re

R,^iZy\-R,'

N—Y ^R8^Z R₇

A27

Re

Re>TN-^R8 ^R7 R_?

A28

	Re
Re\
Re	H r₇

A31

N

Ry

A32

-317485

A33

A34

A3 5

A36

R⁵, if applicable to the A group, is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, Ci-C4alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶ , and R⁶ , if applicable to the A group, are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

R⁷ and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C1-C4 haloalkylamino, or phenyl;

R⁸ is hydrogen, Ci-Cé alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Côalkoxycarbonyl, C]-C₆alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.

In some embodiments, the compound is a compound of Formula (I):

wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cg alkyl, or C7-C10 arylalkyl, and R¹and R¹ are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

-417485

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R , R , and R are independently CiC10 alkyl, C₃-Cô cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C₃-C₆ alkenyl, C₃Cô haloalkenyl, C₃-Cô alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, C]-C₆alkoxycarbonyl, Cj-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Ci-C₆dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or t A I O f A f

R and R taken together represent =CR (R ), wherein R and R are independently hydrogen, Ci-Cô alkyl, C₃-Cô alkenyl, C₃-Cô alkynyl, Ci-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, Al8, Al9, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C₃ alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, or phenyl;

Q

R is hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C₃-Cô alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof, with the proviso that the compound is not a compound of Formula (I):

-517485

(I) wherein

X is N, CH, CF, CCI, or CBr;

R¹ is OR¹, wherein R¹ is hydrogen or C1-C4 alkyl;

R is chlorine;

R³ and R⁴ are hydrogen;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17,

A18, A19, or A20;

R⁵ is hydrogen, halogen, OH, amino, CN, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamino, or cyclopropyl;

R⁶, R⁶ , and R⁶ are independently hydrogen, halogen, OH, NH2, CN, C1-C3 alkyl, C1-C3 alkoxy, cyclopropyl, or vinyl;

R⁷and R⁷ are independently hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, cyclopropyl, or Ci-C3 alkylamino, or phenyl; and

R⁸ is hydrogen, C1-C3 alkyl, phenyl, or C1-C3 alkylcarbonyl;

or an N-oxide or agriculturally acceptable sait thereof.

In some embodiments, the compound is a compound of Formula (I):

wherein

X is CF;

R is OR , wherein R is hydrogen, C|-C₈ alkyl, or C7-C10 arylalkyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, Cj-Cio alkoxy, or OH;

-617485

R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-C₆ alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³(R⁴), wherein R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or C]-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, or phenyl;

R⁸ is hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, C|-C₆alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof

In some embodiments, R is Cl, methoxy, vinyl, or 1-propenyl, and R and R are hydrogen. In certain embodiments, R² is Cl, and R³ and R⁴ are hydrogen.

In some embodiments, A is Al5 and/or R⁵ is hydrogen or F.

In one embodiment, the compound is 4-amino-3-chloro-5-fluoro-6-(7-fluoro-177-indol-6-yl) picolinic acid. In one embodiment, the compound is methyl 4-amino-3-chloro-5-fluoro-6-(7fluoro-177-indol-6-yl) picolinate.

Also provided are methods of controlling undesirable végétation comprising (a) contacting the undesirable végétation or area adjacent to the undesirable végétation or (b) pre-emergently

-717485 contacting soil or water a herbicidally effective amount of at least one compound of Formula (I) or agriculturally acceptable dérivative thereof.

Also provided are novel precursors of Formula (II):

(Π) wherein:

R⁷ and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, C₂-C₄ alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C₂-C₄ haloalkylamino, or phenyl;

R⁸ is hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, Q-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-C₆alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

Z is B(OR²²)2, BF3M, or Sn(R²³)3) wherein each R²² is independently hydrogen or C1-C4 alkyl, or the two OR²² moieties combine to form -O-C(CH3)₂-C(CH3)₂-O- or -O-CH₂-C(CH3)₂-CH₂-O-; M is a métal cation, e.g. sodium or potassium, and R is C1-C4 alkyl;

provided the following compound is excluded:

Detailed Description

DEFINITIONS

As used herein, herbicide and herbicidal active ingrédient mean a compound that controls undesirable végétation when applied in an appropriate amount.

As used herein, control of or controlling undesirable végétation means killing or preventing the végétation, or causing some other adversely modifying effect to the végétation e.g., déviations from naturel growth or development, régulation, desiccation, retardation, and the like.

-817485

As used herein, a herbicidally effective or végétation controlling amount is an amount of herbicidal active ingrédient the application of which controls the relevant undesirable végétation.

As used herein, applying a herbicide or herbicidal composition means delivering it directly to the targeted végétation or to the locus thereof or to the area where control of undesired végétation is desired. Methods of application include, but are not limited to pre-emergently contacting soil or water, post-emergently contacting the undesirable végétation or area adjacent to the undesirable végétation.

As used herein, plants and végétation include, but are not limited to, dormant seeds, germinant seeds, emerging seedlings, plants emerging from végétative propagules, immature végétation, and established végétation.

As used herein, agriculturally acceptable salts and esters refer to salts and esters that exhibit herbicidal activity, or that are or can be converted in plants, water, or soil to the referenced herbicide. Exemplary agriculturally acceptable esters are those that are or can by hydrolyzed, oxidized, metabolized, or otherwise converted, e.g., in plants, water, or soil, to the corresponding carboxylic acid which, depending on the pH, may be in the dissociated or undissociated form.

Suitable salts include those derived from alkali or alkaline earth metals and those derived from ammonia and amines. Preferred cations include sodium, potassium, magnésium, and aminium cations of the formula:

r¹³r¹⁴r15r¹⁶ _n+ wherein R¹³, R¹⁴, R¹⁵ and R¹⁶ each, independently represents hydrogen or C1-C12 alkyl, C3-C12 alkenyl or C3-C12 alkynyl, each of which is optionally substituted by one or more hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or phenyl groups, provided that R¹³, R¹⁴, R¹⁵ and R¹⁶are sterically compatible. Additionally, any two R¹³, R¹⁴, R¹⁵ and R¹⁶ together may represent an aliphatic difunctional moiety containing one to twelve carbon atoms and up to two oxygen or sulfiir atoms. Salts of the compounds of Formula I can be prepared by treatment of compounds of Formula I with a métal hydroxide, such as sodium hydroxide, with an amine, such as ammonia, trimethylamine, diethanolamine, 2-methylthiopropylamine, bisallylamine,

2-butoxyethylamine, morpholine, cyclododecylamine, or benzylamine or with a tetraalkylammonium hydroxide, such as tétraméthylammonium hydroxide or choline hydroxide. Amine salts are often preferred forms of the compounds of Formula I because

-917485 they are water-soluble and lend themselves to the préparation of désirable aqueous based herbicidal compositions.

Compounds of the formula (I) include N-oxides. Pyridine N-oxides can be obtained by oxidation of the corresponding pyridines. Suitable oxidation methods are described, for example, in Houben-Weyl, Methoden der organischen Chemie [Methods in organic chemistry], expanded and subséquent volumes to the 4th édition, volume E 7b, p. 565 f. As used herein, unless otherwise specified, acyl refers to formyl, C1-C3 alkylcarbonyl, and C1-C3 haloalkylcarbonyl. Cj-Cô acyl refers to formyl, C1-C5 alkylcarbonyl, and C1-C5 haloalkylcarbonyl (the group contains a total of 1 to 6 carbon atoms).

As used herein, alkyl refers to saturated, straight-chained or branched saturated hydrocarbon moieties. Unless otherwise specified, C1-C10 alkyl groups are intended. Examples include methyl, ethyl, propyl, 1-methyl-ethyl, butyl, 1-methyl-propyl, 2-methyl-propyl, 1,1-dimethylethyl, pentyl, 1-methyl-butyl, 2-methyl-butyl, 3-methyl-butyl, 2,2-dimethyl-propyl, 1-ethylpropyl, hexyl, 1,1-dimethyl-propyl, 1,2-dimethyl-propyl, 1-methyl-pentyl, 2-methyl-pentyl,

3-methyl-pentyl, 4-methyl-pentyl, 1,1-dimethyl-butyl, 1,2-dimethyl-butyl, 1,3-dimethylbutyl, 2,2-dimethyl-butyl, 2,3-dimethyl-butyl, 3,3-dimethyl-butyl, 1-ethyl-butyl, 2-ethylbutyl, 1,1,2-trimethyl-propyl, 1,2,2-trimethyl-propyl, 1-ethyl-1-methyl-propyl, and l-ethyl-2methyl-propyl.

As used herein, “haloalkyl” refers to straight-chained or branched alkyl groups, wherein these groups the hydrogen atoms may partially or entirely be substituted with halogen atoms. Unless otherwise specified, Ci-Cs groups are intended. Examples include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1 chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2-difluoroethyl, 2,2-dichloro-2-fluoroethyl,

2,2,2-trichloroethyl, pentafluoroethyl, and l,l,l-trifluoroprop-2-yl.

As used herein, alkenyl refers to unsaturated, straight-chained, or branched hydrocarbon moieties containing a double bond. Unless otherwise specified, C₂-Cs alkenyl are intended. Alkenyl groups may contain more than one unsaturated bond. Examples include ethenyl, 1 propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1propenyl, 2-methyl-1 -propenyl, l-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl- 1-butenyl, 3-methyl-1butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2methyl-3-butenyl, 3-methyl-3-butenyl, l,l-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl,

-1017485

1.2- dimethyl-2-propenyl, 1-ethyl-l-propenyl, l-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-l-pentenyl, 2-methyl-l-pentenyl, 3-methyl-lpentenyl, 4-methyl-l-pentenyl, l-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2pentenyl, 4-methyl-2-pentenyl, l-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3pentenyl, 4-methyl-3-pentenyl, l-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4pentenyl, 4-methyl-4-pentenyl, l,l-dimethyl-2-butenyl, l,l-dimethyl-3-butenyl, 1,2dimethyl-l-butenyl, 1,2-dimethyl-2-butenyl, l,2-dimethyl-3-butenyl, 1,3-dimethyl-l-butenyl,

1.3- dimethyl-2-butenyl, l,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-lbutenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-l-butenyl, 3,3dimethyl-2-butenyl, 1-ethyl-l-butenyl, l-ethyl-2-butenyl, l-ethyl-3-butenyl, 2-ethyl-lbutenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, l,l,2-trimethyl-2-propenyl, 1-ethyl-l-methyl-

2-propenyl, l-ethyl-2-methyl-l-propenyl, and l-ethyl-2-methyl-2-propenyl. Vinyl refers to a group having the strutcture -CH=CH2; 1-propenyl refers to a group with the structureCH=CH-CH3; and 2- propenyl refers to a group with the structure -CH2-CH=CH2.

As used herein, alkynyl represents straight-chained or branched hydrocarbon moieties containing a triple bond. Unless otherwise specified, C2-C8 alkynyl groups are intended. Alkynyl groups may contain more than one unsaturated bond. Examples include C2-C6alkynyl, such as ethynyl, 1-propynyl, 2-propynyl (or propargyl), 1-butynyl, 2-butynyl, 3butynyl, l-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 3-methyl-lbutynyl, 1-methyl-2-butynyl, l-methyl-3-butinyul, 2-methyl-3-butynyl, 1,1-dimethyl-2propynyl, l-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 3methyl-1-pentynyl, 4-methyl-1-pentynyl, l-methyl-2-pentynyl, 4-methyl-2-pentynyl, 1methyl-3-pentynyl, 2-methyl-3-pentynyl, 1 -methyl-4-pentynyl, 2-methyl-4-pentynyl, 3methyl-4-pentynyl, 1,1 -dimethyl-2-butynyl, 1,1 -dimethyl-3 -butynyl, 1,2-dimethyl-3 -butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-1-butynyl, l-ethyl-2-butynyl, l-ethyl-3-butynyl, 2ethyl-3-butynyl, and l-ethyl-l-methyl-2-propynyl.

As used herein, alkoxy refers to a group of the formula R-O-, where R is alkyl as defined above. Unless otherwise specified, alkoxy groups wherein R is a Ci-Cs alkyl group are intended. Examples include methoxy, ethoxy, propoxy, 1-methyl-ethoxy, butoxy, 1-methylpropoxy, 2-methyl-propoxy, 1,1-dimethyl-ethoxy, pentoxy, 1-methyl-butyloxy, 2-methylbutoxy, 3-methyl-butoxy, 2,2-di-methyl-propoxy, 1-ethyl-propoxy, hexoxy, 1,1-dimethylpropoxy, 1,2-dimethyl-propoxy, 1-methyl-pentoxy, 2-methyl-pentoxy, 3-methyl-pentoxy, 4methyl-penoxy, 1,1-dimethyl-butoxy, 1,2-dimethyl-butoxy, 1,3-dimethyl-butoxy, 2,2dimethyl-butoxy, 2,3-dimethyl-butoxy, 3,3-dimethyl-butoxy, 1-ethyl-butoxy, 2-ethylbutoxy,

-1117485

1,1,2-trimethyl-propoxy, 1,2,2-trimethyl-propoxy, 1-ethyl-1-methyl-propoxy, and l-ethyl-2methyl-propoxy.

As used herein, haloalkoxy refers to a group of the formula R-O-, where R is haloalkyl as defined above. Unless otherwise specified, haloalkoxy groups wherein R is a Cj-Cs alkyl group are intended. Examples include chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromoethoxy, 1fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2fluoroethoxy, 2-chloro,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, and l,l,l-trifluoroprop-2-oxy.

As used herein, alkylthio refers to a group of the formula R-S- where R is alkyl as defined above. Unless otherwise specified, alkylthio groups wherein R is a Cj-Cg alkyl group are intended. Examples include methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methyl-propylthio, 2-methylpropylthio, 1,1-dimethylethylthio, pentylthio, 1methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2,2-dio-methylpropylthio, 1ethylpropylthio, hexylthio, 1,1-dimethyl propylthio, 1,2-dimethyl propylthio, 1methylpentylthio, 2-methylpentylthio, 3-methyl-pentylthio, 4-methyl-pentylthio, 1,1dimethyl butylthio, 1,2-dimethyl-butylthio, 1,3-dimethyl-butylthio, 2,2-dimethyl butylthio,

2,3-dimethyl butylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1,2trimethyl propylthio, 1,2,2-trimethyl propylthio, 1-ethyl-1-methyl propylthio, and l-ethyl-2methylpropylthio.

As used herein, haloalkylthio refers to an alkylthio group as defined above wherein the carbon atoms are partially or entirely substituted with halogen atoms. Unless otherwise specified, haloalkylthio groups wherein R is a Ci-C8 alkyl group are intended. Examples include chloromethylthio, bromomethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, dichlorofluoro-methylthio, chlorodifluoromethylthio, 1-chloroethylthio, 1-bromoethylthio, 1fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2fluoroethylthio, 2-chloro-2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2trichloroethylthio, pentafluoroethylthio, and l,l,l-trifluoroprop-2-ylthio.

As used herein, aryl, as well as dérivative terms such as aryloxy, refers to a phenyl, indanyl or naphthyl group with phenyl being preferred. The term heteroaryl, as well as dérivative terms such as heteroaryloxy, refers to a 5- or 6-membered aromatic ring containing one or more heteroatoms, viz., N, O or S; these heteroaromatic rings maybe fused to other aromatic

-1217485

Systems. The aryl or heteroaryl substituents may be unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, cyano, formyl, Cj-Cô alkyl, C₂-Cô alkenyl, C₂-C6 alkynyl, Ci-Cô alkoxy, Cj-Cô haloalkyl, CpCô haloalkoxy, Ci-Ceacyl, Ci-C₆alkylthio, Cj-Cô alkylsulfinyl, Cj-Cô alkylsulfonyl, Cj-Cô alkoxycarbonyl, Ci-Côcarbamoyl, hydroxycarbonyl, Cj-Cô alkylcarbonyl, aminocarbonyl, Ci-Céalkylaminocarbonyl, Cj-Cô dialkylaminocarbonyl, provided that the substituents are sterically compatible and the rules of chemical bonding and strain energy are satisfied. Preferred substituents include halogen, Cj-C₂ alkyl and C]-C₂ haloalkyl.

As used herein alkylcarbonyl refers to an alkyl group bonded to a carbonyl group. C1-C3 alkylcarbonyl and C1-C3 haloalkylcarbonyl refer to groups wherein a C1-C3 alkyl group is bonded to a carbonyl group (the group contains a total of 2 to 4 carbon atoms).

As used herein, alkoxycarbonyl refers to a group of the formula OR wherein R is alkyl. As used herein, arylalkyl refers to an alkyl group substituted with an aryl group. C7-C10 arylalkyl refers to a group wherein the total number of carbon atoms in the group is 7 to 10. As used herein alkylamino refers to an amino group substituted with one or two alkyl groups, which may be the same or different.

As used herein haloalkylamino refers to an alkylamino group wherein the alkyl carbon atoms are partially or entirely substituted with halogen atoms.

As used herein, Ci-Cô alkylaminocarbonyl refers to a group of the formula RNHC(O)wherein R is Ci-Cô alkyl, and Cj-Cô dialkylaminocarbonyl refers to a group of the formula R₂NC(O)- wherein each R is independently Ci-Cô alkyl.

As used herein alkylcarbamyl refers to a carbamyl group substituted on the nitrogen with an alkyl group.

As used herein alkylsulfonyl refers to a group of the formula θ ^R , where R is alkyl.

O

As used herein carbamyl (also referred to as carbamoyl and aminocarbonyl) refers to a group

O of the formula

II

As used herein dialkylphosphonyl refers to a group of the formula ? ^0R where R is

OR independently alkyl in each occurrence.

-1317485

As used herein, Cj-Cô trialkylsilyl refers to a group of the formula -S1R3 wherein each R is independently a Ci-Cô alkyl group (the group contains a total of 3 to 18 carbon atoms).

As used herein Me refers to a methyl group; OMe refers to a methoxy group; z-Pr refers to an isopropyl group.

As used herein, the term “halogen” including dérivative terms such as “halo” refers to fluorine, chlorine, bromine and iodine.

As used herein, plants and végétation include, but are not limited to, germinant seeds, emerging seedlings, plants emerging from végétative propagules, immature végétation, and established végétation.

COMPOUNDS OF FORMULA (I)

The invention provides compounds of Formula (I) as defined above and N-oxides and agriculturally acceptable salts thereof.

In some embodiments, the compound is the carboxylic acid or an agriculturally acceptable ester or sait. In some embodiments, the compound is the carboxylic acid or its methyl ester. In some embodiments:

A is one of groups Al to A20;

R¹ is OR¹, wherein R¹ is hydrogen or C1-C4 alkyl;

R² is chlorine;

R³ and R⁴ are hydrogen;

X is N, CH, CF, CCI, or CBr;

R⁵ is hydrogen, halogen, OH, NH₂, CN, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamino, or cyclopropyl;

R⁶, R⁶ , and R⁶ are independently hydrogen, halogen, OH, NH₂, CN, C1-C3 alkyl, CiC3 alkoxy, cyclopropyl, or vinyl;

R and R are independently hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, cyclopropyl, or C1-C3 alkylamino, or phenyl; and

R⁸ is hydrogen, C1-C3 alkyl, phenyl, or C1-C3 alkylcarbonyl.

In some embodiments, R¹ is OR¹ , wherein R¹ is hydrogen, Ci-Cs alkyl, or C7-C10 arylalkyl.

In some embodiments, R¹ is hydrogen or Ci-Cs alkyl. In some embodiments, R¹ is hydrogen.

-1417485

In some embodiments, R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkynyl, C2-C4alkenyl, C2-C4 haloalkenyl, or C]-C4-alkoxy, or C]-C4 haloalkoxy. In some embodiments, R is halogen, C2-C4-alkenyl, C2-C4 haloalkenyl, or Ci-C4-alkoxy. In some embodiments, R is halogen. In some embodiements, R² is C2-C4-alkenyl or C2-C4 haloalkenyl. In some embodiments, R is C1-C4 alkoxy. In some embodiments, R is Cl, OMe, vinyl, or 1 9 9 propenyl. In some embodiments, R is Cl. In some embodiments, R is OMe. In some embodiments, R is vinyl or 1-propenyl.

In some embodiments, R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, or R³ and R⁴ taken together represent =CR³(R⁴), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6

O alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy, or Cj-Cô alkylamino. In some embodiments, R and R⁴ are independently hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, or R³ and R⁴ taken together represent =CR³(R⁴), wherein R³ and R⁴ are independently hydrogen, C|-C₆ alkyl, Cj-Cô alkoxy or Cj-Cô alkylamino. In some embodiments, R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, formyl, C1-C3 alkylcarbonyl, or C1-C3 haloalkylcarbonyl. In some embodiments, at least one of R³ and R⁴are hydrogen. In some embodiments, R³ and R⁴ are both hydrogen.

In some embodiments, X is N, CH or CF. In some embodiments, X is N. In some embodiments, X is CH. In some embodiments, X is CF.

In some embodiments, A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, A18, A19, or A20.

In some embodiments, A is one of A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, and A36.

In some embodiments, A is one of groups Al, A2, A3, A7, A8, A9, A10, A13, A14, and Al5. In some embodiments, A is one of groups Al, A2, A3, Al3, A14, and Al5. In some embodiments, A is one of groups Al3, A14, and Al5. In some embodiments, A is Al5. In some embodiments, R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, or amino. In some embodiments, R⁵is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or amino. In some embodiments, R⁵ is hydrogen, halogen, C1-C4 alkyl or C1-C4 alkoxy. In some embodiments, R⁵ is hydrogen or F. In some embodiments, R⁵ is hydrogen.

In other embodiments, R⁵ is F.

-1517485

In some embodiments, R⁶ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkoxy, or C1-C3 haloalkoxy. In some embodiments, R⁶ is hydrogen or fluorine. In some embodiments, R⁶ is hydrogen. In some embodiments, R⁶ is fluorine.

In some embodiments, R is hydrogen or halogen. In some embodiments, R is hydrogen, F, or Cl. In some embodiments, R⁶ is hydrogen or F. In some embodiments, R⁶ is hydrogen.

In some embodiments, R⁶ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, C2-C4 alkynyl, CN, or NO2. In some embodiments, R⁶ is hydrogen. In some embodiments, R⁶ is halogen. In some embodiments, R⁶ is Ci-C4 alkyl. In some embodiments, R⁶ isCiC4 haloalkyl. In some embodiments, R⁶ is cyclopropyl. In some embodiments, R⁶ is C2-C4 alkynyl. In some embodiments, R⁶ is CN. In some embodiments, R⁶ is NO2.

In some embodiments:

R² is halogen, C2-C4-alkenyl, C2-C4 haloalkenyl, or Ci-C4-alkoxy;

R³ and R⁴ are both hydrogen; and

X is N, CH, or CF.

In some embodiments:

•y

R is halogen;

R³ and R⁴ are both hydrogen; and

X is N, CH, or CF.

In some embodiments:

R² is C2-C4-alkenyl or C2-C4 haloalkenyl;

R³ and R⁴ are both hydrogen; and

X is N, CH, or CF.

In some embodiments:

R² is Ci-C4-alkoxy;

R³ and R⁴ are both hydrogen; and

X is N, CH, or CF.

In some embodiments:

R² is halogen, C2-C4-alkenyl, C2-C4 haloalkenyl, or C]-C4-alkoxy;

R³ and R⁴ are both hydrogen;

X is N, CH, or CF;

R⁵ is hydrogen or F;

R⁶ is hydrogen or F;

R⁶ is hydrogen;

R⁶ ,if applicable to the relevant A group, is hydrogen or halogen; and

-1617485

7^e

R and R ,if applicable to the relevant A group, are independently hydrogen or halogen.

In some embodiments:

R is halogen, Ci-C4-alkoxy, or C2-C4-alkenyl ;

R³ and R⁴ are hydrogen;

XisN, CH, or CF; and

A is one of groups Al to A20;

In some embodiments:

R is chlorine;

R³ and R⁴ are hydrogen;

X is N, CH, or CF;

A is one of groups Al to A20;

R⁵ is hydrogen or F;

R⁶ and R⁶ are independently hydrogen or F; and

R and R ,if applicable to the relevant A group, are independently hydrogen, halogen, C1-C4 alkyl, or C1-C4 haloalkyl.

In some embodiments:

R is chlorine, methoxy, vinyl, or 1-propenyl;

R³ and R⁴ are hydrogen; and

X is N, CH, or CF.

In some embodiments:

R is chlorine;

R³ and R⁴ are hydrogen; and

X is N, CH, or CF.

In some embodiments:

R is vinyl or 1-propenyl;

R³ and R⁴ are hydrogen; and

X is N, CH, or CF.

In some embodiments:

R² is methoxy;

R³ and R⁴ are hydrogen; and

X is N, CH, or CF.

In some embodiments:

-1717485

R is chlorine;

R³ and R⁴ are hydrogen; and

Xis N.

In some embodiments:

R is chlorine;

R³ and R⁴ are hydrogen; and

X is CH.

In some embodiments:

R is chlorine;

R³ and R⁴ are hydrogen; and

X is CF.

In some embodiments:

R² is chlorine;

R³ and R⁴ are hydrogen;

X is CF;

A is one of Al, A2, A3, A7, A8, A9, A10, A13, A14, or A15;

R⁵ is F; and

R⁶ is H.

In some embodiments:

R is chlorine, methoxy, vinyl, or 1-propenyl;

R³ and R⁴ are hydrogen;

X is N, CH, or CF; and

A is one of A21-A36.

In some embodiments:

R is chlorine, methoxy, vinyl, or 1-propenyl;

R³ and R⁴ are hydrogen;

X is CF; and

A is one of

NH

O

S

-1817485

,wherein R⁵ is hydrogen

In some embodiments:

R is chlorine, methoxy, vinyl, or 1-propenyl;

R³ and R⁴ are hydrogen;

•y

R is chlorine, methoxy, vinyl, or 1-propenyl; R³ and R⁴ are hydrogen;

In some embodiments:

R² is chlorine, methoxy, vinyl, or 1-propenyl;

R³ and R⁴ are hydrogen;

It is particularly noteworthy that compounds of Formula (I) wherein A is, e.g. Al 5, exhibit a significant increase in activity when X is CF. This is demonstrated by comparing the activity of Compounds 1.21 and 1.22 (wherein X is CH) with that of 1.08 and 1.09 (wherein X is CF). It is also demonstrated by comparing the activity of Compounds 1.23 and 1.24 (wherein X is CH) with that of Compounds 1.15 and 1.16 (wherein X is CF). The increased activity is further enhanced when R⁵ is F.

-1917485

In some embodiments, the compound is a compound of Formula (I):

wherein

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Cj-Cg alkyl, or C7-C10 arylalkyl, and R¹and R are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C]-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

-2017485

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkyl amino, or phenyl; and

R⁸ is hydrogen, C|-C₆ alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, or phenyl;

wherein

X is N, CH, CF, CCI, or CBr;

R¹ is OR¹, wherein R¹ is hydrogen or C1-C4 alkyl;

O

R is chlorine;

R³ and R⁴ are hydrogen;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Al 1, A12, A13, A14, A15, A16, A17, Al 8, A19, or A20;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, OH, NH2, CN, C1-C3 alkyl, C1-C3 alkoxy, cyclopropyl, or vinyl;

R and R are independently hydrogen, halogen, C1-C3 alkyl, Cj-C3 alkoxy, C1-C3 alkylthio, cyclopropyl, or C1-C3 alkylamino, or phenyl; and

R⁸ is hydrogen, C1-C3 alkyl, phenyl, or C1-C3 alkylcarbonyl;

or an N-oxide or agriculturally acceptable sait thereof.

In some of these embodiments, R¹ is OR¹. In some of these embodiments, X is CF. In some of these embodiments, A is Al5. In some of these embodiments, R⁵ is F.

In some embodiments:

X is CY, wherein Y is C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, CiC3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

-2117485

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cg alkyl, or C7-C10 arylalkyl, and R¹and R are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR^I8-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkyl carbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Al 1, A12, A13, A14, A15, A16, A17, Al 8, Al 9, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A3 5, or A36;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, or phenyl; and

R⁸ is hydrogen, Ci-Ce alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cé alkoxycarbonyl, Ci-Cé alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl.

In some of these embodiments, R¹ is OR¹. In some of these embodiments, A is Al5. In some of these embodiments, R⁵ is F.

-2217485

In some embodiments:

R is OR¹ or NR¹ R¹ , wherein R¹ is C5-C8 alkyl, or C7-C10 arylalkyl, and R and R¹are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

•y

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R , R , and R are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C₂C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO₂;

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,C]-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, or phenyl;

-2317485

R⁸ is hydrogen, C[-C₆ alkyl, C]-C₆ haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

In some of these embodiments, R¹ is OR¹. In some of these embodiments, X is CF. In some of these embodiments, A is Al 5. In some of these embodiments, R⁵ is F.

In some embodiments:

R² is F, Br, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C₂-C₄ haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, C]-C₆alkoxycarbonyl, Ci-C₆ alkylcarbamyl, Ci-Cô alkylsulfonyl, C|-C₆ trialkylsilyl, C|-C₆dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or C]-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

R⁵ is hydrogen, halogen, Ci-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C₂C4 alkenyl, C₂-C₄ haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

-2417485

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, or phenyl; and

R⁸ is hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, or phenyl.

In some embodiments:

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR^l8-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R , R , and R are independently CjC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, Cj-Cjo alkoxy, or OH;

R³ and R⁴ are independently Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Al 1, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

-2517485

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, or phenyl; and

Q

R is hydrogen, C[-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, or phenyl.

In some embodiments:

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R , R , and R are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, C]-C6 alkylsulfonyl, Cj-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C]-C6 alkoxy or Ci-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

-2617485

£ £, £»i

R , R , and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, or phenyl; and o

R is hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl.

In some of these embodiments, R¹ is OR¹. In some of these embodiments, X is CF. In some of these embodiments, R⁵ is F.

In some embodiments:

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Cj-Cs alkyl, or C7-C10 arylalkyl, and R¹and R¹ are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, C]-C₆ alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

-2717485

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, Al 8, A19,orA20;

R⁵ is C₄ alkyl, Ci-C₄ haloalkyl, halocyclopropyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, C₂-C₄alkynyl, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C₄ alkylamino, or C₂-C₄haloalkylamino;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, Ci-C₄ alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, C₂-C₄ alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, Ci-C₄ alkylamino or C₂-C₄haloalkylamino, OH, CN, or NO₂;

R and R are independently hydrogen, halogen, Cj-C₄ alkyl, Ci-C₄ haloalkyl, cyclopropyl, halocyclopropyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, C₂-C₄ alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, Ci-C₄ alkylamino, C₂-C₄haloalkylamino, or phenyl; and n

R is hydrogen, Cj-Cg alkyl, Ci-Cg haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cg alkoxycarbonyl, Cj-Cg alkylcarbamyl, Ci-Cg alkylsulfonyl, Cj-Cg trialkylsilyl, or phenyl.

In some embodiments:

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Cj-Cg alkyl, or C7-C10 arylalkyl, and R¹and R are independently hydrogen, C]-Ci₂ alkyl, C3-Cj₂ alkenyl, or C3-Cj₂ alkynyl;

o

R is halogen, C[-C₄ alkyl, C]-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, C₂-C₄alkynyl, Ci-C₄ alkoxy, Ci-C₄ haloalkoxy, Ci-C₄ alkylthio, Cj-C₄ haloalkylthio, amino, Ci-C₄alkylamino, C₂-C₄ haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, Ci-C₄ alkyl, or Ci-C₄ haloalkyl; and R , R , and R are independently CjC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, Cj-Cio alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cg alkyl, Cj-Cg haloalkyl, C3-C6 alkenyl, C3Cf, haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cg alkoxycarbonyl, Cj-Cg alkylcarbamyl, Cj-Cg alkylsulfonyl, C[-Cg trialkylsilyl, Cj-Cg dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen,

-2817485

Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Al 1, A12, A13, A14, A15, A16, A17, A18, A19, orA20;

R⁶, R⁶, and R⁶ are independently C4 alkyl, C1-C4 haloalkyl, halocyclopropyl, C3-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C4 alkylamino or C2-C4 haloalkylamino, or NO2;

R⁸ is hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl.

In some embodiments:

R is halogen, Q-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR^l8-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or

-2917485

R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, C|-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, Al7, or A18;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C4-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁷and R⁷ are independently C4 alkyl, C1-C4 haloalkyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 haloalkoxy, C1-C3 haloalkylthio, amino, C4 alkylamino, or C2-C4 haloalkylamino; and

R⁸ is hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, C|-C₆ alkoxycarbonyl, Ci-C₆alkylcarbamyl, Cj-Cô alkylsulfonyl, C|-Cô trialkylsilyl, or phenyl

In some embodiments:

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Ci-Cg haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, C1-G5

-3017485 dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is A3, A6, Ail, A12, Al5, Al8, Al9, or A20;

R⁸ is C3-C6 alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, or Ci-Cô trialkylsilyl.

In some embodiments, the compound is a compound of Formula (I):

wherein

X is CF;

R* is OR¹, wherein R¹ is hydrogen, Ci-Cs alkyl, or C7-C10 arylalkyl;

-3117485 is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently CiC10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, C|-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cê alkoxy or Ci-Cô alkylamino, or, R³ and R⁴taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Al 1, A12, A13, A14, A15, A16, A17, Al 8, Al9, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C₂C4 alkenyl, C₂-C4 haloalkenyl, C₂-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C₂-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C₂-C4 alkenyl, C₂-C4 haloalkenyl, C₂-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO₂;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C₂-C4 alkenyl, C₂-C4 haloalkenyl, C₂-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C₂-C4 haloalkylamino, or phenyl; and

Q

R is hydrogen, Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cé alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.

In some embodiments:

R¹ is OR¹, wherein R¹ is hydrogen, Cj-Cs alkyl, or C7-C10 arylalkyl;

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C₂-C4-alkenyl, C₂-C4 haloalkenyl, C₂-C4 alkynyl, Ci-C4-alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, or C1-C4 haloalkylthio.

R³ and R⁴ are hydrogen, Ci-Cé alkyl, C1-C6 haloalkyl, Cy-Cf, alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, or R³ and R⁴ taken

-3217485 together represent =CR³(R⁴), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3C₆ alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or Cj-Cô alkylamino;

A is Al, A2, A3, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A21, A22, A23, A24, A27, A28, A29, A30, A31, or A32;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, CiC4 alkylamino, or C2-C4 haloalkylamino;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, CN, orNCh;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, cyclopropyl, amino or C1-C4 alkylamino; and

Q

R is hydrogen, Cj-Cô alkyl, C1-C4 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Côalkoxycarbonyl, or Cj-Cô alkylcarbamyl.

In some embodiments, R is halogen, C2-C4-alkenyl, C2-C4 haloalkenyl, or C1-C4alkoxy. In certain embodiments, R is Cl, methoxy, vinyl, or 1-propenyl. In some embodiments, R³ and R⁴ are hydrogen.

In some embodiments, A is Al, A2, A3, A7, A8, A9, A10, A13, A14, or A15. In certain embodiments, A is Al, A2, A3, A13, A14, or Al5. In certain embodiments, A is A15.

In some embodiments, R⁵ is hydrogen or F. In certain embodiments, R⁵ is F. In certain embodiments, R⁵ is H.

In some embodiments, R⁶ is hydrogen or F. In certain embodiments, R⁶ is F. In certain embodiments, R⁶ is H. In some embodiments, R⁶ is hydrogen, halogen, C1-C4 alkyl, CiC4 haloalkyl, cyclopropyl, C2-C4 alkynyl, CN, or NO2. In certain embodiments, R⁶, R⁶, and R⁶are ail hydrogen.

In certain embodiments:

R is Cl, methoxy, vinyl, or 1-propenyl;

R³ and R⁴ are hydrogen;

A is A15;

R⁵ is hydrogen or F; and

R⁶ is hydrogen or F; and

R⁶ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, C2-C4 alkynyl, CN, or NO2.

-3317485

In one embodiment, the compound is 4-amino-3-chloro-5-fluoro-6-(7-fluoro-l/7indol-6-yl) picolinic acid. In one embodiment, the compound is methyl 4-amino-3-chloro-5fluoro-6-(7-fluoro-127-indol-6-yl) picolinate.

EXEMPLARY COMPOUNDS

The following Tables 1-9 describe exemplary compounds of Formula (Γ)

Table 10 sets forth the structure, appearance, préparation method, and precursor(s) used in synthesis of the exemplary compounds. Table 11 sets forth physical data for each of the exemplary compounds.

Blank spaces in compound tables herein indicate hydrogen, or that for the A group indicated in a particular row the column in which the blank occurs is not relevant

Table 1: Compounds of Formula (Γ) with indolyl tails

Ais A3, Al5, A27, or A28:

Re	Re		Re			Re
Re'-ykv		Re’x		•X	R^	'Ύι'	A
	11	Re'	/¼. A				^xi\r^R8
N ^Rs	/ ^Rs	\ >-^r7	Re'
			N-—
Ry ^R7	_R; ^Re		r₈ ^z	Ry		Ry'	Ry
A3	A15	A27	A28

C.No.	R¹	R²	X	A	R⁵	R⁶	R⁶’	-----À R^b	R⁷	R⁷	R⁸
1.01	H	Cl	CF	A3							Me
1.02	Me	Cl	CF	A3
1.03	Me	Cl	CF	A3							Me
1.04	H	Cl	CF	A3
1.05	Me	Cl	CCI	A15
1.06	H	Cl	CCI	A15
1.07	Me	Cl	CCI	A15	F
1.08	Me	Cl	CF	A15
1.09	H	Cl	CF	A15

-3417485

C.No.	R¹	R²	X	A	R⁵	R⁶	R⁶'	R’	r'	R⁷	R⁸
1.10	Me	Cl	CF	A15							Me
1.11	H	Cl	CF	A15							Me
1.12	Me	Cl	CF	A15	F						Si(i-Pr)
1.13	Me	Cl	CF	A15		F
1.14	H	Cl	CF	A15		F
1.15	Me	Cl	CF	A15	F
1.16	H	Cl	CF	A15	F
1.17	H	OMe	CF	A15	F
1.18	Me	vinyl	CF	A15	F
1.19	H	vinyl	CF	A15	F
1.20	Me	OMe	CF	A15	F
1.21	Me	Cl	CH	A15
1.22	H	Cl	CH	A15
1.23	Me	Cl	CH	A15	F
1.24	H	Cl	CH	A15	F
1.25	Me	Cl	CH	A15		F
1.26	H	Cl	CH	A15		F
1.27	Me	Cl	CH	A15	F	F
1.28	Me	Cl	CMe	A15
1.29	H	Cl	CMe	A15
1.30	Me	Cl	N	A15
1.31	Me	Cl	N	A15	F
1.32	Me	OMe	N	A15
1.33	H	OMe	N	A15
1.34	Me	OMe	N	A15	F
1.35	H	OMe	N	A15	F
1.36	Me	OMe	N	A15		F
1.37	H	OMe	N	A15		F
1.38	Me	vinyl	N	A15	F
1.39	H	vinyl	N	A15	F
1.40	Me	Cl	CF	A27
1.41	Me	Cl	CF	A27							Me
1.42	H	Cl	CF	A27							Me
1.43	Me	Cl	CF	A27				Cl
1.44	Me	Cl	CH	A27				Cl
1.45	Me	OMe	N	A27				Cl
1.46	Me	Cl	CF	A28				Cl
1.47	Me	Cl	CF	A28
1.48	H	Cl	CF	A28
1.49	Me	Cl	CH	A28				Cl
1.50	Me	OMe	N	A28				Cl

Table 2: Compounds of Formula (Γ) with benzofuranyl tails

A is Al, A13, A21, or A22:

-3517485

C.No.	R¹	R²	X	A	R⁵	R⁶	R^b	R^ô	r'	R⁷	R⁸
2.01	Me	Cl	CF	Al
2.02	H	Cl	CF	Al
2.03	Me	Cl	CH	Al
2.04	Me	Cl	CH	Al		F
2.05	Me	OMe	N	Al		F
2.06	Me	OMe	N	Al
2.07	Me	Cl	CF	A13
2.08	H	Cl	CF	A13
2.09	Me	Cl	CF	A13	F
2.10	Me	Cl	CF	A13		F
2.11	Me	Cl	CH	A13	F
2.12	Me	Cl	CH	A13		F
2.13	Me	OMe	N	A13	F
2.14	Me	OMe	N	A13		F
2.15	Me	Cl	CF	A21
2.16	Me	Cl	CF	A21				Cl
2.17	H	Cl	CF	A21
2.18	H	Cl	CF	A21				Cl
2.19	Me	Cl	CH	A21				Cl
2.20	Me	Cl	N	A21				Cl
2.21	Me	OMe	N	A21				Cl
2.22	H	OMe	N	A21				Cl
2.23	H	Cl	N	A21				Cl
2.24	Me	Cl	CF	A22				Cl
2.25	Me	Cl	CH	A22				Cl
2.26	Me	OMe	N	A22				Cl

-3617485

Table 3: Compounds of Formula (Γ) with benzothiofuranyl tails

Aïs A2, A14, A23, or A24:

Rs	Re	Re'x	r₆	Re¹'	Re	V
r₇ ^r7	/ ^sR?	r₆ ^x	Àx. Λ. \ >^R’' ^S \ Ry	Re	R?'	's r₇
A2	A14	A23	A24

C.No.	R¹'	R²	X	A	R⁵	R⁶	R⁶	r’^v	R	R	R⁸
3.01	Me	Cl	CCI	A2
3.02	H	Cl	CCI	A2
3.03	Me	Cl	CF	A2
3.04	H	Cl	CF	A2
3.05	Me	Cl	CH	A2
3.06	Me	Cl	CMe	A2
3.07	H	Cl	CMe	A2
3.08	Me	OMe	N	A2
3.09	H	OMe	N	A2
3.10	Me	Cl	CCI	A14
3.11	H	Cl	CCI	A14
3.12	Me	Cl	CF	A14
3.13	H	Cl	CF	A14
3.14	Me	Cl	CF	A14		F
3.15	Me	Cl	CH	A14
3.16	H	Cl	CH	A14
3.17	Me	Cl	CH	A14		F
3.18	Me	Cl	CMe	A14
3.19	H	Cl	CMe	A14
3.20	Me	OMe	N	A14
3.21	H	OMe	N	A14
3.22	Me	OMe	N	A14		F
3.23	Me	Cl	CF	A23
3.24	Me	Cl	CF	A24
3.25	H	Cl	CF	A24
3.26	Me	Cl	CF	A24						Br
3.27	Me	Cl	CH	A24

-3717485

Table 4: Compounds of Formula (Γ) with 1/7-indazolyl tails

A is one of groups A6, Al8, A25, and A26:

r₆	Re	^RA	Re	Re-	Re ykv
Ra /Y.			/¼. A.		/kÂ D
^8xn y *5	^R5	Re'	Ύ L·^-R?	Re'	n^^rs
	N^N		N-N		/=N
^R7	r₈		r₈ ^z		Ry
A6	A18	A25	A26

C.No.	R¹’	R²	X	A	R^S	R⁶	R⁶	!U	R'	R	R⁸
4.01	Me	Cl	CF	A6
4.02	H	Cl	CF	A6
4.03	Me	Cl	CF	A6							Me
4.04	H	Cl	CF	A6							Me
4.05	Me	Cl	CF	A18
4.06	H	Cl	CF	A18
4.07	Me	Cl	CF	A18							Me
4.08	H	Cl	CF	A18							Me
4.09	Me	Cl	CH	A18
4.10	Me	Cl	CF	A25							Me
4.11	H	Cl	CF	A25							Me
4.12	Me	Cl	CF	A25
4.13	Me	Cl	CF	A26

Table 5: Compounds of Formula (Γ) with benzoxazolyl tails

A is A7, A9, A29, or A30:

Re	Re		Re		Re
	rb'xAa	R₆\		Re'x	A
/A/L·	JL· L·				-L·!
O^{Z R}5	N ^r5	^R6	\ /,^N	^R6	\	o

Ry	Ry		Ry			Ry
A7	A9	A29	A30

C.No.	R¹'	R²	X	A	R⁵	R⁶	R⁶	R”	R	R⁷	R⁸
5.01	Me	Cl	CF	A9

-3817485

Table 6: Compounds of Formula (Γ) with benzothiazolyl tails

A is A8, A10, A31, or A32:

Table 7: Compounds of Formula (I') with 177-benzimidazolyl tails

C.No.	R¹'	R²	X	A	R^S	R⁶	R⁶’	R^b	R⁷	R⁷	R⁸
7.01	Me	Cl	CF	A12
7.02	Me	Cl	CF	A12							Me
7.03	H	Cl	CF	A12							Me

Table 8: Compounds of Formula (Γ) with indoxazinyl tails

A is A4, A16, A33, or A34:

-3917485

A4

Al 6

A33

A34

C.No.	R¹	R²	X	A	R⁵	R⁶	R⁶'	R^b	R'	R⁷	R⁸
8.01	Me	Cl	CF	A16				NMe₂

Table 9: Compounds of Formula (!') with 1/f-benzotriazolyl tails

METHODS OF PREPARING THE COMPOUNDS

Exemplary procedures to synthesize the compounds of Formula (I) are provided below.

The 4-amino-6-(heterocyclic)picolinic acids of Formula (I) can be prepared in a number of ways. As depicted in Scheme I, the 4-amino-6-chloropicolinates of Formula (II) can be converted to the 4-amino-6-substituted-picolinates of Formula (III), wherein Ar is as herein defïned, via Suzuki coupling with a boronic acid or ester, in the presence of a base, such as potassium fluoride, and a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a polar, protic solvent mixture, such as acetonitrile-water, at a température, such as 110 °C, e.g., in a microwave reactor (reaction af). 4-Amino-6-substituted-picolinates of Formula (III) can be transformed into the 5-iodo-4-amino-6-substituted-picolinates of Formula (IV) via a reaction with iodinating reagents, such as periodic acid and iodine, in a polar, protic solvent, such as methyl alcohol (reaction bj). Stille coupling of the 5-iodo-4-amino-6-substituted-picolinates of Formula (IV) with a stannane, such as tetramethyltin, in the presence of a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a non-reactive solvent, such as 1,2dichloroethane, at a température, such as 120-130 °C, e.g., in a micro wave reactor, pro vides 5(substituted)-4-amino-6-substituted-picolinates of Formula (I-A), wherein Zi is alkyl, alkenyl, alkynyl, haloalkenyl and alkylthio (reaction c/).

-4017485

Altematively, 4-amino-6-chloropicolinates of Formula (II) can be transformée! to the

5-iodo-4-amino-6-chloropicolinates of Formula (V) via a reaction with iodinating reagents, such as periodic acid and iodine, in a polar, protic solvent, such as methyl alcohol (reaction έ>₂). Stille coupling of the 5-iodo-4-amino-6-chloropicolinates of Formula (V) with a stannane, such as tetramethyltin, in the presence of a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a non-reactive solvent, such as 1,2-dichloroethane, at a température, such as 120

130 °C, e.g., in a microwave reactor, provides 5-(substituted)-4-amino-6-chloropicolinates of Formula (VI), wherein Zj is alkyl, alkenyl, alkynyl, haloalkenyl and alkylthio (reaction c₂). The 5-substituted-4-amino-6-chloropicolinates of Formula (VI) can be converted to the 5-substituted-

4-amino-6-substituted-picolinates of Formula (I-A), wherein Ar is as herein defined, via Suzuki coupling with a boronic acid or ester, in the presence of a base, such as potassium fluoride, and a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a polar, protic solvent mixture, such as acetonitrile-water, at a température, such as 110 °C, e.g., in a microwave reactor (reaction a₂).

Scheme I

As depicted in Scheme II, the 4,5,6-trichloropicolinate of Formula (VII) can be converted to the corresponding isopropyl ester of Formula (VIII), via a reaction with isopropyl alcohol and concentrated sulfuric acid, e.g., at reflux température under Dean-Stark conditions (reaction d). The isopropyl ester of Formula (VIII) can be reacted with a fluoride ion source, such as césium fluoride, in a polar, aprotic solvent, such as dimethyl sulfoxide (DMSO), at a

-4117485 température, such as 80 °C, under Dean-Stark conditions, to yield the isopropyl 4,5,6trifluoropicolinate of Formula (IX) (reaction e). The isopropyl 4,5,6-trifluoropicolinate of Formula (IX) can be aminated with a nitrogen source, such as ammonia, in a polar, aprotic solvent, such as DMSO, to produce a 4-amino-5,6-difluoropicolinate of Formula (X) (reaction f).

The fluoro substituent in the 6-position of the 4-amino-5,6-difluoropicolinate of Formula (X) can be exchanged with a chloro substituent by treatment with a chloride source, such as hydrogen chloride, e.g., in dioxane, in a Parr reactor, at a température, such as 100 °C, to produce a 4amino-5-fluoro-6-chloro-picolinate of Formula (XI) (reaction g). The 4-amino-5-fluoro-6chloropicolinate of Formula (XI) can be transesterified to the corresponding methyl ester of

Formula (XII) by reaction with titanium(IV) isopropoxide in methyl alcohol at reflux température (reaction h).

Scheme II

As depicted in Scheme III, the 4-amino-5-fluoro-6-chloropicolinate of Formula (XII) can be transformed into the 3-iodo-4-amino-5-fluoro-6-chloropicolinate of Formula (XIII) via

-4217485 reaction with iodinating reagents, such as periodic acid and iodine, in a polar, protic solvent, such as methyl alcohol (reaction Z?j). Stille coupling of the 3-iodo-4-amino-5-fluoro-6chloropicolinates of Formula (XIII) with a stannane, such as tributyl(vinyl)stannane, in the presence of a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a non-reactive solvent, such as 1,2-dichloroethane, at a température, such as 120-130 °C, e.g., in a microwave reactor, provides 3-(substituted)-4-amino-5-fluoro-6-chloropicolinates of Formula (XIV), wherein R is alkyl, alkenyl, alkynyl, haloalkenyl and alkylthio (reaction cj). Altematively, the

3-iodo-4-amino-5-fluoro-6-chloropicolinates of Formula (XIII) can be treated with césium carbonate and a catalytic amount of both copper(I) iodide and 1,10-phenanthroline in the presence of a polar, protic solvent, such as methyl alcohol, at a température, such as 65 °C, to provide a 3-(substituted)-4-amino-5-fluoro-6-chloropicolinic acids of Formula (XIV), wherein R is alkoxy or haloalkoxy (reaction z’y), which can be esterified to the methyl esters, e.g., by treatment with hydrogen chloride (gas) and methyl alcohol at 50 °C (reaction jî). The 3(substituted)-4-amino-5-fluoro-6-chloropicolinates of Formula (XIV) can be converted to the 4amino-6-substituted-picolinates of Formula (I-B), wherein Ar is as herein defined, via Suzuki coupling with a boronic acid or ester, in the presence of a base, such as potassium fluoride, and a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a polar, protic solvent mixture, such as acetonitrile-water, at a température, such as 110 °C, e.g., in a microwave reactor (reaction 03).

Altematively, the 4-amino-5-fluoro-6-chloropicolinates of Formula (XII) can be converted to the 4-amino-5-fluoro-6-substituted-picolinates of Formula (XV), wherein Ar is as herein defmed, via Suzuki coupling with a boronic acid or ester, in the presence of a base, such as potassium fluoride, and a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a polar, protic solvent mixture, such as acetonitrile-water, at a température, such as 110 °C, e.g., in a microwave reactor (reaction 04). The 4-amino-5-fluoro-6-substituted-picolinates of Formula (XV) can be transformed into the 3-iodo-4-amino-5-fluoro-6-substituted-picolinates of Formula (XVI) via reaction with iodinating reagents, such as periodic acid and iodine, in a polar, protic solvent, such as methyl alcohol (reaction 64). Stille coupling of the 3-iodo-4-amino-5-fluoro-6substituted-picolinates of Formula (XVI) with a stannane, such as tributyl(vinyl)stannane, in the presence of a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a non-reactive solvent, such as 1,2-dichloroethane, at a température, such as 120-130 °C, e.g., in a microwave reactor, provides 3-(substituted)-4-amino-5-fluoro-6-substituted-picolinates of Formula (I-B), wherein R is alkyl, alkenyl, alkynyl, haloalkenyl and alkylthio (reaction C4). Altematively, the

3-iodo-4-amino-5-fluoro-6-substituted-picolinates of Formula (XVI) can be treated with césium

-4317485 carbonate and a catalytic amount of both copper(I) iodide and 1,10-phenanthroline in the presence of a polar, protic solvent, such as methyl alcohol, at a température, such as 65 °C, to provide a 3-(substituted)-4-amino-5-fluoro-6-substituted-picolinic acids of Formula (I-B), wherein R² is alkoxy or haloalkoxy (reaction 12), which can be esterified to the methyl esters,

e.g., by treatment with hydrogen chloride (gas) and methyl alcohol, at a température, such as 50 °C (reaction72).

Scheme III

XII

a₄

XV

As depicted in Scheme IV, the 4-acetamido-6-(trimethylstannyl)picolinates of

Formula (XVII) can be converted to the 4-acetamido-6-substituted-picolinates of Formula (XVIII), wherein Ar is as herein defined, via Stille coupling with an aryl bromide or aryl iodide, in the presence of a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a solvent, such as 1,2-dichloroethane, e.g., at reflux température (reaction k). 4-Amino-6substituted-picolinates of Formula (I-C), wherein Ar is as herein defined, can be synthesized from 4-acetamido-6-substituted-picolinates of Formula (XVIII) via standard deprotecting methods, such as hydrochloric acid gas in methanol (reaction Γ).

-4417485

Scheme IV

As depicted in Scheme V, 2,4-dichloro-5-methoxypyrimidine (XIX) can be transformed into 2,4-dichloro-5-methoxy-6-vinylpyrimidine (XX) via a reaction with vinyl magnésium bromide, in a polar, aprotic solvent, such as tetrahydrofuran (reaction m). 2,4Dichloro-5-methoxy-6-vinylpyrimidine (XX) can be transformed into 2,6-dichloro-5methoxypyrimidine-4-carboxaldehyde (XXI) via treatment with ozone, e.g., in a dichloromethane:methanol solvent mixture (reaction ri). 2,6-Dichloro-5-methoxypyrimidine-4carboxaldehyde (XXI) can be transformed into methyl 2,6-dichloro-5-methoxypyrimidine-410 carboxylate (XXII) via treatment with bromine, e.g., in a methanol:water solvent mixture (reaction o). Methyl 2,6-dichloro-5-methoxypyrimidine-4-carboxylate (XXII) can be transformed into methyl 6-amino-2-chloro-5-methoxypyrimidine-4-carboxylate (XXIII) via treatment with ammonia (e.g., 2 équivalents) in a solvent, such as DMSO (reactionp). Finally,

6-amino-2-substituted-5-methoxypyrimidine-4-carboxylates of Formula (I-D), wherein Ar is as herein defined, can be prepared via Suzuki coupling with a boronic acid or ester, with 6-amino-

2-chloro-5-methoxypyrimidine-4-carboxylate (XXIII), in the presence of a base, such as potassium fluoride, and a catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride, in a polar, protic solvent mixture, such as acetonitrile-water, at a température, such as 110 °C, e.g., in a microwave reactor (reaction a§).

-4517485

Scheme V

The compounds of Formulae I-A, I-B, I-C, and I-D obtained by any of these processes, can be recovered by conventional means and purified by standard procedures, such as by recrystallization or chromatography. The compounds of Formula (I) can be prepared from compounds of Formulae I-A, I-B, I-C, and I-D using standard methods well known in the art.

COMPOSITIONS AND METHODS

In some embodiments, the compounds provided herein are employed in mixtures containing a herbicidally effective amount of the compound along with at least one agriculturally acceptable adjuvant or carrier. Exemplary adjuvants or carriers include those that are not phytotoxic or significantly phytotoxic to valuable crops, e.g., at the concentrations employed in applying the compositions for sélective weed control in the presence of crops, and/or do not react or significantly react chemically with the compounds provided herein or other composition ingrédients. Such mixtures can be designed for application directly to weeds or their locus or can be concentrâtes or formulations that are \diluted with additional carriers and adjuvants before application. They can be solids, such as, for example, dusts, granules, water dispersible granules, or wettable powders, or liquids, such as, and for example, emulsifiable concentrâtes, solutions, émulsions or suspensions. They can also be provided as a pre-mix or tank-mixed.

Suitable agricultural adjuvants and carriers that are useful in preparing the herbicidal mixtures of the disclosure are well known to those skilled in the art. Some of these adjuvants include, but are not limited to, crop oil concentrate (minerai oil (85%) + emulsifiers (15%)); nonylphenol ethoxylate; benzylcocoalkyldimethyl quatemary ammonium sait; blend of

-4617485 petroleum hydrocarbon, alkyl esters, organic acid, and anionic surfactant; C9-C11 alkylpolyglycoside; phosphated alcohol ethoxylate; natural primary alcohol (C12-C16) ethoxylate; di-sec-butylphenol EO-PO block copolymer; polysiloxane-methyl cap; nonylphenol ethoxylate + urea ammonium nitrate; emulsified methylated seed oil; tridecyl alcohol (synthetic) ethoxylate (8EO); tallow amine ethoxylate (15 EO); PEG(400) dioleate-99.

Liquid carriers that can be employed include water and organic solvents. The organic solvents typically used include, but are not limited to, petroleum fractions or hydrocarbons such as minerai oil, aromatic solvents, paraffmic oils, and the like; vegetable oils such as soybean oil, rapeseed oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cottonseed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; esters of the above vegetable oils; esters of monoalcohols or dihydric, trihydric, or other lower polyalcohols (4-6 hydroxy containing), such as 2-ethylhexyl stéarate, w-butyl oleate, isopropyl myristate, propylene glycol dioleate, di-octyl succinate, di-butyl adipate, di-octyl phthalate and the like; esters of mono-, di- and poly-carboxylic acids and the like. Spécifie organic solvents include toluene, xylene, petroleum naphtha, crop oil, acetone, methyl ethyl ketone, cyclohexanone, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol monomethyl ether and diethylene glycol monomethyl ether, methyl alcohol, ethyl alcohol, isopropyl alcohol, amyl alcohol, ethylene glycol, propylene glycol, glycérine, 7V-methyl-2pyrrolidinone, Λζ/V-dimethyl alkylamides, dimethyl sulfoxide, liquid fertilizers, and the like. In some embodiments, water is the carrier for the dilution of concentrâtes.

Suitable solid carriers include talc, pyrophyllite clay, silica, attapulgus clay, kaolin clay, kieselguhr, chalk, diatomaceous earth, lime, calcium carbonate, bentonite clay, Fuller's earth, cottonseed hulls, wheat flour, soybean flour, pumice, wood flour, walnut shell flour, lignin, and the like.

In some embodiments, one or more surface-active agents are utilized in the compositions of the présent disclosure. Such surface-active agents are, in some embodiments, employed in both solid and liquid compositions, e.g., those designed to be diluted with carrier before application. The surface-active agents can be anionic, cationic or nonionic in character and can be employed as emulsifying agents, wetting agents, suspending agents, or for other purposes. Surfactants conventionally used in the art of formulation and which may also be used in the présent formulations are described, inter alia, in McCutcheon ’s Détergents and Emulsifiers Annual, MC Publishing Corp., Ridgewood, New Jersey, 1998, and in Encyclopedia of Surfactants, Vol. I-III, Chemical Publishing Co., New York, 1980-81. Typical surface-active agents include salts of alkyl sulfates, such as diethanolammonium lauryl sulfate;

-4717485 alkylarylsulfonate salts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkylene oxide addition products, such as nonylphenol-Cis ethoxylate; alcohol-alkylene oxide addition products, such as tridecyl alcohol-Ciô ethoxylate; soaps, such as sodium stéarate; alkylnaphthalenesulfonate salts, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl) sulfosuccinate; sorbitol esters, such as sorbitol oleate; quatemary amines, such as lauryl trimethylammonium chloride; polyethylene glycol esters of fatty acids, such as polyethylene glycol stéarate; block copolymers of ethylene oxide and propylene oxide; salts of mono- and dialkyl phosphate esters; vegetable or seed oils such as soybean oil, rapeseed/canola oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cottonseed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; and esters of the above vegetable oils, e.g., methyl esters.

Oftentimes, some of these materials, such as vegetable or seed oils and their esters, can be used interchangeably as an agricultural adjuvant, as a liquid carrier or as a surface active agent.

Other adjuvants commonly used in agricultural compositions include compatibilizing agents, antifoam agents, sequestering agents, neutralizing agents and buffers, corrosion inhibitors, dyes, odorants, spreading agents, pénétration aids, sticking agents, dispersing agents, thickening agents, freezing point depressants, antimicrobial agents, and the like. The compositions may also contain other compatible components, for example, other herbicides, plant growth régulants, fongicides, insecticides, and the like and can be formulated with liquid fertilizers or solid, particulate fertilizer carriers such as ammonium nitrate, urea and the like.

The concentration of the active ingrédients in the herbicidal compositions of this disclosure is generally from about 0.001 to about 98 percent by weight. Concentrations from about 0.01 to about 90 percent by weight are often employed. In compositions designed to be employed as concentrâtes, the active ingrédient is generally présent in a concentration from about 5 to about 98 weight percent, preferably about 10 to about 90 weight percent. Such compositions are typically diluted with an inert carrier, such as water, before application. The diluted compositions usually applied to weeds or the locus of weeds generally contain about 0.0001 to about 1 weight percent active ingrédient and preferably contain about 0.001 to about 0.05 weight percent.

The présent compositions can be applied to weeds or their locus by the use of conventional ground or aerial dusters, sprayers, and granule applicators, by addition to irrigation or flood water, and by other conventional means known to those skilled in the art.

-4817485

In some embodiments, the compounds and compositions described herein are applied as a post-emergence application, pre-emergence application, in-water application to flooded paddy rice or water bodies (e.g., ponds, lakes and streams), or bum-down application.

In some embodiments, the compounds and compositions provided herein are utilized to control weeds in crops, including but not limited to citrus, apple, rubber, oil, palm, forestry, direct-seeded, water-seeded and transplanted rice, wheat, barley, oats, rye, sorghum, com/maize, pastures, grasslands, rangelands, fallowland, turf, tree and vine orchards, aquatics, or row-crops, as well as non-crop settings, e.g., industrial végétation management (IVM) or rights-of-way. In some embodiments, the compounds and compositions are used to control woody plants, broadleaf and grass weeds, or sedges.

In some embodiments, the compounds and compositions provided herein are utilized to control undesirable végétation in rice. In certain embodiments, the undesirable végétation is Brachiaria platyphylla (Groseb.) Nash (broadleaf signalgrass, BRAPP), Digitaria sanguinalis (L.) Scop. (large crabgrass, DIGSA), Echinochloa crus-galli (L.) P. Beauv. (bamyardgrass, ECHCG), Echinochloa colonum (L.) LINK (junglerice, ECHCO), Echinochloa oryzoides (Ard.) Fritsch (early watergrass, ECHOR), Echinochloa oryzicola (Vasinger) Vasinger (late watergrass, ECHPH), Ischaemum rugosum Salisb. (saramollagrass, ISCRU), Leptochloa chinensis (L.) Nees (Chinese sprangletop, LEFCH), Leptochloa fascicularis (Lam.) Gray (bearded sprangletop, LEFFA), Leptochloa panicoides (Presl.) Hitchc. (Amazon sprangletop, LEFPA), Panicum dichotomiflorum (L.) Michx. (fall panicum, PANDI), Paspalum dilatatum Poir. (dallisgrass, PASDI), Cyperus difformis L. (smallflower flatsedge, CYPDI), Cyperus esculentus L. (yellow nutsedge, CYPES), Cyperus iria L. (rice flatsedge, CYPIR), Cyperus rotundus L. (purple nutsedge, CYPRO), Eleocharis species (ELOSS), Fimbristylis miliacea (L.) Vahl (globe fringerush, FIMMI), Schoenoplectus juncoides Roxb. (Japanese bulrush, SPCJU), Schoenoplectus maritimus L. (sea clubrush, SCPMA), Schoenoplectus mucronatus L. (ricefield bulrush, SCPMU), Aeschynomene species, (jointvetch, AESSS), Alternanthera philoxeroides (Mari.) Griseb. (alligatorweed, ALRPH), Alisma plantago-aquatica L. (common waterplantain, ALSPA), Amaranthus species, (pigweeds and amaranths, AMASS), Ammannia coccinea Rottb. (redstem, AMMCO), Eclipta alba (L.) Hassk. (American false daisy, ECLAL), Heteranthera limosa (SW.) Willd./Vahl (ducksalad, HETLI), Heteranthera reniformis R. & P. (roundleaf mudplantain, HETRE), Ipomoea hederacea (L.) Jacq. (ivyleaf momingglory, IPOHE), Lindernia dubia (L.) Pennell (low false pimpemel, LIDDU), Monochoria korsakowii Regel & Maack (monochoria, MOOKA), Monochoria vaginalis (Burm. F.) C. Presl ex Kuhth, (monochoria, MOOVA), Murdannia nudiflora (L.) Brenan (doveweed, MUDNU), Polygonum pensylvanicum

-4917485

L., (Pennsylvania smartweed, POLPY), Polygonum persicaria L. (ladysthumb, POLPE), Polygonum hydropiperoides Michx. (POLHP, mild smartweed), Rotala indica (Willd.) Koehne (Indian toothcup, ROTIN), Sagittaria species, (arrowhead, S AGS S), Sesbania exaltata (Raf.) Cory/Rydb. Ex Hill (hemp sesbania, SEBEX), or Sphenoclea zeylanica Gaertn. (gooseweed, SPDZE).

In some embodiments, the compounds and compositions provided herein are utilized to control undesirable végétation in cereals. In certain embodiments, the undesirable végétation is Alopecurus myosuroides Huds. (blackgrass, ALOMY), Apera spica-venti (L.) Beauv. (windgrass, APESV), Avena fatua L. (wild oat, AVEFA), Bromus tectorum L. (downy brome, BROTE), Lolium multiflorum Lam. (Italian ryegrass, LOLMU), Phalaris minor Retz, (littleseed canarygrass, PHAMI), Poa annua L. (annual bluegrass, POANN), Setaria pumila (Poir.) Roemer & J.A. Schultes (yellow foxtail, SETLU), Setaria viridis (L.) Beauv. (green foxtail, SETVI), Cirsium arvense (L.) Scop. (Canada thistle, CIRARJ, Galium aparine L. (catchweed bedstraw, GALAP), Kochia scoparia (L.) Schrad. (kochia, KCHSC), Lamium purpureum L. (purple deadnettle , LAMPU), Matricaria recutita L. (wild chamomile, MATCH), Matricaria matricarioides (Less.) Porter (pineappleweed, MATMT), Papaver rhoeas L. (common poppy, PAPRH), Polygonum convolvulus L. (wild buckwheat, POLCO), Salsola tragus L. (Russian thistle, SASKR), Stellaria media (L.) Vill. (common chickweed, STEME), Veronica persica Poir. (Persian speedwell, VERPE), Viola arvensis Murr. (field violet, VIOAR), or Viola tricolor L. (wild violet, VIOTR).

In some embodiments, the compounds and compostions provided herein are utilized to control undesirable végétation in range and pasture. In certain embodiments, the undesirable végétation is Ambrosia artemisiifolia L. (common ragweed, AMBEL), Cassia obtusifolia (sickle pod, CASOB), Centaurea maculosa auct. non Lam. (spotted knapweed, CENMA), Cirsium arvense (L.) Scop. (Canada thistle, CIRAR), Convolvulus arvensis L. (field bindweed, CONAR), Euphorbia esula L. (leafy spurge, EPHES), Lactuca serriola L./Tom. (prickly lettuce, LACSE), Plantago lanceolata L. (buckhom plantain, PLALA), Rumex obtusifolius L. (broadleaf dock, RUMOB), Sida spinosa L. (prickly sida, SIDSP), Sinapis arvensis L. (wild mustard, SINAR), Sonchus arvensis L. (perennial sowthistle, SONAR), Solidago species (goldenrod, SOOSS), Taraxacum officinale G.H. Weber ex Wiggers (dandelion, TAROF), Trifolium repens L. (white clover, TRFRE), or Urtica dioica L. (common nettle, URTDI).

In some embodiments, the compounds and compositions provided herein are utilized to control undesirable végétation found in row crops. In certain embodiments, the undesirable végétation is Alopecurus myosuroides Huds. (blackgrass, ALOMY), Avena fatua L. (wild oat,

-5017485

AVEFA), Brachiaria platyphylla (Groseb.) Nash (broadleaf signalgrass, BRAPP), Digitaria sanguinalis (L.) Scop. (large crabgrass, DIGSA), Echinochloa crus-galli (L.) P. Beauv. (bamyardgrass, ECHCG), Echinochloa colonum (L.) Link (junglerice, ECHCO), Loliurn multiflorum Lam. (Italian ryegrass, LOLMU), Panicum dichotomiflorum Michx. (fall panicum, PANDI), Panicum miliaceum L. (wild-proso millet, PANMI), Setaria faberi Herrm. (giant foxtail, SETFA), Setaria viridis (L.) Beauv. (green foxtail, SETVI), Sorghum halepense (L.) Pers. (Johnsongrass, SORHA), Sorghum bicolor (L.) Moench ssp. Arundinaceum (shattercane, SORVU), Cyperus esculentus L. (yellow nutsedge, CYPES), Cyperus rotundus L. (purple nutsedge, CYPRO), Abutilon theophrasti Medik. (velvetleaf, ABUTH), Amaranthus species (pigweeds and amaranths, AMASS), Ambrosia artemisiifolia L. (common ragweed, AMBEL), Ambrosia psilostachya DC. (western ragweed, AMBPS), Ambrosia trifida L. (giant ragweed, AMBTR), Asclepias syriaca L. (common milkweed, ASCSY), Chenopodium album L. (common lambsquarters, CHEAL), Cirsium arvense (L.) Scop. (Canada thistle, CIRAR), Commelina benghalensis L. (tropical spiderwort, COMBE), Datura stramonium L. (jimsonweed, DATST), Daucus carota L. (wild carrot, DAUCA), Euphorbia heterophylla L. (wild poinsettia, EPHHL), Erigeron bonariensis L. (hairy fleabane, ERIBO), Erigeron canadensis L. (Canadian fleabane, ERICA), Helianthus annuus L. (common sunflower, HELAN), Jacquemontia tamnifolia (L.) Griseb. (smallflower momingglory, IAQTA), Ipomoea hederacea (L.) Jacq. (ivyleaf momingglory, IPOHE), Ipomoea lacunosa L. (white momingglory, IPOLA), Lactuca serriola L./Tom. (prickly lettuce, LACSE), Portulaca oleracea L. (common purslane, POROL), Sida spinosa L. (prickly sida, SIDSP), Sinapis arvensis L. (wild mustard, SINAR), Solanum ptychanthum Dunal (eastem black nightshade, SOLPT), oxXanthium strumarium L. (common cocklebur, XANST).

In some embodiments, application rates of about 1 to about 4,000 grams/hectare (g/ha) are employed in post-emergence operations. In some embodiments, rates of about 1 to about 4,000 g/ha are employed in pre-emergence operations.

In some embodiments, the compounds, compositions, and methods provided herein are used in conjunction with one or more other herbicides to control a wider variety of undesirable végétation. When used in conjunction with other herbicides, the presently claimed compounds can be formulated with the other herbicide or herbicides, tank-mixed with the other herbicide or herbicides or applied sequentially with the other herbicide or herbicides. Some of the herbicides that can be employed in conjunction with the compounds of the présent disclosure include: 4-CPA, 4-CPB, 4-CPP, 2,4-D, 2,4-D choline sait, 2,4-D esters and amines, 2,4-DB, 3,4DA, 3,4-DB, 2,4-DEB, 2,4-DEP, 3,4-DP, 2,3,6-TBA, 2,4,5-T, 2,4,5-TB, acetochlor, acifluorfen,

-5117485 aclonifen, acrolein, alachlor, allidochlor, alloxydim, allyl alcohol, alorac, ametridione, ametryn, amibuzin, amicarbazone, amidosulfuron, aminocyclopyrachlor, aminopyralid, amiprofos-methyl, amitrole, ammonium sulfamate, anilofos, anisuron, asulam, atraton, atrazine, azafenidin, azimsulfuron, aziprotryne, barban, BCPC, beflubutamid, benazolin, bencarbazone, benfluralin, benfuresate, bensulfuron-methyl, bensulide, benthiocarb, bentazon-sodium, benzadox, benzfendizone, benzipram, benzobicyclon, benzofenap, benzofluor, benzoylprop, benzthiazuron, bicyclopyrone, bifenox, bilanafos, bispyribac-sodium, borax, bromacil, bromobonil, bromobutide, bromofenoxim, bromoxynil, brompyrazon, butachlor, butafenacil, butamifos, butenachlor, buthidazole, buthiuron, butralin, butroxydim, buturon, butylate, cacodylic acid, cafenstrole, calcium chlorate, calcium cyanamide, cambendichlor, carbasulam, carbetamide, carboxazole, chlorprocarb, carfentrazone-ethyl, CDEA, CEPC, chlomethoxyfen, chloramben, chloranocryl, chlorazifop, chlorazine, chlorbromuron, chlorbufam, chloreturon, chlorfenac, chlorfenprop, chlorflurazole, chlorflurenol, chloridazon, chlorimuron, chlomitrofen, chloropon, chlorotoluron, chloroxuron, chloroxynil, chlorpropham, chlorsulfuron, chlorthal, chlorthiamid, cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim, cliodinate, clodinafop-propargyl, clofop, clomazone, clomeprop, cloprop, cloproxydim, clopyralid, cloransulam-methyl, CMA, copper sulfate, CPMF, CPPC, credazine, cresol, cumyluron, cyanatryn, cyanazine, cycloate, cyclosulfamuron, cycloxydim, cycluron, cyhalofop-butyl, cyperquat, cyprazine, cyprazole, cypromid, daimuron, dalapon, dazomet, delachlor, desmedipham, desmetryn, di-allate, dicamba, dichlobenil, dichloralurea, dichlormate, dichlorprop, dichlorprop-P, diclofop, diclosulam, diethamquat, diethatyl, difenopenten, difenoxuron, difenzoquat, diflufenican, diflufenzopyr, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimexano, dimidazon, dinitramine, dinofenate, dinoprop, dinosam, dinoseb, dinoterb, diphenamid, dipropetryn, diquat, disul, dithiopyr, diuron, DMP A, DNOC, DSMA, EBEP, eglinazine, endothal, epronaz, EPTC, erbon, esprocarb, ethalfluralin, ethbenzamide, ethametsulfuron, ethidimuron, ethiolate, ethobenzamid, etobenzamid, ethofumesate, ethoxyfen, ethoxysulfuron, etinofen, etnipromid, etobenzanid, EXD, fenasulam, fenoprop, fenoxaprop, fenoxaprop-P-ethyl, fenoxaprop-P-ethyl + isoxadifen-ethyl, fenoxasulfone, fenteracol, fenthiaprop, fentrazamide, fenuron, ferrous sulfate, flamprop, flamprop-M, flazasulfuron, florasulam, fluazifop, fluazifop-P-butyl, fluazolate, flucarbazone, flucetosulfuron, fluchloralin, flufenacet, flufenican, flufenpyr-ethyl, flumetsulam, flumezin, flumiclorac-pentyl, flumioxazin, flumipropyn, fluometuron, fluorodifen, fluoroglycofen, fluoromidine, fluoronitrofen, fluothiuron, flupoxam, flupropacil, flupropanate, flupyrsulfuron, fluridone, flurochloridone, fluroxypyr, flurtamone, fluthiacet, fomesafen, foramsulfuron, fosamine, furyloxyfen, glufosinate,

-5217485 glufosinate-ammonium, glyphosate, halosafen, halosulfuron-methyl, haloxydine, haloxyfopmethyl, haloxyfop-P-methyl, halauxifen-methyl, hexachloroacetone, hexaflurate, hexazinone, imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, imazosulfuron, indanofan, indaziflam, iodobonil, iodomethane, iodosulfuron, iofensulfuron, ioxynil, ipazine, ipfencarbazone, iprymidam, isocarbamid, isocil, isomethiozin, isonoruron, isopolinate, isopropalin, isoproturon, isouron, isoxaben, isoxachlortole, isoxaflutole, isoxapyrifop, karbutilate, ketospiradox, lactofen, lenacil, linuron, MAA, ΜΑΜΑ, MCPA esters and amines, MCPA-thioethyl, MCPB, mecoprop, mecoprop-P, medinoterb, mefenacet, mefluidide, mesoprazine, mesosulfuron, mesotrione, metam, metamifop, metamitron, metazachlor, metazosulfuron, metflurazon, methabenzthiazuron, methalpropalin, methazole, methiobencarb, methiozolin, methiuron, methometon, methoprotryne, methyl bromide, methyl isothiocyanate, methyldymron, metobenzuron, metobromuron, metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, molinate, monalide, monisouron, monochloroacetic acid, monolinuron, monuron, morfamquat, MSMA, naproanilide, napropamide, napropamide-M, naptalam, neburon, nicosulfuron, nipyraclofen, nitralin, nitrofen, nitrofluorfen, norflurazon, noruron, OCH, orbencarb, orrizo-dichlorobenzene, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxapyrazon, oxasulfuron, oxaziclomefone, oxyfluorfen, paraflufen-ethyl, parafluron, paraquat, pebulate, pelargonic acid, pendimethalin, penoxsulam, pentachlorophenol, pentanochlor, pentoxazone, perfluidone, pethoxamid, phenisopham, phenmedipham, phenmedipham-ethyl, phenobenzuron, phenylmercury acetate, picloram, picolinafen, pinoxaden, piperophos, potassium arsenite, potassium azide, potassium cyanate, pretilachlor, primisulfuron-methyl, procyazine, prodiamine, profluazol, profluralin, profoxydim, proglinazine, prohexadione-calcium, prometon, prometryn, propachlor, propanil, propaquizafop, propazine, propham, propisochlor, propoxycarbazone, propyrisulfuron, propyzamide, prosulfalin, prosulfocarb, prosulfuron, proxan, prynachlor, pydanon, pyraclonil, pyraflufen, pyrasulfotole, pyrazogyl, pyrazolynate, pyrazosulfuron-ethyl, pyrazoxyfen, pyribenzoxim, pyributicarb, pyriclor, pyridafol, pyridate, pyriftalid, pyriminobac, pyrimisulfan, pyrithiobac-methyl, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine, quinonamid, quizalofop, quizalofop-P-ethyl, rhodethanil, rimsulfuron, saflufenacil, S-metolachlor, sebuthylazine, secbumeton, sethoxydim, siduron, simazine, simeton, simetryn, SMA, sodium arsenite, sodium azide, sodium chlorate, sulcotrione, sulfallate, sulfentrazone, sulfometuron, sulfosate, sulfosulfuron, sulfuric acid, sulglycapin, swep, TCA, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbuchlor, terbumeton, terbuthylazine, terbutryn, tetrafluron, thenylchlor, thiazafluron, thiazopyr, thidiazimin, thidiazuron, thiencarbazone-methyl, thifensulfuron, thiobencarb,

-5317485 tiocarbazil, tioclorim, topramezone, tralkoxydim, triafamone, tri-allate, triasulfuron, triaziflam, tribenuron, tricamba, triclopyr esters and amines, tridiphane, trietazine, trifloxysulfuron, trifluralin, triflusulfuron, trifop, trifopsime, trihydroxytriazine, trimeturon, tripropindan, tritac, tritosulfuron, vemolate and xylachlor.

The compounds and compositions of the présent disclosure can generally be employed in combination with known herbicide safeners, such as benoxacor, benthiocarb, brassinolide, cloquintocet (e.g., mexyl), cyometrinil, daimuron, dichlormid, dicyclonon, dimepiperate, disulfoton, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, harpin proteins, isoxadifen-ethyl, mefenpyr-diethyl, MG 191, MON 4660, naphthalic anhydride (NA), oxabetrinil, R29148 and 7V-phenylsulfonylbenzoic acid amides, to enhance their selectivity.

The compounds, compositions, and methods described herein be used to control undesirable végétation on glyphosate-tolerant-, glufosinate-tolerant-, dicamba-tolerant-, phenoxy auxin-tolerant-, pyridyloxy auxin-tolerant-, aryloxyphenoxypropionate-tolerant-, acetyl CoA carboxylase (ACCase) inhibitor-tolerant-, imidazolinone-tolerant-, acetolactate synthase (ALS) inhibitor-tolerant-, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitor -tolérant-, protoporphyrinogen oxidase (PPO) inhibitor -tolérant-, triazine-tolerant-, and bromoxyniltolerant- crops (such as, but not limited to, soybean, cotton, canola/oilseed râpe, rice, cereals, corn, turf, etc), for example, in conjunction with glyphosate, glufosinate, dicamba, phenoxy auxins, pyridyloxy auxins, aryloxyphenoxypropionates, ACCase inhibitors, imidazolinones, ALS inhibitors, HPPD inhibitors, PPO inhibitors, triazines, and bromoxynil. The compositions and methods may be used in controlling undesirable végétation in crops possessing multiple or stacked traits conferring tolérance to multiple chemistries and/or inhibitors of multiple modes-ofaction.

The compounds and compositions provided herein may also be employed to control herbicide résistant or tolérant weeds. Exemplary résistant or tolérant weeds include, but are not limited to, biotypes résistant or tolérant to acetolactate synthase (ALS) inhibitors, photosystem II inhibitors, acetyl CoA carboxylase (ACCase) inhibitors, synthetic auxins, photosystem I inhibitors, 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase inhibitors, microtubule assembly inhibitors, lipid synthesis inhibitors, protoporphyrinogen oxidase (PPO) inhibitors, carotenoid biosynthesis inhibitors, very long chain fatty acid (VLCFA) inhibitors, phytoene desaturase (PDS) inhibitors, glutamine synthetase inhibitors, 4-hydroxyphenyl-pyruvatedioxygenase (HPPD) inhibitors, mitosis inhibitors, cellulose biosynthesis inhibitors, herbicides with multiple modes-of-action such as quinclorac, and unclassified herbicides such as arylaminopropionic acids, difenzoquat, endothall, and organoarsenicals. Exemplary résistant or

-5417485 tolérant weeds include, but are not limited to, biotypes with résistance or tolérance to multiple herbicides, multiple chemical classes, and multiple herbicide modes-of-action.

The described embodiments and following examples are for illustrative purposes and are not intended to limit the scope of the daims. Other modifications, uses, or combinations with respect to the compositions described herein will be apparent to a person of ordinary skill in the art without departing from the spirit and scope of the claimed subject matter.

SYNTHESIS OF PRECURSORS

Préparation 1: Methyl 4-amino-3,6-dichloropicolinate (Head A)

Prepared as described in Fields et al., WO 2001051468 Al.

Préparation 2: Methyl 4-amino-3,6-dichloro-5-fluoropicolinate (Head B)

CH

Prepared as described in Fields et al.,

Tetrahedron Letters 2010, 571, 79-81.

Préparation 3: 2,6-Dichloro-5-methoxy-4-vinyl pyrimidine

To a solution of commercially available 2,6-dichloro-5-methoxy pyrimidine (100 grams (g), 0.55 moles (mol)) in dry tetrahydrofuran (THF) was added, dropwise, lmolar (M) vinyl magnésium bromide in tetrahydrofuran solvent (124 g, 0.94 mol) over one hour (h) at room température. The mixture was then stirred for 4 h at room température. Excess Grignard reagent was quenched by addition of acetone (200 milliliters (mL)) while the température of the mixture

-5517485 was maintained at a température below 20 °C. Thereafter, 2,3-dichloro-5,6-dicyano-pbenzoquinone (DDQ; 151g, 0.67 mol) was added at once and stirred ovemight. A yellow solid precipitated out. The solid was filtered and washed with ethyl acetate (500 mL). The filtrate was concentrated under reduced pressure and the resulting crude compound was diluted with ethyl acetate (2 liters (L)). The resulting undissolved, dark, semi-solid was separated by filtration using ethyl acetate. It was further concentrated under reduced pressure to provide a crude compound, which was purified by column chromatography. The compound was eluted with 5% to 10% ethyl acetate in hexane mixture to provide the title compound (70 g, 60%): mp 60-61 °C; ’H NMR (CDC1₃) δ 3.99 (s, 3H), 5.85 (d, 1H), 6.75 (d, 1H), 6.95 (dd, 1H).

Préparation 4: 2,6-Dichloro-5-methoxy-pyrimidine-4-carbaIdehyde

A solution of 2,6-dichloro-5-methoxy-4-vinyl pyrimidine (50 g, 0.24 mol) in dichloromethane:methanol (4:1,2 L) was cooled to -78 °C. Ozone gas was bubbled therethrough for 5 h. The reaction was quenched with dimethyl sulfide (50 mL). The mixture was slowly warmed to room température and concentrated under reduced pressure at 40 °C to provide the title compound (50.5 g, 100%); high-performance liquid chromatorgraphy (HPLC; 85% acetonitrile buffered with 0.1% volume per volume (v/v) acetic acid).

Préparation 5: Methyl 2,6-dichloro-5-methoxy-pyrimidine-4-carboxylate

CH₃

A solution of 2,6-dichloro-5-methoxy-pyrimidine-4-carbaldehyde (50 g, 0.24 mol) in methanol (1 L) and water (60 mL) was prepared. To the solution, sodium bicarbonate (400 g) was added. A 2 M solution of bromine (192 g, 1.2 mol) in methanol/water (600 mL, 9:1) was added dropwise to the pyrimidine solution over 45 minutes (min) at 0 °C while stirring the mixture. The stirring was continued at the same température for 1 h. Later, the mixture was stirred at room température for 4 h. While stirring, the reaction mixture was thereafter poured

-5617485 onto a mixture of crushed ice (2L), sodium bisulfite (50 g), and sodium chloride (200 g). The product was extracted with ethyl acetate (IL x 2), and the combined organic layer was dried over sodium sulfate and filtered. Evaporation of the solvent under reduced pressure produced a thick material, which solidified on long standing to afford the title compound (50.8 g, 87%); ESIMS m/z 238 ([M+H]⁺).

Préparation 6: Methyl 6-amino-2-chloro-5-methoxy-pyrimidine-4-carboxyIate (Head C)

A solution of methyl 2,6-dichloro-5-methoxy-pyrimidine-4-carboxylate (25 g, 0.1 mol) and dimethyl sulfoxide (DMSO) was prepared. To this solution was added, at 0-5 °C, a solution of ammonia (2 eq) in DMSO. This mixture was stirred at the same 0-5 °C température for 10 to 15 min. Later, the mixture was diluted with ethyl acetate, and the resulting solid was filtered off. The ethyl acetate filtrate was washed with a brine solution and dried over sodium sulfate. Upon concentration, the crude product was obtained. The crude product was stirred in a minimum amount of ethyl acetate and filtered to obtain the pure compound. Additional pure compound was obtained from the filtrate which, after concentration, was purified by flash chromatography. This produced the title compound (11 g, 50%): mp 158 °C; 'H NMR (DMSOJ₆) δ 3.71 (s, 3H), 3.86 (s, 3H), 7.65 (br s, 1H), 8.01 (br s, 1H).

Préparation 7: Methyl 4-amino-3,6-dichloro-5-iodopicolinate

CH₃

Methyl 4-amino-3,6-dichloropicolinate (10.0 g, 45.2 mmol), periodic acid (3.93 g, 17.2 millimoles (mmol)), and iodine (11.44 g, 45.1 mmol) were dissolved in methanol (30 mL) and stirred at reflux at 60 °C for 27 h. The reaction mixture was concentrated, diluted with diethyl ether, and washed twice with saturated aqueous sodium bisulfite. The aqueous layers were extracted once with diethyl ether, and the combined organic layers were dried over anhydrous sodium sulfate. The product was concentrated and purified by flash chromatography

-5717485 (silica gel, 0-50% ethyl acetate/hexanes) to provide the title compound as a pale yellow solid (12.44 g, 35.9 mmol, 79%): mp 130.0-131.5 °C; *H NMR (400 MHz, CDC1₃) δ 5.56 (s, 2H), 3.97 (s, 3H); ¹³C NMR (101 MHz, CDC1₃) δ 163.80, 153.00, 152.75, 145.63, 112.12, 83.91, 53.21; EIMSm/z 346.

Préparation 8: Methyl 4-amino-3,6-dichloro-5-methylpicolinate (Head D)

NH₂

H₃C^L/CI JL cr n ch₃

O

A mixture of methyl 4-amino-3,6-dichloro-5-iodopicolinate (8.1 g, 23.4 mmol), tetramethylstannane (8.35 g, 46.7 mmol), and bis(triphenylphosphine)palladium(II) chloride (2.5 g, 3.5 mmol) in 1,2-dichloroethane (40 mL) was irradiated in a Biotage Initiator microwave at 120 °C for 30 min, with extemal infrared (IR)-sensor température monitoring from the side. The reaction mixture was loaded directly onto a silica gel cartridge and purified by flash chromatography (silica gel, 0-50% ethyl acetate/hexanes) to provide the title compund as an orange solid (4.53 g, 83 %): mp 133-136 °C; *H NMR (400 MHz, CDC1₃) δ 4.92 (s, 2H), 3.96 (s, 3H), 2.29 (s, 3H); ¹³CNMR (101 MHz, CDC1₃) δ 164.34, 150.24, 148.69, 143.94, 117.01, 114.60, 53.02, 14.40; ESIMS m/z 236 ([M+H]⁺), 234 ([M-H]').

Préparation 9: Methyl 6-amino-2,5-dichloropyrimidine-4-carboxylate (Head E)

NH_?

X teK .0^ cr n y ch₃ o

Prepared as described in Epp et al., WO 2007082076 Al.

Préparation 10: Methyl 4-amino-6-chloro-5-fluoro-3-methoxypicolinate (Head F) ch₃

I ^JO

NH₂

F.

Cl

O

-5817485

Prepared as described in Epp et al., WO 2013003740 Al.

Préparation 11: Methyl 4-amino-6-chloro-5-fluoro-3-vinylpicolinate (Head G) nh₂ ch₂ ch₂

FCl

Methyl 4-amino-6-chloro-5-fluoro-3-iodopicolinate (7.05 g, 21.33 mmol, prepared as described in Epp et al., WO 2013003740 Al) and vinyltri-n-butyltin (7.52 mL, 25.6 mmol) were suspended in dichloroethane (71.1 mL) and the mixture was degassed with Argon for 10 min. Bis(triphenylphosphine)palladium(II) chloride (1.497 g, 2.133 mmol) was then added, and the reaction mixture was stirred at 70 °C ovemight (clear orange solution). The reaction was monitored by gas chromatography-mass spectrometry (GC-MS). After 20 h, the reaction mixture was concentrated, adsorbed onto Celite, and purified by column chromatography (silica gel (S1O2), hexanes/ethyl acetate gradient) to afford the title compound (3.23 g, 65.7 %) as a light brown solid: mp 99-100°C; ’H NMR (400 MHz, CDC1₃) δ 6.87 (dd, J= 18.1, 11.6 Hz,

1H), 5.72 (dd, J= 11.5, 1.3 Hz, 1H), 5.52 (dd, J= 18.2, 1.3 Hz, 1H), 4.79 (s, 2H), 3.91 (s, 3H); ¹⁹F NMR (376 MHz, CDCI3) δ -138.79 (s); EIMS m/z 230.

Préparation 12: Methyl 4-amino-3,5,6-trichloropicolinate (Head H)

NHo

Cl

Prepared as described in Finkelstein et al., WO 2006062979 Al.

Préparation 13: Methyl 4-amino-6-bromo-3-chloro-5-fluoropicolinate (Head I) NH₂

F.

Br

Prepared as described in Amdt et al., US 20120190857 Al.

-5917485

Préparation 14: Methyl 4-amino-3-chloro-5-fluoro-6-(trimethylstannyl)picoiinate (Head J) NH₂

Methyl 4-amino-6-bromo-3-chloro-5-fluoropicolinate (500 mg, 1.8 mmol),

1,1,1,2,2,2-hexamethyldistannane (580 mg, 1.8 mmol) and bis(triphenylphosphine)-palladium(II) chloride (120 mg, 0.18 mmol) were combined in dry dioxane (6 mL), sparged with a stream of nitrogen for 10 min and then heated to 80 °C for 2 h. The cooled mixture was stirred with ethyl acetate (25 mL) and saturated NaCl (25 mL) for 15 min. The organic phase was separated, filtered through diatomaceous earth, dried (NajSC^) and evaporated. The residue was taken up in ethyl acetate (4 mL), stirred and treated in portions with hexane (15 mL). The milky white solution was decanted from any solids produced, filtered through glass wool and evaporated to give the title compound as an off-white solid (660 mg, 100%): *H NMR (400 MHz, CDCI3) δ 4.63 (d, J = 29.1 Hz, 1H), 3.97 (s, 2H), 0.39 (s, 4H); ¹⁹F NMR (376 MHz, CDC1₃) δ -130.28; EIMS m/z 366.

Préparation 15: Methyl 4-acetamido-3-chloro-6-(trimethylstannyl)-picolinate (Head K)

O

H

NH

Prepared as described in Balko et al., WO 2003011853 Al.

Préparation 16: Methyl 4-acetamido-3,6-dichloropicolinate (Head L)

O

X X./°-.

cr ch₃ o

Z-6017485

Prepared as described in Fields et al., WO 2001051468 Al.

Préparation 17: Methyl 4-amino-3-chloro-6-iodopicolinate (Head M)

^xch₃

Prepared as described in Balko et al., WO 2007082098 A2.

Préparation 18: Methyl 4-acetamido-3-chloro-6-iodopicolinate (Head N)

O

Prepared as described in Balko et al., WO 2007082098 A2.

Préparation 19: Methyl 4-amino-6-bromo-3,5-difluoropicolinate (Head O)

Prepared as described in Fields et al., WO 2001051468 Al.

Préparation 20: Methyl 6-amino-2-chloro-5-vinylpyrimidine-4-carboxylate (Head P)

Prepared as described in Epp et al., US 20090088322.

-6117485

Préparation 21: l-Bromo-4-(2,2-diethoxyethoxy)-2-fluorobenzene

4-Bromo-3-fluorophenol (7 g, 0.03665 mol) and potassium carbonate (7.6 g, 0.055 mol) were dissolved in A.A-dimethylformamide (9 mL). 2-Bromo-l,l-diethoxyethane (8.5 mL, 0.055 mol) was added and the reaction mixture was stirred and heated to 135 °C for 7 h. The solvent was removed after the reaction was completed. The residue was dissolved in ethyl acetate and washed with 2M NaOH solution. The organic phase was dried over Na2SO4. The solvent was evaporated to yield l-bromo-4-(2,2-diethoxyethoxy)-2-fluorobenzene as an oil (11.4 g, 100%).

Préparation 22: l-Bromo-3-(2,2-diethoxyethoxy)-2-fluorobenzene

l-Bromo-3-(2,2-diethoxyethoxy)-2-fluorobenzene was prepared from 3-bromo-2fluorophenol as described in Préparation 21.

Préparation 23: 2-Bromo-4-(2,2-diethoxyethoxy)-l-fluorobenzene

OEt

2-Bromo-4-(2,2-diethoxyethoxy)-l-fluorobenzene was prepared from 3-bromo-4fluorophenol as described in Préparation 21.

Préparation 24: l-Bromo-4-chloro-2-(2,2-diethoxyethoxy)benzene

-6217485 l-Bromo-4-chloro-2-(2,2-diethoxyethoxy)benzene was prepared from 2-bromo-5chlorophenol as described in Préparation 21.

Préparation 25: (4-Bromo-3-fluorophenyl)(2,2-diethoxyethyl)sulfane

(4-Bromo-3-fluorophenyl)(2,2-diethoxyethyl)sulfane was prepared from 4-bromo-3fluorobenzenethiol as described in Préparation 21.

Préparation 26: 4-Bromo-7-chlorobenzofuran

To 80 mL of benzene was added polyphosphoric acid (3.47 g, 36.9 mmol) and commercially available 2-(5-bromo-2-chlorophenoxy)acetaldehyde (9.2 g, 36.9 mmol) and separated into eight 20 mL vials containing equal amounts. The vials were heated to an extemal température of 90 °C for 4 days. Upon cooling of the reaction, the benzene was removed by decanting. Celite (50 g) was added to the organic solution and the solvent was removed using a rotary evaporator. The impregnated Celite was loaded onto a Teledyne-Isco purification System and purified by silica gel chromatography using 0-30% ethyl acetate:hexanes to give 4-bromo-7chlorobenzofuran as a white solid (2.7 g, 32%): ^XH NMR (400 MHz, CDCI3) δ 7.73 (d, J= 2.2 Hz, 1H), 7.33 (d, J= 8.3 Hz, 1H), 7.18 (d, J= 8.3 Hz, 1H), 6.85 (d, J= 2.2 Hz, 1H); ¹³C NMR (101 MHz, CDCI3) δ 150.38 (s), 146.14 (s), 130.27 (s), 126.56 (s), 125.32 (s), 116.44 (s), 112.49 (s), 107.71 (s); ESIMS m/z 232 ([M+H]⁺), 230 ([M-H]').

Préparation 27: 6-Bromobenzofuran and 4-bromobenzofuran

-6317485

6-Bromobenzofuran and 4-bromobenzofuran were prepared as described in US20040147559 from l-bromo-3-(2,2-diethoxyethoxy)benzene.

Préparation 28: 5-Bromo-6-fluorobenzofuran and 5-bromo-4-fluorobenzofuran

l-Bromo-4-(2,2-diethoxyethoxy)-2-fluorobenzene (11.4 g, 0.037 mol) was dissolved in toluene (78 mL). Polyphosphoric acid (11.9 g) was added and the mixture was heated to reflux for 5 h. The solvent was removed and the residue was diluted with water and ethyl acetate. The organic phase was washed with 2 M NaOH solution and then dried over Na2SC>4. A mixture of 5-bromo-6-fluorobenzofuran and 5-bromo-4-fluorobenzofuran (4.8 g, 60.3%) were obtained as a mixture after purification via column chromatography.

Préparation 29: 6-Bromo-7-fluorobenzofuran

6-Bromo-7-fluorobenzoiuran was prepared from l-bromo-3-(2,2-diethoxyethoxy)-2fluorobenzene as described in Préparation 28: ESIMS m/z 216 ([M+H]⁺).

Préparation 30: 6-Bromo-5-fluorobenzofuran

F

6-Bromo-5-fluorobenzofuran was prepared from 2-bromo-4-(2,2-diethoxyethoxy)-lfluorobenzene as described in Préparation 28: ESIMS m/z 216 ([M+H]⁺).

-6417485

Préparation 31: 7-Bromo-4-chlorobenzofuran

7-Bromo-4-chlorobenzofuran was prepared from l-bromo-4-chloro-2-(2,2diethoxyethoxy)benzene as described in Préparation 28: ESIMS m/z 232 ([M+H]⁺).

Préparation 32: 5-Bromo-4-fluorobenzo [6] thiophene and 5-bromo-6fluorobenzo [b ] thiophene

Polyphosphoric acid (13.9 g) was stirred in chlorobenzene (50 mL) at 130 °C. (4Bromo-3-fluorophenyl)(2,2-diethoxyethyl)sulfane (7.7 g, 0.0238 mol) in chlorobenzene (15.4 mL) was added dropwise at 130 °C. The mixture was then stirred at 130 °C for 10 h. The solvent was removed and the residue was extracted with toluene, hexane, and then water. The organic phase was combined and washed with saturated sodium bicarbonate (NaHCCh) solution and brine, and then dried over Na2SC>4. The products 5-bromo-4-fluorobenzo[è]thiophene and 5bromo-6-fluorobenzo[à] thiophene were obtained after purification via column chromatography (3.6 g, 65.5%).

Préparation 33: 6-Bromo-5-fluorobenzo[à] thiophene and 4-bromo-5fluor obenzo [Λ] thiophene

-6517485

6-Bromo-5-fluorobenzo[b]thiophene and 4-bromo-5-fluorobenzo[ô]thiophene were prepared from (3-bromo-4-fluorophenyl)(2,2-diethoxyethyl)sulfane as described in Préparation 32: ESIMS m/z 232 ([M+H]⁺).

Préparation 34: 2-(7-Chlorobenzofuran-4-yl)-5,5-dimethyl-l,3,2-dioxaborinane

2-(7-Chlorobenzofuran-4-yl)-5,5-dimethyl-l,3,2-dioxaborinane was prepared as described in Préparation 55 from 4-bromo-7-chlorobenzofuran (prepared as described in W02005056015) to afford a white solid (66%): IR (cm'¹) 669.18,701.26, 741.33, 792.08, 773.25, 842.53, 811.66, 863.44, 876.27, 884.51, 953.31, 993.58, 1027.34, 1132.28, 1059.34, 1157.92, 1217.21, 1207.86, 1253.95, 1238.65, 1302.38, 1266.72, 1359.16, 1335.94, 1370.05, 1422.73, 1438.38, 1480.37, 1577.30, 1602.05, 2903.59, 2871.91, 2940.30, 2955.31, 3140.15, 3161.21; *H NMR (400 MHz, CDC1₃) δ 7.69 (d, ./=2.1 Hz, 1H), 7.63 (d, J=7.8 Hz, 1H), 7.28 (dd, J= 6.7, 2.6 Hz, 1H), 7.27 (d, J= 2.2 Hz, 1H), 3.82 (s, 4H), 1.05 (s, 6H); ESIMS m/z 265 ([M+H]⁺), 263([M-H]’).

Préparation 35: 2-(Benzofuran-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane and 2(benzofuran-4-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane

2-(Benzofuran-6-yl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane and 2-(benzofuran-4yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane were prepared as described in Préparation 55 from 4bromobenzofuran and 6-bromobenzofuran to afford the mixture as a clear oil (48%): ’H NMR (400 MHz, CDC1₃) δ 7.97 (s, 1H), 7.72 - 7.68 (m, 1H), 7.66 (dd, J= 4.9, 2.6 Hz, 2H), 7.60 (dd, J = 8.0, 5.2 Hz, 2H), 7.30 (dd, J = 7.1, 6.2 Hz, 1H), 7.28 - 7.21 (m, 2H), 6.77 (dd, J= 2.1, 0.8 Hz, 1H), 1.37 (d,J= 6.2 Hz, 22H), 1.29-1.22 (m, 8H); ¹³C NMR (101 MHz, CDC1₃) δ 146.01,

-6617485

145.21, 130.19, 130.11, 128.76, 123.56, 120.60, 117.60, 114.05, 108.45, 106.63, 83.82, 83.69, 83.50, 25.02, 24.98, 24.88; ESIMS m/z 245 ([M+H]⁺), 243([M-H]‘).

Préparation 36: 2-(6-Fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane and

2-(4-fluorobenzofuran-5-yi)-4,4,5,5-tetramethyl-l,3,2-dioxaboro!ane

A mixture of 5-bromo-6-fluorobenzofuran and 5-bromo-4-fluorobenzofuran (1 combined équivalent), potassium acetate (KOAc; 3 eq) and bis(pinacolato) diboron (1.2 eq) were stirred in dioxane (0.1 M with respect to the 5-bromo-6-fluorobenzofuran and 5-bromo-4fluorobenzofuran mixture) under nitrogen flow for 30 min. The catalyst [1,1bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl₂(dppf); 0.15 eq) was added and the nitrogen flow was maintained for 10 min. The reaction mixture was heated to 85 °C ovemight. The solvent was removed, the residue was dissolved in methylene chloride, and the solid was filtered. The filtrate was concentrated and purified through a column to give a mixture of 2-(6-fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and 2-(4fluorobenzofuran-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (63%): 'H NMR (400 MHz, CDC1₃) δ 7.98 (d, J=5.7 Hz, 1H), 7.59 (d,J=2.1 Hz, 1H), 7.18 (d, J =9.4 Hz, 1H), 6.73 (d,J =

1.3 Hz, 1H), 1.38 (s, 12H); *H NMR (400 MHz, CDCI3) δ 7.81 (d, J= 7.0 Hz, 1H), 7.37 (t, J =

7.4 Hz, 1H), 7.30 (d, J= 8.4 Hz, 1H), 6.87 (s, 1H), 1.38 (s, 12H); ¹⁹F NMR (376 MHz, CDC1₃) δ -107.80, -107.81, -107.82, -107.84, -108.47, -108.48; ESIMS m/z 262 ([M+H]⁺).

Préparation 37: 2-(4-Chlorobenzofuran-7-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane

2-(4-Chlorobenzofuran-7-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was prepared as described in Préparation 36 from 7-bromo-4-chlorobenzofuran: ’H NMR (400 MHz, CDCI3) δ

-6717485

7.75 (d, J= 2.2 Hz, 1H), 7.67 (d, J= 7.8 Hz, 1H), 7.24 (d, J= 7.8 Hz, 1H), 6.86 (d, J= 2.2 Hz, 1H), 1.41 (s, 12H); ESIMS m/z 278 ([M+H]⁺).

Préparation 38: 2-(5-Fluorobenzofuran-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane

2-(5-Fluorobenzofuran-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane was prepared as described in Préparation 36 from 6-bromo-5-fluorobenzofuran: *H NMR (400 MHz, CDCI3) δ 7.85 (d, .7=4.3 Hz, 1H), 7.68 (d,J=2.2 Hz, 1H), 7.24-7.20 (m, 1H), 6.75-6.70 (m, 1H), 1.38 (s, 12H); ¹⁹F NMR (376 MHz, CDC1₃) δ -110.23 (dd, J= 9.6,4.1 Hz); ESIMS m/z 262 ([M+H]⁺).

Préparation 39: 2-(7-Fluorobenzofuran-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane

2-(7-Fluorobenzofuran-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane was prepared as described in Préparation 36 from 6-bromo-7-fluorobenzofuran: 'H NMR (400 MHz, CDCI3) δ

7.68 (t, .7= 3.1 Hz, 1H), 7.55 (dd, .7=7.8,4.5 Hz, 1H), 7.34 (t,.7= 6.5 Hz, 1H), 6.80 (dd,J=2.9,

2.2 Hz, 1H), 1.38 (s, 12H); ¹⁹F NMR (376 MHz, CDC1₃) δ -127.62 (dd, J= 4.2, 3.1 Hz); ESIMS m/z 262 ([M+H]⁺).

-6817485

Préparation 40: 2-(6-Fluorobenzo[o]thiophen-5-yl)-4,4,5,5-tetramethyI-l,3,2-dioxaborolane and 2-(4-fluorobenzo[Z»]thiophen-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane

2-(6-Fluorobenzo[ô]thiophen-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane and 2-(4fluorobenzo[è]thiophen-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane were prepared as described in Préparation 36 from 5-bromo-4-fluorobenzo[ô]thiophene and 5-bromo-6fluorobenzo[ô]thiophene: *H NMR (400 MHz, CDCl₃) δ 8.20 (d, J= 5.5 Hz, 1H), 7.53 (d, J = 9.3 Hz, 1H), 7.35 (d, 7= 5.5 Hz, 1H), 7.30 (d, J= 5.5 Hz, 1H), 1.39 (s, 12H); *H NMR (400 MHz, CDC1₃) δ 7.69 - 7.61 (m, 2H), 7.47 (d, J= 5.6 Hz, 1H), 7.39 (d, J= 5.6 Hz, 1H), 1.39 (s, 12H); ¹⁹F NMR (376 MHz, CDCI3) δ -107.24, -109.56; ESIMS m/z 278 ([M+H]⁺).

Préparation 41: 2-(5-Fluorobenzo[Z»]thiophen-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane and 2-(5-fluorobenzo [Z>] thiophen-4-yl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane

2-(5-Fluorobenzo[à]thiophen-6-yl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane and 2-(5fluorobenzo[ô]thiophen-4-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane were prepared as described in Préparation 36 from 6-bromo-5-fluorobenzo[ô]thiophene and 4-bromo-5fluorobenzo[è]thiophene: *H NMR (400 MHz, CDCI3) δ 8.26 (d, J= 5.1 Hz, 1H), 7.59 (d, J=

5.4 Hz, 1H), 7.45 (d, J =9.9 Hz, 1H), 7.28 (d, J =5.4 Hz, 1H), 1.39 (s, 12H); ’HNMR (400

MHz, CDCI3) δ 7.92 (d, J= 5.5 Hz, 1H), 7.88 (dd, J= 8.8, 4.9 Hz, 1H), 7.55 (d, J= 5.5 Hz, 1H),

7.07 (t, 7= 9.1 Hz, 1H), 1.42 (s, 12H); ¹⁹FNMR (376 MHz, CDCI3) δ-107.32,-107.34,-107.35, -107.36, -111.00, -111.02, -111.02, -111.03, -111.04, -111.04; ESIMS m/z 278 ([M+H]⁺).

-6917485

Préparation 42: 2-(Benzo[/)]thiophen-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane

6-Bromobenzo[ô]thiophene (3.09 g, 14.5 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'bi(l,3,2-dioxaborolane) (4.42 g, 17.4 mmol), PdC12(dppf) (0.54 g, 0.74 mmol), and KOAc (2.89 g, 29.4 mmol) in anhydrous dioxane (48 mL) was stirred at reflux at 80 °C for 4 h. The reaction mixture was cooled and diluted with ethyl acetate, filtered through a pad of Celite, and washed with brine. The aqueous layer was extracted with ethyl acetate. The organic layers were dried, filtered, and adsorbed onto silica gel. Purification by flash chromatography (0 - 30% ethyl acetate/hexanes) provided 2-(benzo[6]thiophen-6-yl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane (3.266 g, 87%) as a yellow oily solid: ^!H NMR (400 MHz, CDC13) δ 8.38 (d, J= 0.7 Hz, 1H), 7.79 (ddd, J= 20.2, 8.0, 0.8 Hz, 2H), 7.51 (d, J= 5.5 Hz, 1H), 7.34 (dd, J= 5.4, 0.7 Hz, 1H), 1.37 (s, 12H); ¹³C NMR (101 MHz, CDC13) δ 141.78, 129.75, 129.58, 128.18, 123.87, 122.94, 83.89, 24.92; EIMS m/z 260.

Préparation 43: 5-Fluoro-6-(4,4,5,5-tetramethyI-l,3,2-dioxaborolan-2-yl)-lJ7-indole

To a round bottom flask, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (1.424 g, 5.61 mmol), [l,r-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.342 g, 0.467 mmol), and potassium acetate (0.917 g, 9.34 mmol) were charged as solids. The flask was sealed, and pumped and purged (3x) with inert gas. Then 6-bromo-5-fluoro-177-indole (1.0 g, 4.67 mmol) in dioxane (15.57 mL) was added. The reaction mixture was stirred and warmed to an internai température of 85 °C. After 18 h the reaction mixture was cooled and filtered through a pad of Celite, washing with excess ethyl acetate. The filtrate was diluted with water and partitioned. The aqueous layer was extracted with ethyl acetate (3x15 mL). The combined organic layers were dried over MgSC>4, filtered and concentrated in vacuo. The crude product

-7017485 was purified using a Teledyne ISCO purification System with a gradient eluent System of ethyl acetate and hexanes to yield the title compound as a peach-colored solid (656 mg, 54%): *H NMR (400 MHz, DMSO-t/₆) δ 1.31 (s, 12H), 6.42 (ddd, J = 2.9, 1.9, 0.9 Hz, 1H), 7.22 (d, J = 10.5 Hz, 1H), 7.52 (t, J = 2.8 Hz, 1H), 7.69 (d, J = 4.8 Hz, 1H), 11.24 (s, 1H); ¹⁹F NMR (376 MHz, DMSO-Z) δ -116.07; ESIMS m/z 262.0 ([M+H]⁺), 260.0 ([M-H]).

Préparation 44: 7-Bromo-4-chloro-l/7-indole

To a solution of l-bromo-4-chloro-2-nitrobenzene (932 mg, 3.95 mmol) in tetrahydrofuran (10 mL), vinylmagnesium bromide (0.7 M in tetrahydrofuran; 12 mmol) in tetrahydrofuran (15 mL) was added drop wise at -40 °C. After 1 h the reaction mixture was poured into saturated ammonium chloride (NH4CI). The resulting organic layer was concentrated. The resulting residue was purified using a Teledyne ISCO chromatography System with a gradient eluent System of 2% ethyl acetate in hexane to yield the title compound (400 mg, 44%): ’H NMR (300 MHz, CDCI3) δ 6.73 (t, J= 2.8 Hz, 1H), 7.02 (d, J= 8.1 Hz, 1H), 7.19 7.39 (m, 2H), 8.43 (s, 1H).

Préparation 45: 4-Bromo-7-chloro-l//-indole

4-Bromo-7-chloro-lH-indole was prepared from 4-bromo-l-chloro-2-nitrobenzene as described in Préparation 44: *H NMR (300 MHz, CDC1₃) δ 6.49 - 6.74 (m, 1H), 7.07 (d, J= 8.1 Hz, 1H), 7.15 - 7.42 (m, 2H), 8.49 (s, 1H).

Préparation 46: 6-Bromo-7-fluoro-l/f-indole

-7117485

6-Bromo-7-fluoro-l/7-indole was prepared from l-bromo-2-fluoro-3-nitrobenzene as described in Préparation 44 (250 mg, 25.2%): *H NMR (300 MHz, CDCI3) δ 6.52 - 6.62 (m, 1H), 7.13 - 7.34 (m, 3H), 8.38 (s, 1H); ESIMS m/z 215.0 ([M+H]⁺).

Préparation 47 (Precursor Example 1): 4-Chloro-7-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)-l//-indo!e

To a solution of 7-bromo-4-chloro-l/7-indole (8 g, 0.03 mol) in dioxane, KOAc (9.8 g, 0.1 mol), dichloro[l,l’-bis(diphenylphosphino)ferrocene]-palladium(II) (2.19 g, 0.003 mol), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (13.2 g, 0.052 mol) were charged as solids. The reaction mixture was placed under inert atmosphère and the flask was sealed. The reaction was heated to 100 °C for 16 h. The reaction mixture was then treated with H2O and extracted with ethyl acetate. The organic layer was partitioned and concentrated. The resulting residue was purfied using a Teledyne ISCO chromatography System with a gradient eluent System of ethyl acetate in hexane to yield the title compound (1.3 g, 15.6%): ’H NMR (300 MHz, CDCI3) δ 1.40 (s, 12H), 6.58 - 6.73 (m, 1H), 7.14 (d, J= 7.6 Hz, 1H), 7.28 - 7.36 (m, 1H), 7.56 (d, J= 7.6 Hz, 1H), 9.34 (s, 1H).

Préparation 48: 7-Chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaboroIan-2-yl)-l//-indole

7-Chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l/7-indole was prepared as described in Préparation 47 from 4-bromo-7-chloro-l//-indole (4.2 g, 43.7%): ’H NMR (300 MHz, CDCI3) δ 1.38 (s, 26H), 7.08 (dd, J= 3.2, 2.2 Hz, 1H), 7.20 (d, J= 7.6 Hz, 1H), 7.30 (t, J = 2.8 Hz, 1H), 7.56 (d, J= 7.6 Hz, 1H), 8.40 (s, 1H).

-7217485

Préparation 49 (Precursor Example 2): 7-Fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan2-yl)-lH-indole

7-Fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole was prepared as described in Préparation 47 from 6-bromo-7-fluoro-l/7-indole (150 mg, 45.5%): *H NMR (300 MHz, CDC1₃) δ 1.26 (s, 25H), 1.39 (s, 24H), 7.27 (d, J= 4.5 Hz, 2H), 7.40 (d, J= 2.6 Hz, 2H), 8.43 (s, 1H); ¹⁹F NMR (282 MHz, CDC13) δ -124.52; ¹³C NMR (101 MHz, CDC13) δ 24.87 (d, J = 15.9 Hz), 77.30,83.49 (d, J= 6.9 Hz), 103.25, 115.98 (d, J= 3.3 Hz), 126.08 (d, .7=7.7 Hz).

Préparation 50 (Precursor Example 3): 7-FIuoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan2-yl)-l-(triisopropylsilyl)-l/7-indole

7-Fluoro-l-(triisopropylsilyl)-17f-indole (4.0 g, 14 mmol) (Prepared accordingto M. Schlosser, et al., Eur. J. Org. Chem. 2006, 2956-2969) was dissolved in 30 mL dry THF, cooled to -75 °C, treated in portions with sec-butyl lithium (10 mL, 1.4 M, 14 mmol) and stirred for 2 h at -75 °C. 2-Isopropoxy-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (3.0 mL, 2.7 g, 14 mmol) was added in portions and the mixture was stirred for 1 h at -75 °C. The cooling bath was removed and the température was allowed to rise to 5 °C over 30 min. The reaction was quenched by addition of 5 mL saturated NH4CI and partitioned between ethyl acetate and water. The organic phase was washed with saturated sodium chloride (NaCl), dried (Na2SC>4), evaporated onto silica gel, and purified by flash chromatography (SiCh; eluting with hexanes) to give the title compound as a thick oil (4.2 g, 73%): *H NMR (400 MHz, CDC1₃) δ 7.43 (dd, J= 7.9, 4.6 Hz, 1H), 7.38 (m, 2H), 1.75 (m, 3H), 1.38 (s, 12H), 1.13 (d, J = 7.6 Hz, 18H); ¹⁹F NMR (376 MHz, CDCI3) δ -113.07; EIMS m/z 417.

-7317485

Préparation 51: 2-Ethynyl-4,6-difluoroaniline

Step 1: 2-Bromo-4,6-difluoroaniline (10 g, 48 mmol), copper (I) iodide (Cul; 180 mg, 0.96 mmol), bis(triphenylphosphine)palladium(II) chloride (680 mg, 0.96 mmol) and ethynyltrimethylsilane (7.1 g, 72 mmol) were combined with 10 mL dry DMF and heated to 50 °C for 18 h. An additional 2 mL ethynyltrimethylsilane, 200 mg bis(triphenylphosphine)palladium(II) chloride, and 60 mg Cul were added and heating was continued for 4 h. After cooling, the mixture was diluted with ethyl acetate and stirred with 1 normal (N) hydrochloric acid (HCl). The dark mixture was filtered through Celite to remove fine solids. The organic phase was washed with water, saturated NaCl, dried and concentrated. Purification by flash chromatography (SiC>2, eluting with 0-20% EtOAc in hexanes) afforded 9 g of material that consisted of a 70/30 ratio of the TMS alkyne dérivative and the starting bromide.

Step 2: The mixture was carried in to the desilylation without further purification. The TMS dérivative was dissolved in methanol (500 mL) and treated with 8.5 g KF. A clear solution formed which was stirred ovemight at room température (RT). Most of the volatiles were removed under vacuum, the residue was taken up in ethyl acetate and washed water and with saturated NaCl. The solution was dried, evaporated and purified by flash chromatography (S1O2, eluting with 0-10% ethyl acetate in hexanes) to provide the title compound (4.2 g, 70 area % pure by flame-ionization detector-gas chromatography (FID-GC)): *H NMR (400 MHz, CDCI3) δ 6.83 (m, 1H), 4.13 (m, 1H), 3.46 (s, 1H); ¹⁹F NMR (376 MHz, CDCI3) δ -124.04, 124.88, -126.94, -130.08; EIMS m/z 153. This material was carried through to the cyclization step without further purification.

Préparation 52: 5,7-Difluoro-lZT-indole

F

The impure 2-ethynyl-4,6-difluoroaniline (4.2 g, 19 mmol) from the previous préparation was dissolved in éthanol (75 mL), treated with sodium gold(III) chloride dihydrate

-7417485 (310 mg, 0.77 mmol) and stirred for 3 h under an atmosphère of nitrogen. The mixture was concentrated, taken up in ethyl acetate, washed with water, washed with saturated NaCl, dried over sodium sulfate (NaiSOzi) and evaporated. Purification by flash chromatography (SiO2, 100-200 mesh; eluting with 0-15% EtOAc in hexanes containing 2% acetic acid) provided the title product (2.0 g, ca 85% purity): *H NMR (400 MHz, CDC1₃) δ 8.32 (s, 1H), 7.26 (dd, J= 4.8, 2.0 Hz, 1H), 7.09 (dd, J= 9.1, 2.2 Hz, 1H), 6.74 (ddd, J= 11.2, 9.3, 2.0 Hz, 1H), 6.55 (td, J = 3.3, 2.2 Hz, 1H); ¹⁹F NMR (376 MHz, CDC1₃) δ -122.11, -131.96; EIMS m/z 153.

Préparation 53: 5,7-Difluoro-l-(triisopropylsilyl)-l//-indole

A-Butyl lithium (2.7 mL, 2.5 M, 6.9 mmol) was added to 10 mL dry THF at -70 °C. 5,7-Difluoro-177-indole (1.0 g, 6.5 mmol) in 5 mL THF was added in portions to the solution and the mixture was stirred for 30 min at -75 ⁰ C. Triisopropylchlorosilane (1.5 mL, 1.3 g, 6.9 mmol) was added, stirring was continued for 1 h at -75 °C and then the mixture was allowed to warm to -5 °C over 2 h. After treatment with 5 mL saturated NH4CI, the mixture was mixed with 30 mL ether and the organic phase was washed with 5 mL saturated NaCl, dried (Na2SC>4) and evaporated. The product was purified by flash chromatography(SiO2; hexanes) to provide the title compound as a clear oil (1.5 g; 74%): *H NMR (400 MHz, CDCI3) δ 7.35 (d, J= 3.1 Hz, 1H), 7.07 (dd, J= 8.7, 2.3 Hz, 1H), 6.69 (m, 1H), 6.59(t, J= 3.1 Hz, 1H), 1.67 (m, 3H), 1.13 (d, J= 7.6 Hz, 18H); ^l9F NMR (376 MHz, CDCI3) δ -120.64, -120.65, -122.49, -122.49; EIMS m/z 309.

Préparation 54: 5,7-Difluoro-6-iodo-l-(triisopropyIsilyl)-ljî-indole

-7517485

5,7-Difluoro-l-(triisopropylsilyl)-177-indole (1.4 g, 4.5 mmol) and pentamethyldiethylene -triamine( 830 mg, 4.8 mmol) were combined in 10 mL dry THF, cooled to -70 °C and treated in portions with sec-butyl lithium (3.4 mL, 1.4 M, 4.8 mmol) and stirred for 3 h at this température. Iodine (1.3 g, 5.0 mmol) in 5 mL THF was added, the mixture was stirred for 50 min, quenched by addition of 3 mL saturated NH4CI and partitioned between diethyl ether and water. The organic phase was washed with saturated NaCl, dried (Na₂SO₄), evaporated and purified by flash chromatography (SiO₂; hexanes) to provide the title compound as a clear oil which solidified on standing (1.9 g, 90%): mp 74-76 °C; *H NMR (400 MHz, CDC1₃)Ô7.34 (d, J =3.1 Hz, 1H), 7.14 (dd, J= 7.7, 0.9 Hz, 1H), 6.60 (t,J=3.1 Hz, 1H), 1.67 (m,3H), 1.13 (d, J=7.6 Hz, 18H); ¹⁹F NMR (376 MHz, CDC1₃) δ-101.37,-105.33.

Préparation 55: 2-(2,2-dimethylbenzo[d] [l,3]dioxol-5-yl)-4,4,5,5-tetramethyl-l,3,2dioxaborolane

To DMSO (lOmL) was added potassium acetate (1.671 g, 17.03 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (1.729 g, 6.81 mmol), 5-bromo2,2-dimethylbenzo[d][l,3]dioxole (1.3 g, 5.68 mmol), and PdC12(dppf) (0.415 g, 0.568 mmol). The reaction was heated to an extemal température of 80 °C for 18 hours. Upon cooling, the reaction was poured reaction into 50mL ice water. The ice water mixture was transferred to a separatory funnela and two extractions with EtOAc (50mL) were completed. The organic layers were combined, dried over Na₂SO₄, and filtered. The solutiown was concentrated onto 5g of celite using EtOAc as solvent. The impregnated celite was loaded onto a Teledyne Isco purification System and purified by silica gel chromatograpy using 0-30% EtOAc:hexanes to yield 2-(2,2dimethylbenzo[d][l,3]dioxol-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (767mg, 49%) as a red semi-solid: *H NMR (400 MHz, CDC1₃) δ 7.31 (dt, J= 6.6, 3.3 Hz, 1H), 7.15 (s, 1H), 6.74 (d,J=7.7 Hz, 1H), 1.66 (s, 6H), 1.32 (s, 12H); ¹³CNMR(101 MHz, CDCI3) δ 129.21 (s), 113.78 (s), 108.15 (s), 83.59 (s), 25.86 (s), 24.82 (s); ESIMS m/z 277 ([M+H]⁺), 275 ([M-H]').

-7617485

EXAMPLES OF SYNTHESIS OF COMPOUNDS OF FORMULA (I)

Example 1. Methyl 4-amino-3-chloro-5-fluoro-6-(7-fluoro-lÆ-indol-6-yl)picolinate (Compound No. 1.14)

Methyl 4-amino-3,6-dichloro-5-fluoropicolinate (0.650 g, 2.72 mmol), 7-fluoro-6(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-17/-indole (0.817 g, 3.13 mmol), bis(triphenylphosphine)palladium(II) chloride (0.191 g, 0.272 mmol), and césium fluoride (0.826 g, 5.44 mmol) were combined in acetonitrile (4.53 mL) and water (4.53 mL). The reaction mixture was irradiated in a Biotage Initiator microwave at 110 °C in a sealed vial for 30 min. The cooled reaction mixture was partitioned between ethyl acetate and water. The organic phase was dried and concentrated. The product was purified by flash chromatography (SiCh; eluting with 5-40% ethyl acetate in hexanes) to provide the title compound as an white solid (0.517 g, 52.4 % yield). Note: Potassium fluoride replaced césium fluoride in some examples that refer to this particular example.

The préparation method used in this example is referred to in Table 10 as “Coupling 1”.

Example 2: Methyl 4-amino-3-chloro-5-fluoro-6-(lZ7-indol-5-yl)picolinate (Compound No.

1-2)

CH lH-Indol-5-ylboronic acid (220 mg, 1.4 mmol, 1.1 equiv) and methyl 4-amino-3,6dichloro-5-fluoropicolinate (300 mg, 1.3 mmol, 1.0 equiv) were sequentially added to a 5 mL Biotage microwave vessel, followed by césium fluoride (380 mg, 2.5 mmol, 2.0 equiv), palladium(II) acetate (14 mg, 0.063 mmol, 0.05 equiv), and sodium 3,3',3

-7717485 phosphinetriyltribenzenesulfonate (71 mg, 0.13 mmol, 0.10 equiv). A 3:1 mixture of water:acetonitrile (2.5 mL) was added and the resulting dark brown mixture was placed in a Biotage microwave and heated to 150 °C for 5 min, with extemal IR-sensor température monitoring from the side of the vessel. The cooled reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (15 x 30 mL). The combined organic layers were dried (sodium sulfate), gravity filtered, and concentrated by rotary évaporation. The residue was purified by reverse phase column chromatography (5% acetonitrile to 100% acetonitrile gradient) to yield the title compound as a tan powder (290 mg, 73%).

The préparation method used in this example is referred to in Table 10 as “Coupling 2”.

Example 3: Methyl 4-amino-6-(benzo[iZ]thiazol-5-yl)-3-chloro-5-fluoropicolinate (Compound No. 6.1)

To a 5 mL microwave vial was added methyl 4-amino-6-bromo-3-chloro-5fluoropicolinate (200 mg, 1.0 mmol), benzo[<7]thiazol-5-ylboronic acid (237 mg, 1.35 mmol), potassium fluoride (KF; 122 mg, 2.12 mmol), TPPTS-Na (tris-(3-sulfomatophenyl)-phosphine4hydrate sodium sait, 67 mg, 0.106 mmol) and Pd(OAc)2 (11 mg, 0.053 mmol). Subsequently, CH3CN (1.0 mL) and H2O (3.0 mL) were added, and the reaction vial was sealed and heated in a Biotage micro wave at 150 °C for 5 min, with extemal IR-sensor température monitoring from the side of the vessel. The reaction mixture was cooled to room température and diluted with dichloromethane, and washed with water. The organic extracts were combined, dried (Na2SÛ4), filtered, and concentrated in vacuo. The crude product was purified by triturating with diethyl (Et₂O) to yield the title compound as a brown solid (172 mg, 51%).

The préparation method used in this example is referred to in Table 10 as “Coupling 3”.

-7817485

Example 4: Methyl 4-amino-6-(benzo[h]thiophenyl-5-yl)-3,5-dichloropicolinate (Compound

No. 3.1)

To a 5 mL microwave vial was added methyl 4-amino-3,5,6-trichloropicolinate (0.232 g, 0.909 mmol), 2-(benzo[h]thiophen-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (0.260 g, 0.999 mmol), césium fluoride (0.276 g, 1.817 mmol) and (PPl^PdCh (0.064 g, 0.091 mmol). The reaction vial was then sealed and placed under inert atmosphère. Subsequently, dioxane (4.0 mL) and H2O (1.0 mL) were added and the reaction mixture was heated in a Biotage microwave at 120 °C for 60 min, with extemal IR-sensor température monitoring from the side of the vessel. The reaction mixture was cooled to room température and diluted with ethyl acetate (5 mL) and poured into brine solution. The layers were separated and the aqueous phase was extracted with ethyl acetate (3x10 mL). The organic extracts were combined, dried (MgSCU), fîltered, and concentrated in vacuo. The crude product was purified using a Teledyne ISCO purification System with a gradient eluent System of ethyl acetate and hexanes. Further purification was performed, as needed, using a Teledyne ISCO reverse phase System with a gradient eluent System of acetonitrile and H2O to yield the title compound as a white solid.

The préparation method used in this example is referred to in Table 10 as “Coupling 4”.

Example 5: Methyl 4-amino-3-chloro-6-(7-chlorobenzofuran-4-yl)-5-fluoropicolinate (Compound No. 2.16)

CH₃

Potassium fluoride (0.365 g, 6.28 mmol), palladium diacetate (0.047 g, 0.209 mmol),

2-(7-chlorobenzofuran-4-yl)-5,5-dimethyl-l,3,2-dioxaborinane (0.609 g, 2.301 mmol), sodium

3,3',3-phosphinetriyltribenzenesulfonate tetrahydrate (0.134 g, 0.209 mmol), and methyl 4

-7917485 amino-3,6-dichloro-5-fluoropicolinate (0.5 g, 2.092 mmol) were combined in a microwave reactor vial. To these were added water (3 mL) and acetonitrile (1 mL). The reaction mixture was heated at 150 °C in a microwave reactor for 6 min. The cooled reaction mixture was diluted with ethyl acetate and water and filtered through a cotton plug. The organic phase was dried (Na2SC>4) and concentrated under vacuum. Purification by reverse phase chromatography provided the title compound as a white solid (127 mg, 12.5% yield).

The préparation method used in this example is referred to in Table 10 as “Coupling 5”.

Example 6 Methyl 4-amino-3-chloro-6-(7-fluoro-l/7-indol-6-yl)picolinate (Compound No.

1.22)

Methyl 4-acetamido-3,6-dichloropicolinate (400 mg, 1.520 mmol),7-fluoro-6(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-177-indole (437 mg, 1.673 mmol), césium fluoride (462 mg, 3.04 mmol), and (PPl^PdCh (107 mg, 0.152 mmol) were charged as solids into a micro wave reaction vessel and dioxane (4 mL) and water (1 mL) were added. The reaction vessel was sealed and irradiated in a Biotage Initiator microwave at 110 °C for 2 h, with extemal IR-sensor température monitoring from the side. The reaction mixture was partitioned between ethyl acetate and water. The organic phase was filtered and concentrated. The intermediate product was purified by flash chromatography (ISCO 40 g silica 10-75% EtOAc: Hexanes 16 CV). Fractions containing product were combined and concentrated to give 524 mg of a white solid intermediate methyl 4-acetamido-3-chloro-6-(7-fluoro-lH-indol-6-yl)picolinate (0.524 g, 1.448 mmol) which was subsequently diluted with methanol (10.0 mL). Then acetyl chloride (0.725 mL, 10.20 mmol) was added. The reaction mixture was allowed to stir at room température for 18 h. The reaction mixture was concentrated to dryness. The resulting residue was dissolved in ethyl acetate and poured into saturated NaHCCh solution. The layers were partitioned and the aqueous layer was extracted with ethyl acetate (3x15 mL). The organic extracts were combined, washed with saturated NaCl solution, dried (MgSÛ4), filtered and concentrated in vacuo. The crude product was purified using a Teledyne ISCO purification

-8017485

System with a gradient eluent System of ethyl acetate and hexanes to yield the title compound as a white solid (365 mg, 79%).

The préparation method used in this example is referred to in Table 10 as “Coupling 6”.

Example 7: Methyl 4-amino-3-chloro-6-(5,7-difluoro-l//-indoI-6-yI)picolinate (Compound No. 1.26)

5,7-Difluoro-6-iodo-l-(triisopropylsilyl)-17/-indole (450 mg, 1.0 mmol), methyl 4acetamido-3-chloro-6-(trimethylstannyl)picolinate (450 mg, 1.1 mmol) were combined in 7 mL dry DMF, deaerated with a stream of nitrogen for 15 min, treated with bis(triphenylphosphine)palladium(II) chloride (72 mg, 0.10 mmol) and copper (I) iodide and heated to 60 °C for 2 h. The mixture was partitioned between ethyl acetate and water. The organic phase was washed with water, washed with saturated NaCl, dried (Na2SÛ4), and evaporated. Purification by flash chromatography (S1O2, 100-200 mesh; eluting with 0-30% EtOAc in hexanes) provide 200 mg of the silylated TV-acetamide product. This material was slurried in methanol (15 mL), treated with 2 mL acetyl chloride and heated at reflux for 2 h. The volatiles were removed under vacuum and the residue was purified by flash chromatography (S1O2; 0-40% ethyl acetate in hexanes) to provide 30 mg of the title compound plus 60 mg of title compound that was still protected by the TIPS group on the indole nitrogen. The TIPS dérivative was dissolved in 5 mL dry THF, treated with tetrabutylammonium fluoride hydrate (140 mg, 0.5 mmol) and stirred for 1 h at 20 °C. The mixture was partitioned between 20 mL ethyl acetate and saturated NaCl. The organic phase was dried (Na2SÛ4) and evaporated. Purification by flash chromatography (SiO2; 0-50% ethyl acetate in hexanes) provided another 30 mg of the title compound as a white solid (60 mg, 16%).

The préparation method used in this example is referred to in Table 10 as “Coupling 7”.

-8117485

Example 8: Methyl 4-amino-3-chIoro-5-fluoro-6-(7-fluoro-127-indol-6-yl)picolinate (Compound No. 1.14)

7-Fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(triisopropylsilyl)-l/7indole (500 mg, 1.2 mmol), methyl 4-amino-3,6-dichloro-5-fluoropicolinate (290 mg, 1.2 mmol), césium fluoride (360 mg, 2.4 mmol) and bis(triphenylphosphine)palladium(II) chloride (84 mg, 0.12 mmol) were combined in 4 mL of a 1:1 v/v acetonitrile-water mixture and heated at 115 °C for 25 min in a Biotage Initiator microwave reactor. The mixture was partitoned between ethyl acetate and saturated NaCl and the organic phase was dried and evaporated. Purification by flash chromatography (SiO₂; eluting with 0-20% ethyl acetate in dichloromethane) provided impure product. The material was purified by flash chromatography again (SiO₂; eluting with 0-30% ethyl acetate in hexanes) to provide the title compound as a white solid (220 mg, 52%).

The préparation method used in this example is referred to in Table 10 as “Coupling 8”.

Example 9: Methyl 4-amino-5-fluoro-6-(7-fluoro-117-indol-6-yl)-3-vinylpicolinate (Compound No. 1.17)

7-Fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(triisopropylsilyl)-l/7indole (320 mg, 0.77 mmol), methyl 4-amino-6-chloro-5-fluoro-3-vinylpicolinate (190 mg,0.84 mmol), sodium carbonate (81 mg, 0.77 mmol) and bis(triphenylphosphine)palladium(II) chloride (54 mg, 0.08 mmol) were combined in 4 mL of a 1:1 v/v acetonitrile-water mixture and heated to 115 °C for 30 min in a Biotage Initiator microwave reactor. The mixture was partitioned between ethyl acetate and water. The organic phase was washed with saturated NaCl, dried (Na₂SO4), and evaporated. Purification by flash chromatography (SiO₂; eluting with 0-20%

-8217485 ethyl acetate in hexanes) provided 220 mg of the TIPS protected product. This material was dissolved in 10 mL of THF, treated with tetrabutylammonium fluoride hydrate (260 mg, 1.0 mmol) and stirred for 1 h. The mixture was partitioned between saturated NaCl and ethyl acetate. The organic phase was washed with saturated NaCl, dried (Na₂SO4), and evaporated. Purification by flash chromatography (SiO₂; eluting with 0-20% ethyl acetate in hexanes) provided the title compound as a white solid (100 mg, 37%).

The préparation method used in this example is referred to in Table 10 as “Coupling 9”.

Example 10: Préparation of methyl 4-amino-3-chloro-5-fluoro-6-(7-fluoro-l(triisopropylsilyl)- l/7-indol-6-yl)picoIinate (Compound 1.12)

7-Fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(triisopropylsilyl)-l//indole (1.0 g, 2.4 mmol), methyl 4-amino-3,6-dichloro-5-fluoropicolinate (630 mg, 2.6 mmol), sodium carbonate (250 mg, 2.4 mmol) and with bis(triphenylphosphine)palladium(II) chloride (170 mg, 0.24 mmol) were combined in 10 mL of 1:1 v/v acetonitrile-water and heated at 110 °C for 30 min in a Biotage Initiator microwave reactor. The mixture was stirred with 30 mL ethyl acetate and 20 mL water and filtered through glass wool to remove dark solids. The organic phase was washed with saturated NaCl, dried (Na₂SO4), and evaporated. Purification by flash chromatography (SiO₂; eluting with 0-30% ethyl acetate in hexanes) provided the title compound as a white solid (520 mg; 42%).

The préparation method used in this example is referred to in Table 10 as “Coupling 10”.

-8317485

Example 11: Methyl 4-ammo-6-(3-bromobenzo[/>]thiophen-7-yl)-3-chloro-5fluoropicolinate (Compound No. 3.26)

Methyl 4-amino-6-(benzo[ô]thiophen-7-yl)-3-chloro-5-fluoropicolinate (0.500 g,

1.485 mmol) was dissolved in dichloromethane (9.90 mL) and cooled to -5 °C in an acetone bath to which was added a few pièces of dry ice. Bromine (114 pL, 2.227 mmol) was dissolved in dichloromethane (9.90 mL) and added dropwise. The reaction mixture was stirred ovemight, and then partitioned between ethyl acetate and water. The organic phase was dried and concentrated and the product purified by flash chromatography (S1O2; 5-40% ethyl acetate / hexane gradient) followed by a second purification by reverse phase chromatography to provide the title compound as a grey solid (0.278 g, 45%).

Example 12: 4-Amino-3-chloro-5-fluoro-6-(7-fluoro-l//-indol-6-yl)picolinic acid (Compound 1.38)

To a reaction vessel containing methyl 4-amino-3-chloro-5-fluoro-6-(7-fluoro-lHindol-6-yl)picolinate (0.500 g, 1.481 mmol) was added methanol (14.81 mL) and sodium hydroxide (2.96 mL, 5.92 mmol). The reaction mixture was stirred ovemight at RT then acidfied by adding a slight excess of 2 N HCl. The mixture was concentrated and the precipitate that formed was washed with water and dried under vacuum to provide 4-amino-3-chloro-5-fluoro-6(7-fluoro-177-indol-6-yl)picolinic acid (0.400 g, 79% yield) as an off-white solid.

The préparation method used in this example is referred to in Table 10 as “Hydrolysis 1:.

-8417485

Example 13: 4-Amino-6-(benzo[6]thiophen-5-yl)-3,5-dichloropicolinic acid (Compound 3.2)

In a 100 mL round bottom flask, methyl 4-amino-6-(benzo[6]thiophen-5-yl)-3,5dichloropicolinate (210 mg, 0.595 mmol) was dissolved in methanol (2.3 mL), tetrahydrofuran (2.3 mL), and H2O (1.2 mL). Lithium hydroxide hydrate (74.8 mg, 1.784 mmol) was added as a solid. The reaction mixture was stirred at room température until complété. The reaction mixture was concentrated to dryness. The resulting residue was dissolved in H2O (2.0 mL) and 1 N HCl was used to adjust the pH to 3.0, causing a precipitate to form. This suspension was extracted with ethyl acetate (3x15 mL). The organic extracts were combined, washed with saturated NaCl solution, dried (MgSCU), filtered and concentrated. Additional purification of the resulting solid was performed, as needed, using a Teledyne ISCO reverse phase System with a gradient eluent System of acetonitrile and H2O to yield the title compound as a white solid (110 mg, 55%).

The préparation method used in this example is referred to in Table 10 as “Hydrolysis 15 2”.

Table 10. Compound Number, Structure, Appearance, and Préparation Method

Compound Number	Structure	Appear- ance	Préparation Method:	Precursor(s)
1.01	nh₂ /L· JL· /Oh il ^N XL· ° Hsc-v ητ	White Powder	Hydrolysis 1	Compound 1.03

-8517485

Compound Number	Structure	Appear- ance	Préparation Method:	Precursor(s)
			nh₂
		F.	J_r ^c·
1.02		ίΓπ	Λ\/Ο. ^N γΓ	ch₃	Tan Powder	Coupling 2	As described
	HN		0
			nh₂
		F	Vy^c1				Head B;
1.03		J< x<J	X- /G N o	ch₃	White Powder	Coupling 2	1-Methyl-1Hindol-5-
	H₃c-						ylboronic acid
			nh₂
		F.	yV^ci
1.04			J-L N Y	_ZOH	Tan Powder	Hydrolysis 1	Compound 1.02
	HN'		0
			nh₂
		Cl.	Αγ⁰¹				Head H;
1.05	X		N 0	ch₃	Yellow Solid	Coupling 1	(12/-indol-6yl)boronic acid
	V	NH
			nh₂
		^Cl\	J^XI
1.06			Ji <>L. . N γ	OH	Yellow Solid	Hydrolysis 1	Compound 1.05
			0
	c	—NH

-8617485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
1.07	nh₂ Ut Λ r il ^N if ^CHs ⁰ V-NH	White Solid	Coupling 9	Head H
1.08	nh₂ yx X. Xa f X N Y ^CH3 XX ° Xnh	Off-White Foam	Coupling 2	Head B; 177-Indol-6ylboronic acid
1.09	nh₂ R^Lzi U^- JU /°^hil ^N xx ° Xnh	White Powder	Hydrolysis 1	Compound 1.08
1.10	nh₂ uf5r^cl r ^{N CH3} AX o v_N ^r ch₃	Tan Powder	Coupling 2	Head B; 1 -Methyl-6(4,4,5,5tetramethyl1,3,2dioxaborolan2-yl)-177indole
1.11	nh₂ ^FJy=' aAV^hAZ ⁰ Y CH.	Pale Yellow Powder	Hydrolysis 1	Compound 1.10

-8717485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
1.12	nh₂ F-yk/Ci Λ N CH₃ V-n ^XSi(/-Pr)₃	White Solid	Coupling 10	Head B
1.13	nh₂ _F ^f-A<^cixA H ^N [Γ ^CHs ° \^NH	Off-White Solid	Coupling 4	Head B; 5-fluoro-6(4,4,5,5tetramethyl1,3,2dioxaborolan2-yl)-17findole
1.14	nh₂ _F Uy Λ/'ν^τ^οη ⁰ V- NH	Tan Solid	Hydrolysis 2	Compound 1.13
1.15	nh₂ ^fyV^ci/Y >1 /0^ fl ^N iT ^CH3 JA ⁰ 'c—NH	White Solid	Coupling 4	Head B; 7-fluoro-6(4,4,5,5tetramethyl1,3,2dioxaborolan2-yl)-177indole
1.16	nh₂ ^f.X=' ^vUf AA_f ° v— NH	Tan Solid	Hydrolysis 2	Compound 1.15

-8817485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
1.17	nh₂ ch₃ ^F °	White Solid	Hydrolysis 1	Compound 1.20
1.18	nh₂ çh₂ JL .0^ 1 II ^{N CH3} AA o NH	White Solid	Coupling 9	Head G
1.19	nh₂ çh₂ Γ¥^ν^Τ°^η ^{F 0}	Tan Solid	Hydrolysis 1	Compound 1.18
1.20	nh₂ ch₃ N^<^J^x'°^CH₃ AA ⁰V^NH	White Solid	Coupling 8	Head F
1.21	nh₂ A J\ il ^N [Γ ^CHs JU ⁰ NH	White Solid	Coupling 1	Head A, (lH-indol-6yl)boronic acid

-8917485

Compound Number	Structure	Appear- ance	Préparation Method:	Precursor(s)
1.22	nh₂ JL /OH il ^N îf AA ° NH	Orange Solid	Hydrolysis 1	Compound 1.21
1.23	nh₂ A/^ci J-L A λ il ^{N CHs} ° v—NH	White Solid	Coupling 6	As described
1.24	nh₂ ίΊ θ' iqLⁿA°^h v—-NH	Yellow Solid	Hydrolysis 2	Compound 1.23
1.25	nh₂ ^f A^CI Â. A <A /0^ l· ^N lT ^CH3 AA o Anh	White Solid	Coupling 6	Head L; 5fluoro-6(4,4,5,5tetramethyl1,3,2dioxaborolan- 2-yl)-l/7indole
1.26	nh₂ ^F iiV /'ίΓ^ζ'Τ°^Η/// ° AnH	White Solid	Hydrolysis 2	Compound 1.25

-9017485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
1.27	nh₂ ^F n^cl /L Al A\ /°r il ^N lT ^CH3 ^{F 0} Anh	White Solid	Coupling 7	Head K
1.28	nh₂ ^H3^CvK/^CI fl ^{N CH}3 AA o Anh	Yellow Powder	Coupling 1	Head D; (177-indol-6yl)boronic acid
1.29	nh₂ ^H3^C\A/^CI /^ A -A /OH Ci ^N * Anh	Pale Pink Flaky Solid	Hydrolysis 1	Compound 1.28
1.30	nh₂ A xi i A\| n^Y°ch₃ AA ° Anh	White Solid	Coupling 1	Head E
1.31	nh₂ A /^Cl Ί Ay AC<⁰ch₃ ⁰ 'Y—N H	Yellow Solid	Coupling 8	Head E

-9117485

Compound Number	Structure	Appear- ance	Préparation Method:	Precursor(s)
				nh₂	ch₃			Head C;
			N jl		0			6-(4,4,5,5tetramethyl-
1.32	f\|			N	~]f ch₃	White Solid	Coupling 4	1,3,2dioxaborolan-
	v	NH			0			2-yl)-177indole
				nh₂	O
			N	ch₃
1.33				N	Ύχ^οη	Yellow Solid	Hydrolysis 2	Compound 1.32
	c				0
	—NH
				nh₂	o			Head C; 7-fluoro-6-
			N		ch₃			(4,4,5,5-
			J!		..CL			tetramethyl-
1.34	îî			N	Y ch₃	White Solid	Coupling 4	1,3,2-
					0			dioxaborolan-
	v		F					2-yl)-177-
	NH						indole
				nh₂	n
				N'^A	< ch₃
1.35				N	\z^OH	Yellow Solid	Hydrolysis 2	Compound 1.34
	c			F	0
	—NH
				nh₂	o			Head C; 5-fluoro-6-
		F	N		ch₃			(4,4,5,5-
1.36			1	\ -Α- Ν	ch₃	White Solid	Coupling 4	tetramethyl- 1,3,2-
	1!				o			dioxaborolan-
	v.							2-yl)-177-
	-NH						indole

-9217485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
		nh₂
	F	A N CH₃
1.37	(Γι'	A A .OH N ]<	Yellow Solid	Hydrolysis 2	Compound 1.36
		0
	V-nh
		nh₂ ch₂

1.38	yzz	^/γ%Η₃	Tan Solid	Coupling 8	HeadP
	A-NH	0 F
		nh₂ ch₂r il
		nAZ
1.39		A <A /OH	White Solid	Hydrolysis 1	Compound 1.38
	/A^ V-NH	k o F
		nh₂			Head B;
1.40	R	fl ⁰¹ ^Ν^<>γ^χ0^ΟΗ₃	White Solid	Coupling 1	4-(4,4,5,5tetramethyl1,3,2dioxaborolan-
	AA\ HN—-V	O			2-yl)-17Z- indole
1.41	F^	nh₂ Uy ^ClA <A /0^ N ]< CH₃	White Solid	Coupling 1	Head B; l-methyl-4(4,4,5,5tetramethyl1,3,2-
	AA\	0			dioxaborolan-
	M h₃c				2-yl)-lÆ- indole

-9317485

Compound Number	Structure	Appear- ance	Préparation Method:	Precursor(s)
			nh₂
			'ϊΓί'	/Cl
1.42			AL xY N	V^/0H	Off-White Solid	Hydrolysis 1	Compound 1.41
				0
		U /
		H₃C
			nh₉				Head B;
		R		XI			7-chloro-4-
			NI			(4,4,5,5-
			Jt Λ	/0^			tetramethyl-
1.43			N	'-'Ηβ	White Solid	Coupling 4	1,3,2-
	Cl			0			dioxaborolan-
	A //					2-yl)-177-
		HN—					indole
							Head L; 7-
			nh₂				chloro-4-
				XI			(4,4,5,5-
1.44			C X N	x^ Y ch₃	Off-White Solid	Coupling 6	tetramethyl- 1,3,2-
		1 1				dioxaborolan-
	Cl	X\<X\ HN—		0			2-yl)-17/-
						indole
							Head C;
			nh₂				7-chloro-4-
			N'X	X^ ch₃			(4,4,5,5-
1.45			a X N	>< ch₃	Off-White Solid	Coupling 4	tetramethyl- 1,3,2-
						dioxaborolan-
	Cl	HN—		0			2-yl)-177-
						indole
			NH2				Head B;
				XI			4-chloro-7-
						(4,4,5,5-
				/0-			tetramethyl-
1.46			N	Y ch₃	White Solid	Coupling 4	1,3,2-
	Cl	/A		0			dioxaborolan-
	Ύ NH				2-yl)-lZ7-
							indole

-9417485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
			nh₂					Head B;
		R					7-(4,4,5,5-
						Off-White		tetramethyl-
1.47			\ <A N [i	_XO	''CH·,	Solid	Coupling 1	1,3,2-
				V» IJ		dioxaborolan-
		⁰ NH					2-yl)-lÆ-
						indole
			nh₂
		F,	yA	Cl
1.48			xk. -ixk^ N		,OH	Tan Solid	Hydrolysis 1	Compound 1.47
		AA		0
		\ -	NH
			nh₂	Cl				Head L; 4chloro-7-
			ΑΥκ				(4,4,5,5-
1.49	Cl	A	xA> A< N	0	CK ch₃	Off-White Solid	Coupling 6	tetramethyl - 1,3,2dioxaborolan-
		NH					2-yl)-177-
								indole
			nh₂	XL				Head C; 4-chloro-7-
			nA	ch₃			(4,4,5,5-
1.50		iPi	A A N		-CK ch₃	Off-White Solid	Coupling 4	tetramethyl- 1,3,2-
	Cl	AA		0			dioxaborolan-
		NH					2-yl)-ltt-
								indole
			nh₂
		F.	A	Cl	CK ch₃			Head B; 2(benzofuran-5-
2.01		/¾.	xL> xK N		Yellow	134	yl)-4,4,5,5-
	1		0		Solid	tetramethyl-
	o'	AA					1,3,2-
	z=J						dioxaborolane

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
		nh₂
		V\	Cl
2.02		ζ J N		OH	White Solid	Hydrolysis 1	Compound 2.01
			0
	⁰ /
		nh₂
2.03			.Cl 0		Yellow Solid	Coupling 1	Head L; benzofuran-5-
	CQ	N	0	^xCH₃		ylboronic acid

		nh₂					Head A; 2-(6-
	F <		Cl				fluorobenzofur
2.04	I fi ilT	/À N	0	ch₃	Off-White Solid	Coupling 1	an-5-yl)- 4,4,5,5-
			0			tetramethyl-
	⁰ /					1,3,2-
						dioxaborolane
		nh₂	çh₃				Head C; 2-(6-
	F <	A/	.0				fluorobenzofur
	1 I		0				an-5-yl)-
2.05		N	ΌΗ·>	White Solid	Coupling 1	4,4,5,5-
	fi T	0				tetramethyl-
	⁰ /					1,3,2-
						dioxaborolane
		nh₂	çh₃ ,0
	N
	Jl		0		Lt Yellow		Head C;
2.06		N	ch₃	Oil At	Coupling 1	benzofuran-5-
	jJ		0		Room Temp		boronic acid
	o

-9617485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
2.07	nh₂ ^FXf^cl /^ Ul A il ^N if ch₃ °	White Solid	134	Head B; 2(benzofuran-6- yl)-4,4,5,5tetramethyl1,3,2dioxaborolane
2.08	nh₂ X X /OH ^N if /X ⁰ Vo	Off-White Solid	Hydrolysis 1	Compound 2.07
2.09	nh₂ Cl /^ /A U\ X il ^N if ^CH3 J'/f O V— O	Light Yellow Solid	Coupling 1	Head B; 2-(7fluorobenzofur an-6-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
2.10	nh₂ F Xf⁰¹ /V /Λ x [f^y ^N [f ^ch3 °	White Solid	Coupling 1	Head B; 2-(5fluorobenzofur an-6-yl)- 4,4,5,5tetramethyl1,3,2dioxaborolane
2.11	nh₂ /L^^c\|/<\ UL /Οχ. r il ^N if ^Ch*³ ⁰	Off-White Solid	Coupling 1	Head A; 2-(7fluorobenzofur an-6-yl)4,4,5,5tetramethyl1,3,2dioxaborolane

-9717485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
2.12	nh₂ F A^^ci JL 1 II ^N 1Γ ^CHs\/ ⁰	Beige Solid	Coupling 1	Head A; 2-(5fluorobenzofur an-6-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
2.13	nh₂ ch₃n^zK^/O N^Y°^CH₃ AA_f ° U	White Solid	Coupling 1	Head C; 2-(7fluorobenzofur an-6-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
2.14	nh₂ ch₃ J^ /0 F N J^ JL r il ^{N CH3} A^J ⁰ v<T	Off-White Solid	Coupling 1	Head C; 2-(5fluorobenzofur an-6-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
2.15	nh₂ br><⁰^CH₃ °	White Solid	Coupling 5	Head B; 2- (benzofuran-4- yl)-4,4,5,5tetramethyl1,3,2dioxaborolane
2.16	nh₂ ^FW^CI A zU Il ^N if ^CH3 c, JLîJx ⁰ o*-!]	White Solid	Coupling 5	Head B; 2-(7chlorobenzofor an-4-yl)-5,5dimethyl-1,3,2dioxaborinane

-9817485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
2.17	nh₂ Ογ<=1 Cï ^N ÏÏ°^H\/ °	Tan Solid	Hydrolysis 1	Compound 2.15
2.18	nh₂ F^X,CI /^. /-U J-L /OH H ^N 1Γ X ⁰o^/	Off-White Solid	Hydrolysis 1	Compound 2.16
2.19	nh₂ X/d XK il ^{N CH}3 /XX 0 ^CIQ 0-^	Light Yellow Solid	Coupling 5	Head M; 2-(7chlorobenzofur an-4-yl)-5,5dimethyl-1,3,2dioxaborinane
2.20	nh₂ X /θ¹ 1 Ν^άγ°^χΟΗ₃ JL 0 ^CIO 0-v	Tan Solid	Coupling 5	Head E; 2-(7chlorobenzofur an-4-yl)-5,5dimethyl-1,3,2dioxaborinane
2.21	nh₂ X z⁰-, n ch₃ ^N ï JL zX o ^ci'\X o-y	Tan Solid	Coupling 5	Head C; 2-(7chlorobenzofur an-4-yl)-5,5dimethyl-1,3,2dioxaborinane

-9917485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
2.22	nh₂ A \|< CH₃/ïx /X X /OH [Γη ^N X JL o O-A	Tan Solid	Hydrolysis 1	Compound 2.21
2.23	nh₂ X /Cl rAyy /^ /X X /OH \|f η ^N Y JL/Y o °'^ΧΧ Ο—V	Tan Solid	Hydrolysis 1	Compound 2.20
2.24	nh₂ Ύ^Τ /ïx X A /Οχ JY N Y ^CH3 JL J ⁰ a y \	Off-White Solid	Coupling 1	Head B; 2-(4chlorobenzofur an-7-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
2.25	nh₂ /X A -iX /O_x J Y^NY CH₃ JLX\ 0 cr yX	Off-White Solid	Coupling 1	Head A; 2-(4chlorobenzofur an-7-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
2.26	nh₂ ch₃ nXa⁰ n^y°-ch₃ JLX\ o cr y^xo	Off-White Solid	Coupling 1	Head C; 2-(4chlorobenzofur an-7-yl)4,4,5,5tetramethyl1,3,2dioxaborolane

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
			nh₂					Head H; 2-
		Ck		Cl				(benzo[ô]thiop
			L					hen-5-yl)-
3.01			N	/0^ >< CH.	White Solid	Coupling 4	4,4,5,5-
	ί			._o			tetramethyl-
				0				1,3,2-
								dioxaborolane
			nh₂				Head H; 2-
		Ck		.ci				(benzo[6]thiop
					OH			hen-5-yl)-
3.02			N		White Solid	Hydrolysis 2	4,4,5,5tetramethyl-

		-/R		0				1,3,2-
	s^z							dioxaborolane
			NH2
		R	Ak-	.Cl				Head B; 2(benzo[6]thiop
			L	0				hen-5-yl)-
3.03	f\|		N	ch₃	White Solid	Coupling 2	4,4,5,5-
	II	/R		0				tetramethyl-
	s^z							1,3,2-
								dioxaborolane
			NH;	?
		F.		Cl
3.04			JL N	O	.OH	Tan Solid	Hydrolysis 1	Compound 3.03
	s^z
			nh₂	.Cl				Head L; 2(benzo[ô]thiop
3.05	s	V	ÔC N	0 0	ch₃	Yellow Solid	Coupling 1	hen-5-yl)- 4,4,5,5tetramethyl-
	e^z						1,3,2-
								dioxaborolane

-10117485

Compound Number	Structure	Appear- ance	Préparation Method:	Precursor(s)
3.06	nh₂ ^H3^C\^V/^CI J-L il ^N lT ^CH3 XJ ⁰ S /	Off-White Solid	Coupling 1	Head D; 2(benzo[ô]thiop hen-5-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
3.07	nh₂ ^H3^C^%_v/^CI /^ X /OH ί\| η ^N Y AJ ⁰ S /	Off-White Solid	Hydrolysis 1	Compound 3.06
3.08	nh₂ ch₃ n^<^<°''ch₃ ⁰ s /	White Solid	Coupling 4	Head C; 2(benzo[ô]thiop hen-5-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
3.09	nh₂ ch₃ _ΓΥΥ_γ ^0ΗJ../J ⁰ s /	White Solid	Hydrolysis 2	Compound 3.08
3.10	nh₂ α^Αχι /^ /Λ <A /0^ il ^N îT ^CHs °	White Solid	Coupling 1	Head H; 2(benzo[6]thiop hen-6-yl)4,4,5,5tetramethyl1,3,2dioxaborolane

Compound Number	Structure	Appear- ance	Préparation Method:	Precursor(s)
	Cl\	nh₂	/^Cl
	TiX
3.11		Y A N	a^^0H	Yellow Solid	Hydrolysis 1	Compound 3.10
	/JJ		0
	AI
		nh₂
	F.		Cl			Head B; 2-
3.12	AR/ /JJ	. <îY N	/A ch₃ 0	Light Yellow Solid	Coupling 5	(benzothiophen -6-yl)-4,4,5,5tetramethyl1,3,2-
	AI					dioxaborolane
		nh₂
	F_x		Cl
3.13	At	J- N	JjDH	Tan Solid	Hydrolysis 1	Compound 3.12
	II 1		0
	at
		nh₂				Head B; 2-(5-
	F. F T''		Cl			fluorobenzothi
			-C/ Ά CH-î	Light		ophen-6-yl)-
3.14	i\|Yf	N	Yellow	Coupling 1	4,4,5,5-
	ÂJ	0	Solid		tetramethyl- 1,3,2-
	AI					dioxaborolane
		nh₂	,CI			Head A; 2-
		A/			(benzo[ô]thiop
3.15		N	O / o ΞΕ ω	Off-White Brittle Solid	Coupling 1	hen-6-yl)- 4,4,5,5-
	/JJ		0		tetramethyl-
	AI					1,3,2-
					dioxaborolane

-10317485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
		nh₂
		fi^l	/^Cl
3.16		\ <> N	..OH	White Solid	Hydrolysis 1	Compound 3.15
			0
	U
		nh₂	Cl			Head A; 2-(5-
	F (i	A/			fluorobenzothi
	JL JI					ophen-6-yl)-
3.17	il	N	'jf ch₃	White Solid	Coupling 1	4,4,5,5-
			0			tetramethyl-
	il					1,3,2-
					dioxaborolane
		NH_?
	H₃c		Cl			Head D; 2(benzo[6]thiop
3.18		<>k N	'jf ch₃	Yellow Solid	Coupling 1	hen-6-yl)- 4,4,5,5-
			0		tetramethyl-
	vl					1,3,2-
					dioxaborolane
		NH_;
	h₃c_x	ïl^	Cl
3.19		k O N	L.oh	Off-White Solid	Hydrolysis 1	Compound 3.18
			0
	vl
		nh₂				Head C; 2-
	N	Αγ-	.0^ CHo			(benzo[è]thiop
3.20	jl ίΤ^ι' A/J	^>k 'N	Y ch₃ 0	Light Yellow Solid	Coupling 4	hen-6-yl)- 4,4,5,5tetramethyl1,3,2-
	vl					dioxaborolane

-10417485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
3.21	nh₂ ch₃ pAV AA ° tr	White Solid	Hydrolysis 2	Compound 3.20
3.22	nh₂ F \| ^CHs ΛΑ ° Vs^T	Off-White Solid	Coupling 1	Head C; 2-(5fluorobenzothi ophen-6-yl)4,4,5,5tetramethyl1,3,2dioxaborolane
3.23	nh₂ ^F\xAx^CI A -A il ^N [Γ ^CHs ⁰	White Solid	Coupling 1	Head B; benzo[è]thioph en-4-ylboronic acid
3.24	nh₂ aS^ A -A .0^ p N >¥ CH₃ AA ⁰ \ ^S	Whjte Solid	Coupling 1	Head B; benzo[à]thioph en-7-ylboronic acid
3.25	nh₂ fAA^0H ° \ ^s	White Solid	Hydrolysis 1	Compound 3.24

-10517485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
3.26	nh₂ >L /O_xί\| ^{N CH}3 ⁰ \ ^S Br	Grey Solid	140	As described
3.27	nh₂ S r^V⁰' \ A». J^· JL Il ^N \|T ^CHsLy 0	Yellow Oil	Coupling 1	Head L; benzo[b]thioph en-7-ylboronic acid
4.01	nh₂ΥγΙχι YOY Il ^N [T ^CH3 JLxJ ⁰ HN J N=^	White Powder	Coupling 2	Head B; l/7-Indazol-5ylboronic acid
4.02	nh₂ ^Fyk/Ci Γύ ^N π ^HJL ° HN Y	White Powder	Hydrolysis 1	Compound 4.01
4.03	nh₂ ^FW^CI /k J-L /O_x\|\| Y N Y ^CH3 Jl J ° Η₃ο~_Νγγ N=^	White Powder	Coupling 2	Head B; 1-Methyl-1/7indazol-5ylboronic acid

-10617485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
4.04	nh₂ /. A JC /OH HsC-nJt ÏA	White Powder	Hydrolysis 1	Compound 4.03
4.05	nh₂ ^FAa /^/A A/°H ^N lT ^CHs AA ° n^nh	White Powder	Coupling 2	Head B; 177-Indazol-6ylboronic acid
4.06	nh₂ F<UyCI Ci ^N k^ohJJ ° N-NH	Off-White Powder	Hydrolysis 1	Compound 4.05
4.07	nh₂ /<^ A A /0^ il ^N [T ^CHa AA ° N-N_x ch₃	White Powder	Coupling 2	Head B; 1 -Methyl-177indazol-6ylboronic acid
4.08	nh₂ F^^CI /^ A- A /OH fl 1^ ^N AA ⁰ N-N ch₃	White Powder	Hydrolysis 1	Compound 4.07

-10717485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
		nh₂	/Cl
	ij				Head A,

4.09		. N	V. /O\ Y ch₃	White Solid	Coupling 1	(177-indazol-6yl)boronic acid
	/AA		0
	v / n-nh
		nh₂				Head B;
	R		.Cl			l-methyl-4-
	η					«4,5,5-
						tetramethyl-
4.10	il A	N	[\| CH₃	Solid	Coupling 1	1,3,2-
			0		dioxabor°lan-
	λ /?					2-yl)-lH-
	n-n					indazole
	h₃c
		NH	2
			Cl
4.11		IL z N	I OH	Off-White Solid	Hydrolysis 1	Compound 4.10
	AA\		o
	\ Il
	n—n
	h₃c^z
		nh₂
	F\.	Ί	Cl			Head B;
4.12		N	ch₃	White Solid	Coupling 1	12Z-indazol-4ylboronic acid
	AA.		o
	\ U
	HN—N
		nh₂
						Head B;
	F\.	Ά/	.Cl			7-(4,4,5,5tetramethyl-
4.13		N	Ί< ch₃	White Solid	Coupling 1	1,3,2-
					dioxaborolan-
	k/\ \ NH		0			2-yl)-177-
	\ !					indazole
	^N

-10817485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
5.01	nh₂f_X/X_/ci Ut U\ f Ύ^ΝΥ ^CH3XX ° ⁰ / \^N	Off White Solid	Coupling 5	Head B; benzooxazole5-boronic acid pinacol ester
6.01	nh₂urSt i\| ^N if ^CH3 \^N	Light Brown Solid	Coupling 3	As described
6.02	nh₂ ^FyV^clίπΛ^Ν<τ^0ΗXX ° s /	Light Brown Solid	Hydrolysis 1	Compound 6.01
7.01	nh₂ Ut^Uf [\| Y ^N Y ^CH3 XX ° N / '^-NH	Off-White Powder	Coupling 2	Head B; 6-(4,4,5,5Tetramethyl1,3,2dioxaborolan2-yl)-177benzo[i7]imida zole
7.02	nh₂ ^faU\z^ciX- X JA Π ^N if ^CH3 XX ° N J \Zn ^xch₃	White Powder	Coupling 2	Head B; l-Methyl-177benzofc/Jimida zol-6-ylboronic acid

-10917485

Compound Number	Structure	Appearance	Préparation Method:	Precursor(s)
7.03	nh₂ ^fAt^ci Λ7 ° N / N ^xch₃	White Powder	Hydrolysis 1	Compound 7.02
8.01	nh₂ ^fyV^ci/A X/ h₃c ^N [Γ ^ch3 h₃c A\ t N-0	Yellow Solid	Coupling 1	Head B; ΛζΎ-dimethyl6-(4,4,5,5tetramethyl1,3,2dioxaborolan2yl)benzo[c?]iso xazol-3-amine
9.01	nh₂ N /J Λ n ch₃ N II ³ ° H	White Solid	Coupling 7	Head K; 6-bromo-177benzo[i/][l,2,3] triazole

Table 11. Analytical Data for Compounds in Table 1

C. No.	MP (°C)	’hnmr
1.01	166- 168	‘h NMR (300 MHz, DMSO-î7₆) δ 8.06 (s, 1H), 7.67 (br d, J= 8 Hz, 1H), 7.53 (d, J= 8 Hz, 1H), 7.39 (d, J= 3 Hz, 1H), 6.77 (br s, 2H), 6.54 (d, J= 3 Hz, 1H), 3.83 (s, 3H)
1.02	221- 224	*H NMR (300 MHz, DMSO-î7₆) δ 8.04 (s, 1H), 7.59 (dt, J= 7, 1.5 Hz, 1H), 7.48 (d, J= 7 Hz, 1H), 7.41 (t, J= 3 Hz, 1H), 6.85 (br s, 2H), 6.54 (m, 1H), 3.89 (s, 3H)
1.03	125- 127	’H NMR (300 MHz, DMSO-î7₆) δ 8.21 (s, 1H), 7.82 (dt, J = 9, 1.5 Hz, 1H), 7.39 (d, J= 9 Hz, 1H), 7.08 (d, J= 3 Hz, 1H), 6.56 (d, J= 3 Hz, 1H), 4.84 (br s, 2H), 3.99 (s, 3H), 3.82 (s, 3H)
1.04	180- 182	^!H NMR (300 MHz, DMSO-î/₆) δ 11.26 (br s, 1H), 8.05 (s, 1H), 7.61 (dt, J

-110J

C. No.	MP (°C)	*HNMR
		= 9, 1.5 Hz, 1H), 7.48 (d, J= 9 Hz, 1H), 7.41 (t, J= 3 Hz, 1H), 7.67 (br s, 2H), 6.54 (m, 1H)
1.05	174- 179	‘H NMR (400 MHz, CDC1₃) δ 8.50 (s, 1H), 7.65 (d, J= 8.2 Hz, 2H), 7.40 (dd, .7=8.3,1.4 Hz, 1H), 7.23 - 7.17 (m, 1H), 6.54 - 6.48 (m, 1H), 5.30 (d, J= 3.9 Hz, 2H), 3.94 (s, 3H)
1.06	160- 164	*H NMR (400 MHz, DMSO-î/₆) δ 13.64 (s, 1H), 11.26 (s, 1H), 7.67 - 7.63 (m, 1H), 7.60 (d, J= 8.3 Hz, 1H), 7.48 - 7.41 (m, 1H), 7.25 (dd, J= 8.2, 1.5 Hz, 1H), 6.89 (s, 2H), 6.48 (dd, .7=2.5, 1.5 Hz, 1H)
1.07	185- 190	’H NMR (400 MHz, DMSO-î/₆) δ 11.79 (s, 1H), 7.94 (s, 2H), 7.55 (m, 1H), 7.52 (m, 1H), 7.40 (d, J= 8.4 Hz, 1H), 6.55 (m, 1H), 3.93 (s, 3H). ¹⁹F NMR (376 MHz, DMSO-J6) δ -132.43. ESIMS m/z 321 [(M+H)⁺],
1.08	66-69	’H NMR (300 MHz, CDC1₃) δ 8.31 (br s, 1H), 8.02 (s, 1H), 7.71 (s, 2H), 7.29 (t, J= 3 Hz, 1H), 6.58 (m, 1H), 4.86 (br s, 2H), 3.99 (s, 3H)
1.09	138- 140	’H NMR (300 MHz, DMSO-îZ₆) δ 7.95 (s, 1H), 7.63 (d, J = 8 Hz, 1H), 7.54 (dt, J = 8, 2 Hz, 1H), 7.47 (t, J= 3 Hz, 1H), 6.79 (br s, 2H), 6.48 (m, 1H)
1.10	116- 119	*H NMR (400 MHz, CDC1₃) δ 7.94 (t, J = 1 Hz, 1H), 7.69 (br s, 2H), 7.13 (d, J= 3 Hz, 1H), 6.50 (dd, J = 3, 1 Hz, 1H), 4.85 (br s, 2H), 3.99 (s, 3H), 3.84 (s, 3H)
1.11	173- 176	’H NMR (400 MHz, DMSO-îZ₆) δ 7.93 (s, 1H), 7.66 (d, J= 8.5 Hz, 1H), 7.59 (d, J= 8.5 Hz, 1H), 7.46 (d, J= 3 Hz, 1H), 6.50 (d, J= 3 Hz, 1H), 6.37 (br s, 2H),3.87 (s, 3H)
1.12	181- 182	’H NMR (400 MHz, CDCI3) δ 7.49 (d, J= 8.1 Hz, 1H), 7.40 (d, J= 3.2 Hz, 1H), 7.29 (dd, J= 8.1, 5.9 Hz, 1H), 4.90 (s, 2H), 3.98 (s, 3H), 1.68 (m, 3H), 1.14 (d, J= 7.6 Hz, 18H). ¹⁹FNMR(376 MHz, CDCI3) δ-124.55, 124.65, -136.90, -137.00. ESIMS m/z 492 [(M-H)'].
1.13		‘H NMR (DMSO-i/g) δ 3.88 (s, 3H), 6.49 (ddd, J = 2.9, 1.9, 0.8 Hz, 1H), 6.96 (s, 2H), 7.43 (d, J = 11.1 Hz, 1H), 7.50 (d, J = 6.0 Hz, 1H), 7.54 (t, J = 2.8 Hz, 1H), 11.32 (s, 1H)
1.14		’H NMR (DMSO-Jô) δ 6.46 - 6.52 (m, 1H), 6.88 (s, 2H), 7.42 (d, J = 11.1 Hz, 1H), 7.49 - 7.56 (m, 2H), 11.33 (s, 1H), 13.56 (s, 1H)
1.15		*H NMR (DMSO-c/ô) δ 3.88 (s, 3H), 6.59 (td, J = 3.2, 1.9 Hz, 1H), 6.99 (s, 2H), 7.08 (dd, J = 8.2, 6.2 Hz, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.52 (t, J = 2.8 Hz, 1H), 11.82 (t, J =2.2 Hz, 1H)
1.16		’HNMR (DMSO-îZ₆) Ô 6.59 (td, J = 3.2,1.9 Hz, 1H), 6.90 (s, 2H), 7.10 (dd, J = 8.2, 6.2 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 7.51 (t, J = 2.8 Hz, 1H), 11.81 (s, 1H), 13.57 (s, 1H)

-11117485

C. No.	MP (°C)	‘H NMR
1.17	133- 140	'H NMR (400 MHz, DMSO-J₆) δ 11.76 (s, 1H), 7.49 (dd, J= 3.0, 2.5 Hz, 1H), 7.44 (d, J= 7.9 Hz, 1H), 7.09 (dd, J= 8.2, 6.2 Hz, 1H), 6.57 (td, J= 3.3, 1.9 Hz, 1H), 6.41 (s, 2H), 3.80 (s, 3H). ¹⁹F NMR (376 MHz, DMSOJ₆) δ -134.66, -134.73. ESIMS m/z 320 [(M+H)⁺J.
1.18	164- 166	*H NMR (400 MHz, CDC1₃) δ 8.45 (s, 1H), 7.49 (dd, J= 8.2, 0.8 Hz, 1H), 7.35-7.28 (m, 2H), 6.94 (dd,J=18.1,11.5 Hz, 1H), 6.61 (td, J= 3.4, 2.1 Hz, 1 H), 5.72 (dd, J= 11.5, 1.5 Hz, 1 H), 5.60 (dd, J= 18.1,1.5 Hz, 1H), 4.72 (s, 2H), 3.91 (s, 2H). ¹⁹F NMR (376 MHz, CDC1₃) δ -135.79, -135.87, -140.98, -141.07. ESIMS m/z 330 [(M+H)⁺],
1.19		*H NMR (400 MHz, DMSO-î/₆) δ 11.76 (d, J= 16.4 Hz, 1H), 7.48 (m, 1H), 7.11 (dd,J=8.2, 6.2 Hz, 1H), 6.79 (dd, J= 17.8, 11.5 Hz, 1H), 6.58 (dd, J= 5.1, 3.2 Hz, 1H), 6.38 (s, 1H), 5.56 (m, 1H). ¹⁹FNMR (376 MHz, DMSO-Jô) δ -134.07, -134.15, -143.26, -143.34. ESIMS m/z 316 [(M+H)⁺].
1.20	203- 205	’H NMR (400 MHz, DMSO-J₆) δ 11.76 (s, 1H), 7.49 (dd, J= 6.0, 3.3 Hz, 1H), 7.44 (d, J= 8.2 Hz, 1H), 7.05 (dd, J= 8.1, 6.3 Hz, 1H), 6.57 (m, 1H), 6.49 (s, 2H), 3.84 (s, 3H), 3.79 (s, 3H). ¹⁹F NMR (376 MHz, DMSO-J₆) δ 134.75, -134.82, -138.34, -138.42. ESIMS m/z 334 [(M+H)⁺].
1.21	83-85	'H NMR (400 MHz, DMSOX) δ 11.20 (s, 1H), 8.00 (m, 1H), 7.59 (m, 1H), 7.53 (m, 1H), 7.43 (dd, J= 3.1, 2.4 Hz, 1H), 7.32 (s, 1H), 6.61 (s, 2H), 6.45 (s, 1H), 3.91 (s, 3H)
1.22	172- 174	*H NMR (400 MHz, DMSO-</₆) δ 11.47 (s, 1H), 7.94 (d, J= 1.2 Hz, 1H), 7.67 (d, J= 8.3 Hz, 2H), 7.52 (t, J= 2.8 Hz, 1H), 7.46 (dd, J= 8.4, 1.7 Hz, 1H), 6.51 (t, J= 2.5 Hz, 1H), NaN (m, 2H)
1.23		‘H NMR (DMSO-îZ₆) δ 3.89 (s, 3H), 6.54 (td, J = 3.4, 1.9 Hz, 1H), 6.75 (s, 2H), 7.31 (d, J =1.5 Hz, 1H), 7.37-7.52 (m, 3H), 11.76 (s, 1H)
1.24		*H NMR (DMSO-J₆) δ 6.50 - 6.62 (m, 1H), 6.71 (s, 2H), 7.27 (d, J = 1.5 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.45 - 7.53 (m, 2H), 11.76 (d, J = 2.4 Hz, 1H), 13.48 (s, 1H)
1.25		’H NMR (DMSO-Jd) δ 3.90 (s, 3H), 6.45 (ddd, J = 2.9, 1.9, 0.9 Hz, 1H), 6.75 (s, 2H), 7.29 (d, J = 1.7 Hz, 1H), 7.40 (d, J = 12.7 Hz, 1H), 7.52 (t, J = 2.8 Hz, 1H), 7.93 (dd, J =6.8, 0.8 Hz, 1H), 11.27 (t, J = 2.3 Hz, 1H)
1.26		‘H NMR (DMSOX) δ 6.45 (t, J = 2.4 Hz, 1H), 6.68 (s, 2H), 7.24 (d, J = 1.6 Hz, 1H), 7.40 (d, J = 12.8 Hz, 1H), 7.52 (t, J = 2.8 Hz, 1H), 7.95 (d, J = 6.7 Hz, 1H), 11.29 (s, 1H), 13.54 (s, 1H)
1.27	169- 171	*H NMR (400 MHz, CDCI3) δ 8.45 (s, 1H), 7.29 (t, J= 2.7 Hz, 1H), 7.16 (d, J= 10.0 Hz, 1H), 6.93 (dd,J= 1.5, 0.8 Hz, 1H), 6.54 (s, 1H), 4.82 (s, 2H), 3.98 (s, 3H). ¹⁹F NMR (376 MHz, CDC1₃) δ -126.04, -135.41. ESIMS

-11217485

C. No.	MP (°C)	‘H NMR
		m/z 336 [(Μ-H)'].
1.28	231- 234	’H NMR (400 MHz, DMSO-J₆) δ 11.15 (s, 1H), 7.57 (d, J =8.1 Hz, 1H), 7.42 (dd, J= 6.3, 3.6 Hz, 2H), 7.05 (dd, J= 8.2,1.5 Hz, 1H), 6.47 (dd, J= 2.5, 1.6 Hz, 1H), 6.39 (s, 2H), 3.85 (s, 3H), 2.14 (s, 3H)
1.29	168- 175	*H NMR (400 MHz, DMSO-J₆) δ 11.31 (s, 1H), 7.66 - 7.60 (m, 1H), 7.49 (s, 1H), 7.48 - 7.43 (m, 1H), 7.07 (dt, J= 15.8, 7.9 Hz, 3H), 6.53 - 6.48 (m, lH),2.13(s, 3H)
1.30	240- 242	‘H NMR (400 MHz, DMSO-J₆) δ 11.33 (s, 1H), 8.37 (s, 1H), 7.96 (dd, J= 8.4, 1.5 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 7.50 (m, 1H), 6.47 (d, J= 1.1 Hz, 1H), 3.94 (s, 3H); ESIMS m/z 303 [(M+H)⁺J.
1.31	185- 190	*H NMR (400 MHz, DMSO-î7₆) δ 11.79 (s, 1H), 7.94 (s, 2H), 7.55 (m, 1H), 7.52 (m, 1H), 7.40 (d, J= 8.4 Hz, 1H), 6.55 (m, 1H), 3.93 (s, 3H). ¹⁹F NMR (376 MHz, DMSO-î/₆) δ -132.43. ESIMS m/z 321 [(M+H)⁺],
1.32	190- 191	‘H NMR (DMSO-Jé) δ 3.74 (s, 3H), 3.92 (s, 3H), 6.46 (ddd, J = 3.0, 1.9, 0.9 Hz, 1H), 7.27 (s, 2H), 7.46 (t, J = 2.7 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.94 (dd, J= 8.4, 1.5 Hz, 1H), 8.33 (d, J = 1.1 Hz, 1H), 11.26 (d, J = 2.3 Hz, 1H).
1.33	154- 157	'H NMR (DMSO-d₆) δ 3.75 (s, 3H), 6.41 - 6.50 (m, 1H), 7.20 (s, 2H), 7.46 (t, J = 2.7 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.96 (dd, J = 8.4, 1.5 Hz, 1H), 8.25 - 8.46 (m, 1H), 11.27 (s, 1H)
1.34		’H NMR (DMSO-Jô) δ 3.75 (s, 3H), 3.90 (s, 3H), 6.53 (td, J = 3.2, 1.9 Hz, 1H), 7.37 (d, J= 8.3 Hz, 3H), 7.44-7.54 (m, 2H), 11.71 (s, 1H)
1.35		’H NMR (DMSO-Jô) δ 3.77 (s, 3H), 6.53 (td, J = 3.2, 1.9 Hz, 1H), 7.12 - 7.35 (m, 2H), 7.37 (d, J = 8.3 Hz, 1H), 7.46 - 7.58 (m, 2H), 11.72 (t, J = 2.2 Hz, 1H), 13.49 (s, 1H)
1.36		’H NMR (DMSO-î/₆) δ 3.76 (s, 3H), 3.89 (s, 3H), 6.44 (ddd, J = 3.0, 1.8, 0.9 Hz, 1H), 7.32 (d, 7 = 11.9 Hz, 3H), 7.51 (t, J = 2.8 Hz, 1H), 7.85 (d,7 = 6.5 Hz, 1H), 11.30 (s, 1H)
1.37		*H NMR (DMSO-J₆) δ 3.75 (s, 3H), 6.43 (ddd, J = 2.9, 1.9, 0.8 Hz, 1H), 7.10 - 7.46 (m, 3H), 7.50 (t, J = 2.7 Hz, 1H), 7.85 (dd, J = 6.4, 0.8 Hz, 1 H), 11.29 (t, J = 2.3 Hz, 1 H), 13.48 (s, 1 H)
1.38	172- 173	*H NMR (400 MHz, DMSO-7₆) δ 11.75 (s, 1H), 7.55 (dd, J= 8.3, 6.7 Hz, 1H), 7.50 (m, 1H), 7.38 (d, J= 8.4 Hz, 1H), 7.21 (s, 1H), 6.67 (dd, J= 17.6, 11.5 Hz, 1H), 6.54 (dd, J= 5.1, 3.2 Hz, 1 H), 5.48 (ddd, J=11.4, 7.3, 1.1 Hz, 1H), 3.83 (s, 1H), 3.33 (s, 1H). ¹⁹F NMR (376 MHz, DMSO-J₆) δ 132.89. ESIMS m/z 313 [(M+H)⁺],
1.39	209-	’H NMR (400 MHz, DMSO-J₆) δ 13.51 (s, 1H), 11.75 (s, 1H), 7.56 (m,

-11317485

C. No.	MP (°C)	‘hnmr
	211	1H), 7.50 (t, J= 2.5 Hz, 1H), 7.38 (d, J= 8.3 Hz, 1H), 7.14 (s, 1H), 6.67 (dd, J= 17.7, 11.5 Hz, 1H), 6.54 (s, 1H), 5.60 (d, J= 17.8 Hz, 1H), 5.49 (d, J= 11.4 Hz, 1H). ¹⁹F NMR (376 MHz, DMSO-î/₆) δ -132.98. ESIMS m/z 299 [(M+H)⁺J.
1.40	233- 236	’H NMR (400 MHz, CDC1₃) δ 8.27 (s, 1H), 7.51 - 7.45 (m, 2H), 7.32 - 7.28 (m, 2H), 6.93 - 6.79 (m, 1H), 4.90 (s, 2H), 3.98 (s, 3H)
1.41	167- 169	‘H NMR (400 MHz, CDC1₃) δ 7.46 (ddd, J= 7.3, 2.1, 0.8 Hz, 1H), 7.41 (d, J= 8.2 Hz, 1H), 7.33 - 7.28 (m, 1H), 7.13 (d, J= 3.1 Hz, 1H), 6.79 - 6.68 (m, 1H), 4.89 (s, 2H), 3.98 (s, 3H), 3.83 (s, 3H)
1.42	158- 160	‘H NMR (400 MHz, DMSO-zZ₆) δ 7.55 (d, J= 7.5 Hz, 1H), 7.38 (d, J= 3.1 Hz, 1H), 7.32 - 7.22 (m, 2H), 6.77 (s, 2H), 6.50 (t, J= 2.3 Hz, 1H), 3.84 (s, 3H)
1.43		*H NMR (DMSO-J₆) δ 3.88 (s, 3H), 6.61 (dt, J = 3.1, 2.0 Hz, 1H), 6.95 (s, 2H), 7.22 - 7.35 (m, 2H), 7.49 (t, J = 2.8 Hz, 1H), 11.65 (s, 1H)
1.44	116	*H NMR (DMSO-J₆) δ 3.91 (s, 3H), 6.74 (s, 2H), 6.97 (dd, J = 3.2, 1.8 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.54 (t, J = 2.8 Hz, 1 H), 11.65 (s, 1 H)
1.45	226	‘H NMR (DMSO-î/ô) δ 3.76 (s, 3H), 3.93 (s, 3H), 7.25 (d, J = 8.1 Hz, 1H), 7.34 (s, 2H), 7.49 (t, J = 2.8 Hz, 1H), 7.59 (dd, J = 3.0, 2.0 Hz, 1H), 7.99 (d, J =8.2 Hz, 1H), 11.55 (s, 1H)
1.46		’H NMR (DMSO-î/ô) δ 3.93 (s, 3H), 6.60 (dd, J = 3.2, 2.0 Hz, 1H), 7.03 (s, 2H), 7.24 (d, J = 8.0 Hz, 1H), 7.50 (dd, J = 8.0, 0.9 Hz, 1H), 7.55 (t, J = 2.8 Hz, 1H), 11.44 (s, 1H)
1.47	96- 100	^lH NMR (300 MHz, CDC1₃) δ 11.33 (s, 1H), 7.97 (d, J= 7.7 Hz, 1H), 7.76 (d, J=7.8Hz, 1H), 7.37-7.29 (m, 1H), 7.18 (t,J= 7.7 Hz, 1H), 6.656.55 (m, 1H), 4.83 (s, 2H), 4.03 (s, 3H)
1.48	171- 175	’H NMR (400 MHz, DMSO-îZ₆) δ 11.12 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 7.4 Hz, 1H), 7.41 (t, J= 2.8 Hz, 1H), 7.13 (t, J= 7.6 Hz, 1H), 6.89 (s, 2H), 6.53 (dd, J = 3.0, 2.1 Hz, 1H)
1.49	186- 188	’H NMR (DMSO-îZô) δ 3.96 (s, 3H), 6.57 (dd, J = 3.2, 2.2 Hz, 1H), 6.81 (s, 2H), 7.23 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.55 7.59 (m, 1 H), 11.51 (s, 1H)
1.50	147- 149	’H NMR (DMSO-îZ₆) δ 3.78 (s, 3H), 3.94 (s, 3H), 6.60 (dd, J = 3.2, 2.2 Hz, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.29 - 7.88 (m, 3H), 8.09 (d, J = 8.2 Hz, 1 H), 11.75 (s, 1H)
2.01	114- 117	’H NMR (400 MHz, CDC1₃) δ 8.16 (t, J = 1.4 Hz, 1H), 7.87 (dt, J= 8.7, 1.8 Hz, 1H), 7.66 (d, J =2.2 Hz, 1H), 7.61 -7.54 (m, 1H), 6.86-6.81 (m,

-11417485

C. No.	MP (°C)	‘H NMR
		1H), 4.90 (s, 2H), 4.00 (s, 3H)
2.02	165- 167	*H NMR (400 MHz, DM S 0-6^) δ 13.60 (s, 1H), 8.13 (s, 1H), 8.07 (d, J= 2.2 Hz, 1H), 7.80 (d, J= 8.7 Hz, 1H), 7.75 - 7.64 (m, 1H), 7.07 (dd, J= 7.9, 6.5 Hz, 1H), 6.88 (s, 2H)
2.03	84-87	’H NMR (400 MHz, DMSO-c?₆) δ 3.90 (d, J = 3.3 Hz, 3H), 6.75 (d, J = 19.2 Hz, 2H), 6.92 - 8.22 (m, 6H)
2.04	98	’H NMR (400 MHz, CDC1₃) δ 8.19 (d, J= 7.7 Hz, 1H), 7.63 (d, J= 2.2 Hz, 1 H), 7.28 (d, J = 11.2 Hz, 1 H), 7.22 (d, J = 2.0 Hz, 1 H), 6.79 (dd, J= 2.2, 0.9 Hz, 1H), 4.80 (s, 2H), 4.01 (s, 3H)
2.05	160	’H NMR (400 MHz, CDC1₃) δ 8.11 (d, J = 7.4 Hz, 1H), 7.63 (d, J= 22 Hz, 1H), 7.29 (d, J= 10.6 Hz, 1H), 6.78 (dd, J= 2.2, 0.9 Hz, 1H), 5.40 (s, 2H), 4.01 (s, 3H), 3.95 (s, 3H)
2.06		’H NMR (400 MHz, CDCI3) δ 8.20 (dd, J= 7.7, 0.8 Hz, 1H), 7.79 (dd, J= 2.1, 0.9 Hz, 1H), 7.69 (d, J= 2.2 Hz, 1H), 7.62 (d, J= 8.2 Hz, 1H), 6.79 (dd, J = 2.1, 1.0 Hz, 1H), 5.32 (s, 2H), 3.95 (s, 3H), 3.93 (s, 3H)
2.07		’H NMR (400 MHz, CDCI3) δ 8.10 (s, 1H), 7.88 - 7.83 (m, 1H), 7.70 (t, J = 2.5 Hz, 1H), 7.69-7.66 (m, 1H), 6.81 (dd, J =22, 1.0 Hz, 1H), 4.91 (s, 2H), 4.00 (d,J=1.5 Hz, 3H)
2.08	168- 170	‘H NMR (400 MHz, DMSO-î/₆) δ 13.59 (s, 1H), 8.11 (d,J=2.2 Hz, 1H), 8.03 (s, 1H), 7.77 (s, 2H), 7.04 (dd, J= 2.1, 0.9 Hz, 1H), 6.90 (s, 2H)
2.09	151	’H NMR (400 MHz, CDC1₃) δ 7.73 (d, J= 2.1 Hz, 1H), 7.48 - 7.41 (m, 2H), 6.85 (s, 1H), 4.94 (s, 2H), 3.97 (d, J= 5.6 Hz, 3H)
2.10	109	’H NMR (400 MHz, CDCI3) δ 7.72 (t, J = 3.3 Hz, 2H), 7.34 (dd, J= 9.5, 5.3 Hz, 1H), 6.79 (dd, J= 22, 0.9 Hz, 1H), 4.93 (s, 2H), 3.98 (s, 3H)
2.11	148	’H NMR (400 MHz, CDC1₃) δ 7.87 (dd, J= 8.2, 6.5 Hz, 1H), 7.71 (d, J = 2.1 Hz, 1H), 7.42 (d, J= 8.2 Hz, 1H), 7.29 (d, J= 1.6 Hz, 1H), 6.82 (dd, J = 3.0, 2.2 Hz, 1H), 4.82 (s, 2H), 4.01 (s, 3H)
2.12	130	’H NMR (400 MHz, CDC1₃) δ 8.15 (d, J = 5.7 Hz, 1H), 7.70 (d, J= 2.2 Hz, 1H), 7.35 - 7.28 (m, 2H), 6.75 (dd, J= 22, 0.9 Hz, 1H), 4.80 (s, 2H), 4.01 (s, 3H)
2.13	178	’H NMR (400 MHz, CDC1₃) δ 7.82 (dd, J= 8.2, 6.3 Hz, 1H), 7.71 (d, J= 2.1 Hz, 1H), 7.39 (d, J= 8.2 Hz, 1H), 6.84 - 6.75 (m, 1H), 5.40 (s, 2H), 4.01 (s, 3H), 3.95 (s, 3H)
2.14	153	’H NMR (400 MHz, CDC1₃) δ 8.06 (d, J= 5.9 Hz, 1H), 7.70 (t, J= 3.4 Hz, 1H), 7.32 (d, J= 10.6 Hz, 1H), 6.75 (dd, J= 22, 0.9 Hz, 1H), 5.39 (s, 2H), 4.01 (s, 3H), 3.96 (s, 3H)

-11517485

C. No.	MP (°C)	’HNMR
2.15	100- 103	^!H NMR (400 MHz, CDC1₃) δ 7.72 - 7.69 (m, 1H), 7.68 - 7.63 (m, 1H), 7.59 (d, J= 8.3 Hz, 1H), 7.42 - 7.36 (m, 1H), 7.20 - 7.15 (m, 1H), 4.94 (s, 2H), 4.00 (d, 7=1.5 Hz, 3H)
2.16	184- 186	‘H NMR (400 MHz, CDC1₃) δ 7.76 (d, J= 2.2 Hz, 1H), 7.61 (dd, J= 8.2, 2.1 Hz, 1H), 7.42 - 7.38 (m, 1H), 7.26 - 7.24 (m, 1H), 4.96 (s, 2H), 4.00 (s, 3H)
2.17	170- 173	*H NMR (400 MHz, DMSO-7₆) δ 13.63 (s, 1H), 8.07 (d, J= 22 Hz, 1H), 7.72 (d, J= 8.2 Hz, 1H), 7.57 (d, J= 7.5 Hz, 1H), 7.44 (t, J= 7.9 Hz, 1H), 7.09 (s, 1H), 6.93 (s, 2H)
2.18		‘H NMR (400 MHz, CDC1₃) δ 7.81 (d, J= 2.3 Hz, 1H), 7.54 (d, J= 8.0 Hz, 2H), 7.45 (d, J= 8.2 Hz, 1H), 6.96 (s, 1H), 5.20 (s, 2H)
2.19	158- 159	^!H NMR (400 MHz, DMSO-J₆) δ 8.24 (d, J= 2.1 Hz, 1H), 7.68 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 8.2 Hz, 1H), 7.50 (d, J= 2.1 Hz, 1H), 7.37 (s, 1H), 6.83 (s, 2H), 3.93 (s, 3H)
2.20		*H NMR (400 MHz, CDC1₃) δ 8.22 (d, J= 8.3 Hz, 1H), 7.79 (dd, J= 12.0, 2.1 Hz, 2H), 7.38 (d, 7 = 8.3 Hz, 1H), 5.61 (s, 2H), 4.05 (s, 3H)
2.21		*H NMR (400 MHz, CDCI3) δ 8.22 - 8.09 (m, 1H), 7.86 (d, J= 2.1 Hz, 1H), 7.77 (d, J= 2.1 Hz, 1H), 7.42 - 7.34 (m, 1H), 5.39 (s, 2H), 4.04 (s, 3H), 3.95 (s, 3H)
2.22	204- 206	*H NMR (400 MHz, DMSO-7₆) δ 8.22 (d, J= 2.1 Hz, 1H), 8.20 (d, J= 8.3 Hz, 1H), 8.00 (d, J= 2.1 Hz, 1H), 7.52 (d, J= 8.3 Hz, 1H), 7.42 (s, 1H), 3.78 (s, 3H)
2.23	173- 174.5	’H NMR (400 MHz, CDCI3) δ 7.76 (d, J= 2.2 Hz, 1H), 7.61 (dd, J= 8.2, 2.1 Hz, 1H), 7.42 - 7.38 (m, 1H), 7.26 - 7.24 (m, 1H), 4.96 (s, 2H), 4.00 (s, 3H)
2.24	167	*H NMR (400 MHz, CDC1₃) δ 7.68 (d, J= 2.2 Hz, 1H), 7.54 (d, J= 8.1 Hz, 1H), 7.37 - 7.34 (m, 1H), 6.93 (d, J= 22 Hz, 1H), 4.95 (s, 2H), 3.99 (d, J =4.7 Hz, 3H)
2.25	169	‘H NMR (400 MHz, CDCI3) δ 8.14 (d, J= 8.2 Hz, 1H), 7.75 (d, J= 10.0 Hz, 2H), 7.34 (d, J= 8.3 Hz, 1H), 6.97 (t, J= 8.0 Hz, 1H), 4.86 (s, 2H), 4.02 (s, 3H)
2.26	178	'H NMR (400 MHz, CDC1₃) δ 8.09 (d, J= 8.2 Hz, 1H), 7.79 (d, J= 2.1 Hz, 1H), 7.32 (d, J= 8.3 Hz, 1H), 6.92 (d, 7= 2.2 Hz, 1H), 5.44 (s, 2H), 4.04 (s, 3H), 3.96 (s, 3H)
3.01	50-56	’H NMR (DMSO-7₆) δ 3.89 (s, 3H), 7.09 (s, 2H), 7.52 - 7.63 (m, 2H), 7.86 (d, 7 = 5.4 Hz, 1H), 8.07-8.17 (m, 2H)

-11617485

C. No.	MP (°C)	’hnmr
3.02	157- 159	’H NMR (DMSO-fik) δ 6.98 (s, 2H), 7.53 - 7.61 (m, 2H), 7.84 (d, J = 5.5 Hz, 1H), 8.06 - 8.13 (m, 2H), 13.70 (s, 1H)
3.03	84-85	’H NMR (400 MHz, DMSO-cZ₆) δ 8.34 (s, 1H), 8.12 (d, J= 8.5 Hz, 1H), 7.87 - 7.78 (m, 2H), 7.60 (dd, J= 5.5, 0.6 Hz, 1H), 6.95 (s, 2H), 3.90 (s, 3H)
3.04	149- 150	’H NMR (400 MHz, DMSO-î/₆) δ 8.36 (s, 1H), 8.11 (d, J= 8.5 Hz, 1H), 7.83 (t, J= 6.1 Hz, 2H), 7.58 (d, J= 5.4 Hz, 1H), 6.71 (s, 2H)
3.05	142- 144	‘H NMR (400 MHz, DMSOY₆) δ 8.41 (d, J = 1.7 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.82 - 7.88 (m, 2H), 7.51 - 7.72 (m, 3H), 7.39 (s, 1H), 3.92 (s, 3H)
3.06	155- 159	*H NMR (400 MHz, CDC1₃) δ 7.94 - 7.88 (m, 2H), 7.48 (d, J = 5.4 Hz, 1H), 7.41 (dd, J= 8.3, 1.7 Hz, 1H), 7.36 (dd, J= 5.4, 0.6 Hz, 1H), 4.83 (s, 2H), 3.96 (s, 3H), 2.19 (s, 3H)
3.07	159- 165	’H NMR (400 MHz, DMSO-îZ₆) δ 8.10 (d, J= 8.3 Hz, 1H), 7.97 (s, 1H), 7.85 (d, J= 5.4 Hz, 1H), 7.54 (d, J= 5.5 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 6.81 (s, 2H), 2.12 (s, 3H)
3.08	125- 127	’H NMR (DMSO-Jô) δ 3.76 (s, 3H), 3.92 (s, 3H), 7.40 (s, 2H), 7.60 (dd, J = 5.4, 0.7 Hz, 1H), 7.81 (d, J = 5.4 Hz, 1H), 8.06 (d, J = 8.6 Hz, 1H), 8.24 (dd, J=8.5, 1.7 Hz, 1H), 8.73 (d,J= 1.5 Hz, 1H)
3.09	137- 139	*H NMR (DMSO-J_tf) δ 3.76 (s, 3H), 7.31 (s, 2H), 7.59 (d, J = 5.4 Hz, 1H), 7.81 (d, J = 5.4 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 8.26 (dd, J = 8.5, 1.7 Hz, 1H), 8.76 (d, J= 1.5 Hz, 1H), 13.54 (s, 1H)
3.10	134- 135	’H NMR (400 MHz, CDC1₃) δ 8.22 - 8.09 (m, 1H), 7.87 (d, J= 8.2 Hz, 1H), 7.66 (dd, <7=8.3,1.6 Hz, 1H), 7.52 (d, J=5.5Hz, 1H), 7.36(dd,J= 5.5, 0.6 Hz, 1H), 5.34 (s, 2H), 3.97 (s, 3H)
3.11	239 (dec)	*H NMR (400 MHz, DMSO-J₆) δ 8.22 (d, J= 0.7 Hz, 1H), 7.96 (d, J= 8.2 Hz, 1H), 7.88 (d,J=5.4 Hz, 1H), 7.59 (dd, .7=8.3,1.6 Hz, 1H), 7.53 (d,J = 5.4 Hz, 1H), 7.02 (s, 2H)
3.12	185- 189	’H NMR (400 MHz, CDC1₃) δ 8.48 (s, 1H), 7.95 (dt, J= 8.4, 1.6 Hz, 1H), 7.90 (d, J= 8.3 Hz, 1H), 7.54 (d, J= 5.4 Hz, 1H), 7.37 (d, J= 5.4 Hz, 1H), 4.91 (s, 2H), 4.01 (s, 3H)
3.13	165- 167	’H NMR (400 MHz, DMSO-^) δ 13.60 (s, 1H), 8.45 (d, J= 6.7 Hz, 1H), 7.99 (t, J= 7.0 Hz, 1H), 7.88 (dd, J= 13.5, 6.4 Hz, 2H), 7.52 (t, J= 4.7 Hz, 1H), 6.83 (d, J =64.9 Hz, 2H)
3.14	112	’H NMR (400 MHz, CDCI3) δ 8.08 (d, J= 6.2 Hz, 1H), 7.60 (d, J= 5.5 Hz, 1H), 7.56 (s, 1H), 7.33 (s, 1H), 4.94 (s, 2H), 3.99 (s, 3H)

-11717485

C. No.	MP (°C)	’hnmr
3.15		'H NMR (400 MHz, CDC1₃) δ 8.55 - 8.44 (m, 1H), 7.92 - 7.79 (m, 2H), 7.50 (d, J = 5.4 Hz, 1H), 7.34 (dd, J = 5.4, 0.7 Hz, 1H), 7.17 (s, 1H), 4.82 (s, 2H), 4.02 (s, 3H)
3.16	176- 177	‘H NMR (400 MHz, DMSO-<4) δ 13.51 (s, 1H), 8.60 - 8.51 (m, 1H), 7.97 (d,J=8.3 Hz, 1H), 7.91 (dd, J =8.4,1.6 Hz, 1H), 7.85 (d, J =5.4 Hz, 1H), 7.51 (dd, J = 5.4, 0.6 Hz, 1H), 7.35 (s, 1H), 6.69 (s, 2H)
3.17	70	‘H NMR (400 MHz, CDC1₃) δ 8.53 (d, J = 7.0 Hz, 1H), 7.58 (d, J = 5.5 Hz, 1H), 7.55 (d, J = 7.1 Hz, 1H), 7.52 (s, 1H), 7.29 (d, J = 5.5 Hz, 1H), 4.81 (s, 2H), 4.02 (s, 3H)
3.18	143- 146	*H NMR (400 MHz, CDCI3) δ 8.01 - 7.94 (m, 1H), 7.85 (d, J= 8.2 Hz, 1H), 7.49 (d, J= 5.4 Hz, 1H), 7.43 (dd, J= 8.2, 1.5 Hz, 1H), 7.36 (dd, J= 5.5, 0.6 Hz, 1H), 4.84 (s, 2H), 3.96 (s, 3H), 2.19 (s, 3H)
3.19	157- 162	’H NMR (400 MHz, DMSO-î/₆) δ 8.11 (s, 1H), 7.97 (d, J= 8.2 Hz, 1H), 7.87 (d, J= 5.5 Hz, 1H), 7.54 (d, J= 5.4 Hz, 1H), 7.46 (dd, J= 8.2, 1.5 Hz, 1H), 6.86 (s, 2H), 2.12 (s, 3H)
3.20	MSMS	*H NMR (DMSO-îZ₆) δ 3.76 (s, 3H), 3.92 (s, 3H), 7.40 (s, 2H), 7.51 (d, J = 5.5 Hz, 1H), 7.88 (d, J = 5.4 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 8.26 (dd, J = 8.5, 1.5 Hz, 1H), 8.79 (d, J = 1.1 Hz, 1H)
3.21	134- 136	'H NMR (DMSO-îZô) δ 3.77 (s, 3H), 7.32 (s, 1H), 7.51 (dd, J = 5.4, 0.8 Hz, 1H), 7.88 (d, J = 5.4 Hz, 1H), 7.94 (d, J = 8.4 Hz, 1H), 8.28 (dd, J = 8.4, 1.5 Hz, 1H), 8.81 - 8.86 (m, 1H)
3.22	168	’H NMR (400 MHz, CDC1₃) δ 8.44 (d, J= 6.8 Hz, 1H), 7.58 (t, J= 4.0 Hz, 1H), 7.54 - 7.52 (m, 1H), 7.30 (d, J= 5.4 Hz, 1H), 5.41 (s, 2H), 4.02 (s, 3H), 3.96 (s, 3H)
3.23	219- 221	’H NMR (400 MHz, CDC1₃) δ 8.01 (d, J= 1.7 Hz, 1H), 7.85 (ddt, J= 9.5, 7.3, 3.6 Hz, 2H), 7.43 - 7.33 (m, 2H), 4.93 (s, 2H), 4.02 (s, 3H)
3.24	121- 123	^]H NMR (400 MHz, CDC1₃) δ 7.97 - 7.85 (m, 2H), 7.54 (d, J= 5.6 Hz, 1H), 7.47 (t, J= 7.7 Hz, 1H), 7.39 (d, J= 5.6 Hz, 1H), 4.96 (s, 2H), 4.04 (s, 3H)
3.25	183- 185	*H NMR (300 MHz, DMSO-J₆) δ 8.00 (dd, J= 7.9, 0.8 Hz, 1H), 7.87 - 7.82 (m, 1H), 7.80 (d, J= 5.5 Hz, 1H), 7.56 - 7.50 (m, 2H), 6.97 (s, 2H)
3.26	181- 184	^!H NMR (600 MHz, CDCI3) δ 8.05 (d, J= 7.5 Hz, 1H), 7.95 (d, J= 8.0 Hz, 1H), 7.58 (t, J= 7.8 Hz, 1H), 7.56 (s, 1H), 4.98 (s, 2H), 4.05 (s, 3H)
3.27		*H NMR (400 MHz, DMSO-î/₆) δ 7.96 (dd, J = 7.8, 1.0 Hz, 1H), 7.76 - 7.84 (m, 2H), 7.53 (d, J = 7.7 Hz, 1H), 7.47 - 7.51 (m, 2H), 6.82 (s, 2H), 3.94 (s, 3H)

-11817485

C. No.	MP (°C)	’hnmr
4.01	188- 190	’H NMR (300 MHz, CDC1₃) δ 10.09 (br s, 1H), 8.36 (s, 1H), 8.16 (s, 1H), 8.03 (dt, J= 9,1.5 Hz, 1H), 7.57 (d, J= 9 Hz, 1H), 4.90 (br s, 2H), 4.00 (s, 3H)
4.02	284- 287	’H NMR (300 MHz, DMSO-î/₆) δ 13.49 (br s, 1H), 13.19 (br s, 1H), 8.28 (s, 1H), 8.21 (s, 1H), 7.89 (dt, J= 9, 1 Hz, 1H), 7.66 (dt, J= 9, 1 Hz, 1H), 6.82 (br s, 2H)
4.03	156- 159	*H NMR (400 MHz, CDC1₃) δ 8.34 (m, 1H), 8.07 (d, J= 1 Hz, 1H), 8.03 (dt,J=9,1.5 Hz, 1H), 7.47 (dt, J =9, 1 Hz, 1H), 4.89 (br s, 2H), 4.10 (s, 3H), 3.99 (s, 3H)
4.04	186- 188	*H NMR (400 MHz, DMSO-îZ₆) δ 13.53 (br s, 1H), 8.28 (s, 1H), 8.19 (s, 1H), 7.92 (d, J= 9 Hz, 1H), 7.75 (d, J= 9 Hz, 1H), 6.81 (br s, 2H), 4.10 (s, 3H)
4.05	185- 187	*H NMR (400 MHz, DMSO-t/₆) δ 13.21 (br s, 1H), 8.16 (s, 1H), 8.01 (s, 1H), 7.88 (dd, J= 9, 1 Hz, 1H), 7.61 (dt, J= 9, 1.5 Hz, 1H), 6.96 (br s, 2H), 3.91 (s, 3H)
4.06	>300	’H NMR (400 MHz, DMSO-4) δ 13.20 (br s, 1H), 8.15 (s, 1H), 8.03 (s, 1H), 7.87 (d, J= 9 Hz, 1H), 7.64 (dt, J= 9, 1.5 Hz, 1H), 6.66 (br s, 2H)
4.07	187- 190	*H NMR (400 MHz, CDC1₃) δ 8.03 (d, J= 1 Hz, 1H), 8.00 (t, J= 1 Hz, 1H), 7.82 (dd, J= 9, 1 Hz, 1H), 7.72 (m, 1H), 4.94 (br s, 2H), 4.15 (s, 3H), 4.01 (s, 3H)
4.08	182- 184	’H NMR (400 MHz, DMSO-J₆) δ 13.68 (br s, 1H), 8.14 (d, J= 1 Hz, 1H), 8.06 (s, 1H), 7.89 (dd, J= 9, 0.5 Hz, 1H), 7.62 (dt, J= 9, 1 Hz, 1H), 6.88 (br s, 2H), 4.13 (s, 3 H)
4.09	191 - 193	’H NMR (400 MHz, DMSO-î/₆) δ 13.19 (s, 1H), 8.08 (d, J= 21.7 Hz, 2H), 7.84 (d, J= 8.5 Hz, 1H), 7.63 (d, J= 8.5 Hz, 1H), 7.38 (s, 1H), 6.76 (s, 2H), 3.91 (s, 3H)
4.10	170- 175	’H NMR (400 MHz, CDC1₃) δ 8.42 (s, 1H), 7.63 (dt, J= 5.8, 2.2 Hz, 1H), 7.53 - 7.45 (m, 2H), 4.96 (s, 2H), 4.12 (s, 3H), 4.01 (s, 3H)
4.11	173- 175	’H NMR (400 MHz, DMSO-J₆) δ 13.62 (s, 1H), 8.23 (s, 1H), 7.88 - 7.70 (m, 1H), 7.63 - 7.45 (m, 2H), 6.93 (s, 2H), 4.11 (d, J= 10.3 Hz, 4H)
4.12	212- 215	’H NMR (400 MHz, CDC1₃) δ 10.10 (s, 1H), 8.55 (s, 1H), 7.66 (dd, J= 7.2, 1.5 Hz, 1H), 7.59 (d, J= 8.4 Hz, 1H), 7.54-7.45 (m, 1H), 4.97 (s, 2H), 4.02 (s, 3H)
4.13	207- 210	’H NMR (400 MHz, CDC1₃) δ 12.67 (s, 1H), 8.23 (d, J= 7.5 Hz, 1H), 8.15 (d,J=1.9 Hz, 1H), 7.89 (d,J=8.0 Hz, 1H), 7.29 (d,J=7.7 Hz, 1 H), 5.02 (s, 2H), 4.12 (s, 3H)

-11917485

C. No.	MP (°C)	’HNMR
5.01		*HNMR (400 MHz, CDC1₃) δ 8.36 (d, 7= 1.5 Hz, 1H), 8.16 (s, 1H), 8.06 - 7.98 (m, 1H), 7.68 (d, 7= 8.6 Hz, 1H), 4.95 (s, 2H), 4.00 (s, 3H)
6.01	216	’H NMR (400 MHz, DMSO-7₆) δ 9.48 (s, 1H), 8.49 (s, 1H), 8.30 (d, 7= 8.8 Hz, 1H), 7.95 (d, 7= 8.5 Hz, 1H), 6.99 (s, 2H), 3.91 (s, 3H)
6.02	186- 187	’H NMR (400 MHz, DMSO-7₆) δ 13.54 (s, 1H), 9.47 (s, 1H), 8.52 (s, 1H), 8.30 (d, 7= 8.5 Hz, 1H), 7.98 (d, 7= 8.5 Hz, 1H), 6.91 (s, 2H)
7.01	219- 221	’H NMR (300 MHz, DMSO-7₆) δ 8.31 (s, 1H), 8.04 (br s, 1H), 7.70 (br s, 2H), 6.92 (br s, 2H), 3.89 (s, 3H)
7.02	218- 220	‘H NMR (300 MHz, DMSO-7₆) δ 8.28 (s, 1H), 7.97 (br s, 1H), 7.75 (d, J= 9 Hz, 1H), 7.68 (dt, 7= 9,1.5 Hz, 1H), 6.94 (br s, 2H), 3.90 (s, 6H)
7.03	230- 235 (dec)	’H NMR (300 MHz, DMSO-7₆) δ 8.76 (s, 1H), 8.13 (s, 1H), 7.83 (s, 2H), 6.92 (br s, 2H),3.98 (s, 3H)
8.01		*H NMR (400 MHz, DMSO-7₆) δ 8.10 (t, 7= 9.8 Hz, 1H), 7.89 (s, 1H), 7.70 (t, 7= 8.2 Hz, 1H), 7.08 (s, 2H), 3.94 - 3.85 (m, 3H), 3.16 (s, 6H)
9.01	129- 33	'H NMR (400 MHz, DMSO-7₆) δ 15.84 (s, 1H), 8.35 (s, 1H), 7.98 (s, 2H), 7.41 (s, 1H), 6.79 (s, 2H), 3.91 (s, 3H)

Table 12: Percent Control Rating Conversion Table

Rating	% Visual Growth Réduction
A	95-100
B	85-94
C	75-84
D	60-74
E	45-59
F	30-44
G	0-29

Example A. Evaluation of Postemergent Ilerbicidal Activity

Post-emergent Test I Seeds of test species were obtained from commercial suppliers and planted into a 5-round pot containing soil-less media mix (Metro-Mix 360®, Sun Gro Horticulture). Postemergence treatments were planted 8-12 days (d) prior to application and

-12017485 cultured in a greenhouse equipped with supplémentai light sources to provide a 16 h photoperiod at 24-29 °C. Ail pots were surface irrigated.

Approximately 10 milligrams (mg) of each compound were dissolved in 1.3 mL acetone-DMSO (97:3, v/v) and diluted with 4.1 mL water-isopropanol-crop oil concentrate (78:20:2, v/v/v) containing 0.02% Triton X-155. Treatments were serial diluted with the above formulation solvent to provide 1.85, 0.926, 0.462 and 0.231 mg/mL of test compound delivered in 2.7 mL/pot (roughly équivalent to 4.0, 2.0, 1.0, and 0.5 kilograms per hectare (kg/ha), respectively).

Formulated compounds were applied using a DeVilbiss® compressed air sprayer at 2-4 pounds per square inch (psi). Following treatment, pots were retumed to the greenhouse for the duration of the experiment. Ail pots were sub-irrigated as need to provide optimum growing conditions. Ail pots were fertilized one time per week by subirrigating with Peters Peat-Lite Spécial® fertilizer (20-10-20).

Phytotoxicity ratings were obtained 10 days after treatment postemergence applications. Ail évaluations were made visually on a scale of 0 to 100 where 0 represents no activity and 100 represents complété plant death.

Some of the compounds tested, application rates employed, plant species tested, and results are given in Table 13.

Table 13. Post-emergent Test I Herbicidal Activity on Key Broadleaf and Grass Weed as well as Crop Species

Compound Number	Application Rate (kg ai/ha)	Visual Growth Réduction (%) 10 Days After Application
AVEFA	ECHCG	HELAN	IPOHE	SETFA
1.10	3.96	G	G	A	F	G
1.48	4	G	G	C	n/t	G
3.05	4	C	A	B	B	A

AVEFA: wild oats (Avena fatua)

ECHCG: bamyardgrass (Echinochloa crus-gallî)

HELAN: sunflower (Helianthus annuus)

IPOHE: ivyleaf momingglory (Ipomoea hederecea) SETFA: giant foxtail (Setaria faberï) kg ai/ha: kilograms active ingrédient per hectare n/t: not tested

-12117485

Example B. Evaluation of Preemergent Herbicidal Activity

Pre-emergent Test I Seeds of test species were planted into round plastic pots (5-inch diameter) containing sandy loam soil. After planting, ail pots were sub-irrigated 16 h prior to compound application.

Compounds were dissolved in a 97:3 v/v (volume/volume) mixture of acetone and DMSO and diluted to the appropriate concentration in a final application solution containing water, acetone, isopropanol, DMSO and Agri-dex (crop oil concentrate) in a 59:23:15:1.0:1.5 v/v ratio and 0.02% w/v (weight/volume) of Triton X-155 to obtain the spray solution containing the highest application rate. The high application rate was serial diluted with the above application solution to provide delivery of the compound at rates 1/2X, 1/4X andl/8X of the highest rate (équivalent to 4.0, 2.0, 1.0, and 0.5 kg/ha, respectively).

Formulated compound (2.7 mL) was applied/pipetted evenly over the soil surface followed by incorporation with water (15 mL). Following treatment, pots were retumed to the greenhouse for the duration of the experiment. The greenhouse was programmed for an approximate 15 h photoperiod which was maintained at about 23-29 °C during the day and 22-28 °C during the night. Nutrients and water were added on a regular basis through surface irrigation and supplémentai lighting was provided with overhead métal halide 1000-Watt lamps as necessary.

Herbicidal effect ratings were obtained 14 days after treatment. Ail évaluations were made relative to appropriate controls on a scale of 0 to 100 where 0 represents no herbicidal effect and 100 represents plant death or lack of emergence from the soil. Some of the compounds tested, application rates employed, plant species tested, and results are given in Table 14.

Table 14. Pre-emergent Test I Herbicidal Activity on Key Broadleaf and Grass Weed as well as Crop Species

Compound Number	Application Rate (kg ai/ha)	Visual Growth Réduction (%) 14 Days After Application
AVEFA	ECHCG	HELAN	IPOHE	SETFA
1.10	3.96	G	F	G	G	G
1.48	4	G	G	C	D	G
3.05	4	F	A	F	A	A

AVEFA: wild oats (Avena fatua)

ECHCG: bamyardgrass (Echinochloa crus-galli)

-12217485

HELAN: sunflower (Helianthus annuus)

IPOHE: ivyleaf momingglory (Ipomoea hederecea) SETFA: giant foxtail (Setaria faberî) kg ai/ha: kilograms active ingrédient per hectare

Example C. Evaluation of Postemergent Herbicidal Activity

Post-emergent Test II: Seeds or nutlets of the desired test plant species were planted in Sun Gro Metro-Mix® 360 planting mixture, which typically has a pH of 6.0 to 6.8 and an organic matter content of about 30 percent, in plastic pots with a surface area of 64 square centimeters (cm ). When required to ensure good germination and healthy plants, a fungicide treatment and/or other chemical or physical treatment was applied. The plants were grown for Ί21 d in a greenhouse with an approximate 15 h photoperiod which was maintained at about 2329 °C during the day and 22-28 °C during the night. Nutrients and water were added on a regular basis and supplémentai lighting was provided with overhead métal halide 1000-Watt lamps as necessary. The plants were employed for testing when they reached the first or second true leaf stage.

A weighed amount, determined by the highest rate to be tested, of each test compound was placed in a 25 mL glass vial and was dissolved in 4 mL of a 97:3 v/v mixture of acetone and DMSO to obtain concentrated stock solutions. If the test compound did not dissolve readily, the mixture was warmed and/or sonicated. The concentrated stock solutions obtained were diluted with 20 mL of an aqueous mixture containing acetone, water, isopropyl alcohol, DMSO, Atplus 411F crop oil concentrate, and Triton® X-155 surfactant in a 48.5:39:10:1.5:1.0:0.02 v/v ratio to obtain spray solutions containing the highest application rates. Additional application rates were obtained by serial dilution of 12 mL of the high rate solution into a solution containing 2 mL of 97:3 v/v mixture of acetone and DMSO and 10 mL of an aqueous mixture containing acetone, water, isopropyl alcohol, DMSO, Atplus 411F crop oil concentrate, and Triton X-155 surfactant in a 48.5:39:10:1.5:1.0:0.02 v/v ratio to obtain 1/2X, 1/4X, 1/8X and 1/16X rates of the high rate. Compound requirements are based upon a 12 mL application volume at a rate of 187 liters per hectare (L/ha). Formulated compounds were applied to the plant material with an overhead Mandel track sprayer equipped with 8002E nozzles calibrated to deliver 187 L/ha over an application area of 0.503 square meters at a spray height of 18 inches (43 cm) above the average plant canopy height. Control plants were sprayed in the same manner with the solvent blank.

-12317485

The treated plants and control plants were placed in a greenhouse as described above and watered by subirrigation to prevent wash-off of the test compounds. After 14 d, the condition of the test plants as compared with that of the untreated plants was determined visually and scored on a scale of 0 to 100 percent where 0 corresponds to no injury and 100 corresponds to complété kill. Some of the compounds tested, application rates employed, plant species tested, and results are given in Tables 15 and 16.

Table 15. Post-emergent Test II Herbicidal Activity on Key Broadleaf Weed and Crop Species

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
1.01	35	G	n/a	G	G	A	G
70	G	G	G	G	A	C
140	F	E	G	G	A	C
1.02	35	G	n/t	G	C	E	E
70	G	B	G	B	E	D
140	G	B	G	A	D	D
1.03	35	G	n/t	G	B	A	G
70	G	n/t	G	B	A	G
140	C	B	G	A	B	E
1.04	35	E	D	F	E	A	E
70	G	D	E	D	A	E
140	G	D	E	D	A	B
1.05	35	E	D	F	B	F	A
70	A	C	E	A	F	A
140	B	A	D	A	E	A
1.06	35	G	A	C	B	G	G
70	G	B	B	A	G	G
140	G	C	B	A	G	G
1.07	35	G	B	G	B	D	A
70	G	A	G	B	D	A
140	G	A	G	B	D	A
1.08	35	B	A	E	A	A	B
70	A	A	C	A	A	A
140	A	A	B	A	A	A
1.09	35	A	A	A	A	B	A

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
70	A	A	A	A	A	A
140	A	A	A	A	A	A
1.10	35	G	G	G	A	G	G
70	G	B	G	A	G	G
140	G	A	G	A	G	E
1.13	35	G	G	G	D	G	E
70	G	F	G	C	G	D
140	G	F	F	B	F	D
1.14	35	G	C	E	D	G	D
70	G	B	D	D	G	C
140	G	B	C	C	D	C
1.15	35	A	A	C	A	A	A
70	A	A	A	A	A	A
140	A	A	A	A	A	A
1.16	35	B	A	A	A	A	A
70	A	A	A	A	A	A
140	A	A	A	A	A	B
1.17	35	E	A	A	A	A	A
70	E	A	A	A	A	A
140	D	A	A	A	A	A
1.19	35	A	A	A	A	A	D
70	A	A	A	A	A	C
140	A	A	A	A	A	A
1.20	35	E	C	A	A	A	A
70	D	B	A	A	A	A
140	D	A	A	A	A	A
1.21	35	D	G	G	E	C	E
70	D	G	G	B	B	C
140	D	E	D	B	A	C
1.22	35	G	C	E	G	E	C
70	G	C	D	G	C	B
140	G	B	D	G	B	B
1.23	35	A	A	D	A	A	D
70	A	A	C	A	A	C
140	A	A	B	A	A	B
1.24	35	B	A	B	B	A	D

-12517485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
70	A	A	E	A	A	C
140	A	A	A	A	A	B
1.25	35	G	C	D	G	G	G
70	G	B	C	D	G	G
140	F	A	B	D	F	G
1.26	35	G	C	B	G	G	G
70	G	B	A	F	F	G
140	G	A	A	F	E	G
1.27	35	D	D	B	B	A	G
70	B	A	A	B	A	G
140	B	A	A	B	A	G
1.28	35	B	G	C	E	G	A
70	B	G	B	D	G	A
140	A	D	B	D	G	A
1.29	35	G	E	C	E	G	D
70	G	G	C	E	G	D
140	G	G	B	C	G	C
1.30	35	G	G	E	F	G	G
70	G	C	E	F	E	G
140	C	D	D	E	D	G
1.31	35	E	D	B	A	A	F
70	D	A	A	A	A	E
140	D	A	A	A	A	D
1.32	35	G	G	F	G	G	E
70	G	F	E	G	D	D
140	G	D	D	C	B	C
1.33	35	G	D	A	G	E	D
70	G	D	A	E	D	D
140	G	C	A	D	C	C
1.34	35	G	G	C	G	G	B
70	G	G	B	E	G	A
140	G	F	A	D	D	A
1.35	35	G	C	A	G	C	F
70	G	B	A	G	C	D
140	G	A	A	B	B	A
1.37	35	G	G	F	G	G	G

-12617485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
70	G	G	D	G	G	G
140	G	G	C	G	G	G
1.39	35	G	A	C	A	B	G
70	G	A	B	C	C	G
1.40	35	G	n/t	G	G	G	G
70	G	A	G	G	G	F
140	G	n/t	G	G	G	E
1.43	35	G	A	G	C	G	D
70	G	A	G	B	G	C
140	D	A	G	B	F	C
1.44	35	G	B	G	B	E	G
70	C	A	G	B	C	G
140	B	A	F	A	B	G
1.45	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	E	G	G	G	F
1.46	35	G	G	G	C	G	G
70	G	G	G	B	G	F
140	G	D	G	A	G	E
1.47	35	G	G	G	C	G	G
70	G	G	G	C	G	G
140	G	F	G	B	G	E
1.48	140	G	G	G	D	G	C
1.49	35	B	G	G	B	G	G
70	B	F	G	B	G	G
140	B	G	G	A	G	E
2.02	35	E	C	G	A	C	C
70	B	A	F	A	A	B
140	B	A	F	A	A	A
2.03	35	A	D	G	B	E	G
70	A	B	G	A	C	D
140	A	B	G	A	C	C
280	A	A	F	A	B	B
2.04	35	C	A	G	A	A	G
70	B	A	G	A	A	G
140	A	A	F	A	A	F

-12717485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
2.05	35	G	B	G	G	F	G
70	G	C	G	G	F	G
140	G	A	G	E	E	F
2.06	35	G	C	F	D	F	D
70	G	A	D	C	C	C
140	C	A	B	B	A	B
2.09	35	B	B	D	A	A	D
70	B	A	C	A	A	C
140	B	A	B	A	A	B
2.10	35	D	B	F	B	A	C
70	D	A	D	A	A	B
140	B	A	C	B	A	A
2.11	35	A	A	C	A	A	E
70	A	A	B	A	A	D
140	A	A	A	A	A	C
2.12	35	B	A	C	A	A	F
70	A	A	B	A	A	D
140	A	A	A	A	A	D
2.13	35	A	D	A	A	A	C
70	A	A	A	A	A	B
140	A	A	A	A	A	A
2.14	35	G	A	A	B	B	D
70	G	A	A	A	A	B
140	G	A	A	A	A	A
2.15	35	E	A	E	A	G	E
70	C	A	C	A	G	C
140	A	A	B	A	G	C
2.16	35	B	A	E	A	G	A
70	A	A	D	A	G	A
140	A	A	D	A	G	A
2.17	140	C	A	C	A	A	B
2.18	35	G	A	E	B	G	C
70	G	A	D	B	G	C
140	G	A	D	B	G	B
2.19	35	A	A	G	A	G	G
70	A	A	D	A	G	C

-12817485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
140	A	A	D	A	G	C
2.20	35	E	A	G	B	G	B
70	D	A	G	A	G	A
140	D	A	F	A	G	A
2.21	35	F	A	F	B	G	D
70	D	A	F	B	G	C
140	D	A	E	A	G	C
2.22	35	F	A	G	A	G	C
70	F	A	E	A	G	B
140	E	A	D	A	G	A
2.23	35	G	A	G	A	G	B
70	G	A	G	A	G	A
140	G	A	G	A	G	A
2.24	35	C	A	D	A	D	C
70	C	A	C	A	C	C
140	A	A	C	A	C	B
2.25	35	C	A	G	A	G	G
70	C	A	E	A	C	F
140	A	A	C	A	B	B
2.26	35	E	A	E	A	E	C
70	D	A	D	A	D	A
140	D	A	D	A	C	A
3.01	35	D	B	G	A	G	C
70	D	A	G	A	G	C
140	C	A	G	A	G	B
3.02	35	G	A	G	B	G	D
70	G	A	G	B	G	C
140	G	A	G	B	G	B
3.03	35	A	A	G	A	A	A
70	A	A	D	A	A	A
140	A	A	D	A	A	A
3.05	35	B	F	G	C	D	G
70	B	E	G	B	D	G
140	A	D	G	B	C	F
280	A	B	G	B	B	E
3.06	35	E	B	F	F	G	A

-12917485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
70	D	B	F	D	G	A
140	B	A	E	D	F	A
3.07	35	G	G	E	G	G	B
70	G	D	D	G	G	B
140	G	C	D	C	G	B
3.08	35	G	G	G	B	D	D
70	F	F	G	B	C	C
140	F	D	F	B	B	B
3.09	35	G	F	E	B	A	D
70	G	C	B	B	A	C
140	E	B	A	A	A	B
3.10	35	G	A	G	C	G	B
70	G	A	G	C	G	B
140	G	A	G	C	G	B
3.11	35	G	n/a	G	B	G	B
70	G	n/a	G	B	G	B
140	G	n/a	G	B	G	B
3.12	35	D	D	G	A	D	B
70	A	D	G	A	D	B
140	A	B	F	A	B	B
3.13	35	G	A	G	B	G	B
70	G	A	G	A	G	B
140	C	A	D	A	D	B
3.14	35	G	B	G	B	F	B
70	G	A	G	B	F	B
140	G	A	G	A	D	A
3.15	35	B	A	F	B	C	D
70	A	A	E	B	C	D
140	A	A	E	A	B	B
3.16	35	D	B	G	B	D	G
70	D	A	G	B	D	G
140	C	B	E	B	D	G
3.17	35	G	C	G	B	E	G
70	E	A	G	A	D	G
140	D	A	D	A	C	F
3.18	35	D	D	G	F	E	A

-13017485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
70	C	C	G	D	G	A
140	C	A	G	D	F	A
3.19	35	G	D	G	D	G	B
70	G	A	G	D	G	B
140	D	C	G	C	G	B
3.20	35	G	G	F	B	C	C
70	G	D	D	A	A	B
140	G	D	D	A	A	B
3.21	35	G	A	C	B	C	D
70	F	A	B	B	B	D
140	E	A	A	A	A	C
3.22	35	G	D	G	D	A	C
70	G	A	F	C	A	B
140	G	A	D	B	A	B
3.23	35	G	G	G	G	G	G
70	G	G	G	E	G	G
140	G	G	G	B	G	G
3.24	35	G	B	E	B	G	D
70	G	B	E	A	G	D
140	G	A	E	A	G	B
3.25	140	G	A	C	A	G	E
3.27	35	G	B	E	C	G	E
70	G	A	D	B	G	D
140	E	A	D	A	G	C
280	C	A	B	A	G	B
4.01	35	G	G	G	G	G	G
70	G	E	G	D	G	G
140	G	D	G	D	G	G
4.03	35	G	G	G	A	E	G
70	G	E	G	A	D	E
140	G	C	G	A	C	D
4.05	35	G	G	G	B	D	D
70	G	A	G	B	A	D
140	E	A	E	A	A	A
4.06	35	G	C	D	G	E	E
70	G	A	C	E	D	D

-13117485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
ABUTH	AMARE	BRSNN	CHEAL	EPHHL	HELAN
140	G	A	B	A	B	C
4.07	140	E	n/t	E	G	D	A
4.08	140	G	n/t	D	A	G	B
4.09	35	G	G	G	E	G	G
70	G	E	G	C	G	F
140	G	B	D	B	G	E
4.10	35	G	G	G	G	G	G
70	G	A	G	G	G	G
140	G	A	G	G	G	E
4.13	35	G	n/t	G	G	G	G
70	G	n/t	G	G	G	G
140	G	n/t	G	D	G	G
5.01	35	D	C	B	D	n/t	B
70	D	B	A	B	A	B
140	D	B	A	B	n/t	A
6.01	35	B	B	A	A	G	B
70	B	A	A	A	B	B
140	B	A	A	A	A	B
6.02	35	B	A	A	A	A	A
70	B	A	A	A	A	A
140	B	A	A	A	A	A
7.02	35	G	G	G	G	G	G
70	G	G	G	C	G	G
140	G	G	G	A	G	G
8.01	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G

ABUTH: velvetleaf (Abutilon theophrasti) AMARE: redroot pigweed (Amaranthus retroflexus) BRSNN: oilseed râpe, canola (Brassica napus)

CHEAL: lambsquarters (Chenopodium album) EPHHL: wild poinsettia (Euphorbia heterophylla) HELAN: sunflower (Helianthus annuus) g ai/ha: grams active ingrédient per hectare

-13217485 n/t: not tested

Table 16. Post-emergent Test II Herbicidal Activity on Key Grass and Sedge Weeds as well as Grass Crops

C. No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
1.01	35	G	G	G	G	G	G
70	G	n/t	G	G	G	A
140	G	C	G	G	G	B
1.02	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	E	G	G	G	G
1.03	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	D	G	G	G	G
1.04	35	G	G	G	G	G	G
70	G	n/t	G	G	G	G
140	G	B	G	G	G	G
1.05	35	G	G	F	G	G	G
70	G	G	E	G	F	F
140	G	D	D	G	E	E
106	35	G	G	G	G	G	G
70	G	D	G	G	G	G
140	G	C	G	G	G	G
1.07	35	G	G	D	G	G	G
70	G	G	C	G	G	G
140	G	G	C	G	G	G
1.08	35	G	B	G	G	G	E
70	G	A	D	G	G	C
140	G	A	C	G	F	B
1.09	35	F	A	B	G	G	D
70	C	A	B	G	G	C
140	B	A	B	G	G	C
1.10	35	G	G	G	G	G	G

-13317485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.12	35	G	G	C	G	E	G
70	G	G	D	G	G	G
140	G	B	C	G	G	G
1.13	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.14	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.15	35	G	C	D	G	E	G
70	D	B	D	G	D	F
140	E	A	B	F	D	D
1.16	35	G	C	D	F	F	G
70	D	B	C	D	D	F
140	B	A	B	D	D	D
1.17	35	E	B	C	G	D	D
70	E	B	B	G	D	C
140	E	B	B	G	D	C
1.19	35	B	B	D	F	D	D
70	C	B	C	E	C	D
140	A	A	B	D	C	B
1.20	35	G	G	E	G	G	F
70	G	D	C	G	E	E
140	G	C	B	G	D	D
1.21	35	G	G	n/t	G	G	G
70	G	G	n/t	G	G	G
140	G	G	n/t	G	G	G
1.22	35	G	G	G	G	G	G
70	G	G	D	G	G	G
140	G	G	B	G	G	G
1.23	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	D	D	G	F	G
1.24	35	G	G	G	G	G	G
70	G	G	E	G	F	G

-13417485

C. No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
140	G	G	D	G	E	G
1.25	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.26	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.27	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.28	35	G	G	G	G	G	G
70	G	G	G	G	F	G
140	G	G	G	G	F	G
1.29	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	F	G	G	G	G	G
1.30	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.31	35	G	C	D	G	C	G
70	G	C	C	G	G	G
140	G	B	B	G	F	G
1.32	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.33	35	G	G	G	G	G	n/t
70	G	G	G	G	G	n/t
140	G	G	G	G	F	n/t
1.34	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	D	G	F	G
1.35	35	G	G	G	G	G	G
70	G	G	G	G	F	G
140	G	G	G	G	E	G
1.37	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G

C. No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
1.39	35	G	G	G	G	G	G
70	G	G	G	G	G	G
1.40	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.43	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.44	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.45	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.46	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.47	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
1.48	140	G	G	G	G	G	G
2.02	35	G	B	D	G	G	A
70	G	B	D	G	F	A
140	G	A	C	G	E	A
2.03	35	G	F	G	G	G	G
70	G	D	G	G	G	G
140	G	B	F	G	G	G
280	G	A	F	G	G	D
2.04	35	G	D	D	G	G	D
70	G	A	C	G	F	C
140	F	A	B	G	E	B
2.05	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
2.06	35	G	G	G	G	G	G
70	G	E	G	G	G	G
140	G	A	G	G	G	G

-13617485

C.No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
2.08	35	G	B	E	G	G	E
70	G	B	D	F	G	D
140	G	A	B	F	G	D
2.09	35	G	D	E	G	G	E
70	G	B	D	F	G	D
140	G	B	D	F	G	D
2.10	35	G	D	D	G	G	G
70	G	D	D	F	F	F
140	F	B	C	F	D	E
2.11	35	G	B	E	G	G	E
70	G	A	D	G	G	D
140	F	A	C	G	F	B
2.12	35	G	A	E	G	G	G
70	G	A	D	G	G	F
140	G	A	D	G	G	D
2.13	35	F	C	G	G	G	G
70	B	A	E	F	E	F
140	B	A	D	F	E	E
2.14	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	C	G	G	G	G
2.15	35	G	G	G	G	G	A
70	G	E	G	G	G	A
140	G	C	G	G	G	A
2.16	35	G	G	G	G	G	E
70	G	G	G	G	G	A
140	G	G	G	G	G	A
2.17	140	A	C	G	G	G	F
2.18	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
2.19	35	G	G	n/t	G	G	G
70	G	G	n/t	G	G	G
140	G	G	n/t	G	G	G
2.20	35	G	n/t	G	G	G	G
70	G	n/t	F	G	G	G
140	G	n/t	D	G	G	G

-13717485

C. No.	Application Rate (g	Visual Growth Réduction (%) 14 Days After Application
ai/ha)	CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
2.21	35	G	n/t	G	G	G	G
70	G	n/t	G	G	G	G
140	G	n/t	G	G	G	G
2.22	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
2.23	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
2.24	35	D	G	G	G	G	G
70	C	G	G	G	G	F
140	B	G	G	G	G	D
2.25	35	G	G	G	G	G	G
70	F	G	G	G	G	G
140	C	G	G	G	G	E
2.26	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.01	35	G	G	G	G	G	G
70	G	G	G	G	G	E
140	G	G	G	G	G	D
3.02	35	G	G	G	G	G	G
70	G	G	G	G	G	D
140	G	G	G	G	G	D
3.03	35	E	B	G	G	G	A
70	E	A	B	G	F	A
140	E	A	B	G	E	A
3.05	35	G	E	G	G	G	G
70	G	C	G	G	G	G
140	G	B	F	G	G	E
280	G	B	D	G	G	D
3.06	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.07	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G

-13817485

C. No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
3.08	35	G	G	G	G	E	F
70	G	G	G	G	D	D
140	F	C	G	G	D	C
3.09	35	G	B	G	G	D	D
70	G	B	G	G	C	C
140	G	B	G	G	B	B
3.10	35	G	G	G	G	G	D
70	G	G	G	G	G	D
140	G	G	G	G	G	D
3.11	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.12	35	G	B	G	G	G	A
70	G	B	G	G	G	A
140	G	B	G	G	G	A
3.13	35	G	D	n/t	G	G	D
70	G	D	n/t	G	G	D
140	G	C	n/t	G	G	D
3.14	35	G	G	G	G	G	G
70	G	G	G	G	G	F
140	G	G	G	G	G	D
3.15	35	G	C	G	G	G	D
70	G	C	G	G	G	D
140	G	A	G	G	G	D
3.16	35	G	C	G	G	G	D
70	G	C	G	G	G	D
140	E	C	G	G	G	C
3.17	35	G	E	G	G	G	F
70	G	D	G	G	G	D
140	G	A	F	G	G	C
3.18	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.19	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.20	35	F	G	G	G	G	G

-13917485

C. No.	Application Rate (g	Visual Growth Réduction (%) 14 Days After Application
ai/ha)	CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
70	F	E	G	G	G	C
140	B	D	D	G	F	B
3.21	35	G	C	G	G	F	F
70	G	B	F	F	F	D
140	G	B	D	F	E	C
3.22	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.23	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.24	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
3.25	140	G	G	G	G	G	G
3.27	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
280	G	G	G	G	G	G
4.01	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
4.03	35	G	D	n/t	G	G	G
70	G	C	n/t	G	G	G
140	G	C	n/t	G	G	G
4.05	35	G	n/t	n/t	G	G	G
70	G	n/t	n/t	G	G	D
140	G	B	A	G	G	D
4.06	35	G	G	G	G	G	G
70	G	E	G	G	G	G
140	G	C	E	G	G	G
4.07	140	G	G	G	G	G	G
4.08	140	G	G	G	G	G	G
4.09	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
4.10	35	G	G	G	G	G	G

-14017485

C. No.	Application Rate (g ai/ha)	Visual Growth Réduction (%) 14 Days After Application
CYPES	ECHCG	SETFA	ORYSA	TRZAS	ZEAMX
70	G	G	G	G	G	G
140	G	G	G	G	G	G
4.13	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
5.01	35	n/t	C	G	G	G	G
70	n/t	C	G	G	G	G
140	n/t	B	G	G	G	G
6.01	35	E	G	G	G	G	G
70	E	E	G	G	G	G
140	E	D	G	G	G	G
6.02	35	E	C	G	G	G	G
70	E	C	E	G	G	G
140	E	B	D	G	F	G
7.02	35	G	G	n/t	G	G	G
70	G	G	n/t	G	G	G
140	G	G	n/t	G	G	G
8.01	35	G	G	G	G	G	G
70	G	G	G	G	G	G
140	G	G	G	G	G	G
9.01	140	G	G	G	G	G	G

ECHCG: bamyardgrass (Echinochloa crus-gallî)

CYPES: yellow nutsedge (Cyperus esculentus)

ORYSA: rice (Oryza sativà)

SETFA: giant foxtail (Setaria faberi)

TRZAS: wheat, spring (Triticum aestivum)

ZEAMX: maize, corn (Zea mays) g ai/ha: grams active ingrédient per hectare n/t: not tested

Example D. Evaluation of Postemergent Herbicidal Activity in Wheat and Barley

Post-emergent Test III. Seeds of the desired test plant species were planted in Sun Gro MetroMix® 306 planting mixture, which typically has a pH of 6.0 to 6.8 and an organic matter content of about 30 percent, in plastic pots with a surface area of 103.2 square centimeters

-14117485 (cm²). When required to ensure good germination and healthy plants, a fongicide treatment and/or other chemical or physical treatment was applied. The plants were grown for 7-36 days (d) in a greenhouse with an approximate 14 hour (h) photoperiod which was maintained at about 18 °C during the day and 17 °C during the night. Nutrients and water were added on a regular basis and supplémentai lighting was provided with overhead métal halide 1000-Watt lamps as necessary. The plants were employed for testing when they reached the second or third true leaf stage.

A weighed amount, determined by the highest rate to be tested, of each test compound was placed in a 25 mL glass vial and was dissolved in 4 mL of a 97:3 v/v mixture of acetone and DMSO to obtain concentrated stock solutions. If the test compound did not dissolve readily, the mixture was warmed and/or sonicated. The concentrated stock solutions obtained were diluted with 20 mL of an aqueous mixture containing acetone, water, isopropyl alcohol, DMSO, Agri-Dex crop oil concentrate, and X-77 surfactant in a 48:39:10:1.5:1.5:0.02 v/v ratio to obtain spray solutions containing the highest application rates. Additional application rates were obtained by serial dilution of 12 mL of the high rate solution into a solution containing 2 mL of 97:3 v/v mixture of acetone and DMSO and 10 mL of an aqueous mixture containing acetone, water, isopropyl alcohol, DMSO, Agri-Dex crop oil concentrate, and X-77 surfactant in a 48:39:10:1.5:1.5:0.02 v/v ratio to obtain 1/2X, 1/4X, 1/8X and 1/16X rates of the high rate. Compound requirements are based upon a 12 mL application volume at a rate of 187 liters per hectare (L/ha). Formulated compounds were applied to the plant material with an overhead Mandel track sprayer equipped with 8002E nozzles calibrated to deliver 187 L/ha over an application area of 0.503 square meters at a spray height of 18 inches (43 cm) above the average plant canopy height. Control plants were sprayed in the same manner with the solvent blank.

The treated plants and control plants were placed in a greenhouse as described above and watered by subirrigation to prevent wash-off of the test compounds. After 21 d, the condition of the test plants as compared with that of the untreated plants was determined visually and scored on a scale of 0 to 100 percent where 0 corresponds to no injury and 100 corresponds to complété kill.

By applying the well-accepted probit analysis as described by J. Berkson in Journal of the American Statistical Society, 48, 565 (1953) and by D. Finney in “Probit Analysis” Cambridge University Press (1952), the above data can be used to calculate GR20, GR50, GRso and GR90 values, which are defined as growth réduction factors that correspond to the effective dose of herbicide required to kill or control 20 percent, 50 percent, 80 percent or 90 percent, respectively, of a target plant.

-14217485

Some of the compounds tested, application rates employed, plant species tested, and results are given in Table 17.

-14317485

Table 17: Activity of Herbicidal Compounds in Wheat and Barley

Visual growth Réduction (%) 21 Days After Application

VIOTR

w

Q

O

1 1

CM CM

CD ko

ω

Q

O

1 1

Ok

KO WD

Ch Ch

VERPE

<

1 f

0.28

CM

KO

<

1 t

0.0004

0.05

SINAR

<

t 1

^F

00

CM

m

<

l 1

WD

F-

SASK R

O

00

1 1

r*

O CD

WD Ck

Q

O

CQ

1 1

O

00 CM

00 F-

PAPR H

<

1 1

0.06

-

CM

<

0.0004

tf o o o o

MATC H

Mm

ω

Q

1 1

WD

>140

03

<

1 1

CD

Ch

KO

LAMP U

<

1

O

CM

O

<

1 1

CD

O

Ch

KCHS C

Q

03

t 1

KO

OO CM

KO

O

CQ

<

t 1

r-

O CM

Ch CD

GALA P

Q

CQ

<

1 1

CD CM

CD

Mm

W

<

1 1

KO CM

CD

O ^F

CIRAR

0-

Q

O

1 1

O CD

O C-

109

Q

CQ

<

1 1

O\

WD CM

CD tF

TRZAS

b

W

Q

CD

1 1

O

Mm

tF

1 1

HORV S

Mm

ω

W

OO

1 1

O

<3

MM

^F TF

1 1

Applica tion Rate (g ai/ha)

17.5

WD cd

O r-

GR20

GR50

GR80

GR90

17.5

WD CD

O F-

GR20

GR50

GR80

o O) ai O

Compo und No.

1.15

KO

-14417485

Visual growth Réduction (%) 21 Days After Application

VIOTR

O

W

Q

1 1

tF tF

Ox

>140

ω

Q

o

1 l

tF CN

OO F-·

O Λ

VERPE

CQ

m

<

1 1

-

OO

CN

Pi

Q

o

1 1

O m

X© X©

o o

SINAR

O

u

<

1 1

en

TF

CN en

CQ

<

1 1

X©

en

Ox

SASK R

Uh

M

U

1 1

Ox CN

o Ox

>140

Q

CQ

l t

m

00 CN

un Ox

PAPR H

Q

<

1 1

-

F-

CN CN

Q

U

1 1

tF CN

CN un

Fr^·

MATC H

Φ

o

O

1 1

>140

O

1 1

•-H

>140

o tf Λ

LAMP U

M

<

1 1

m

X©

Ox

ω

Q

U

1 1

un

en Ox

o tF Λ

KCHS C

kx

w

Q

1 1

un en

o

>140

Q

U

m

1

tf

en en

en o

GALA P

<

1 1

-

TF

O

Q

CQ

1 1

F'

en CM

tF tF

U

o

O

1 i

>140

Q

O

CQ

1 1

tF

un en

un

TRZAS

o

O

o o

1 1

Ü

Û

PL

CM un

1 1

HORV S

Ü

O

>140

1 1

1 t

1 1

O

<3

X© X©

1 1

Applica tion Rate (g ai/ha)

17.5

un en

O F-

GR20

GR50

GR80

GR90

17.5

Un m

O

GR20

GR50

GR80

o OX O

Compo und No,

1.23

TF CN

4· S'

-14517485

Claims

WHAT IS CLAIMED IS:

1. A compound of the Formula (I):

wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

1 1 t 1 H 1 Ht 11

R is OR or NR R , wherein R is hydrogen, Ci-Cg alkyl, or C7-C10 arylalkyl, and R and R are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently C1-C10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C|-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiCô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is one of groups Al to A36

-14617485

Rg Rg R6 ^6

Al

A2

A3

A4

A17

A18

A19

A20

-14717485

Rg Rg Rg Rg

A21

A22

A23

A24

A25

A26

A27

A28

A29 A30 A31 A32

Re Re Rg Rg

A33 A34 A35 A36

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl,

C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN; R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or

C2-C4 haloalkylamino, OH, CN, or NO₂;

-14817485

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

R⁸ is hydrogen, Ci-C₆ alkyl, Ci-Cé haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof, with the proviso that the compound is not a compound of Formula (I):

wherein

X is N, CH, CF, CCI, or CBr;

R¹ is OR¹, wherein R¹ is hydrogen or C1-C4 alkyl;

R² is chlorine;

R³ and R⁴ are hydrogen;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, A18, A19, or A20;

R⁵ is hydrogen, halogen, OH, amino, CN, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamino, or cyclopropyl;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, OH, NH2, CN, C1-C3 alkyl, CiC3 alkoxy, cyclopropyl, or vinyl;

R⁷and R⁷ are independently hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, cyclopropyl, or C1-C3 alkylamino, or phenyl; and

R⁸ is hydrogen, C1-C3 alkyl, phenyl, or C1-C3 alkylcarbonyl;

or an N-oxide or agriculturally acceptable sait thereof.
2. The compound of claim 1 wherein

X is CY, wherein Y is C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy,

C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

-14917485

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Cj-Cs alkyl, or C7-C10 arylalkyl, and R¹ and R¹ are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR^l9R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently C1-C10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiCô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO₂;

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

R⁸ is hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.

-15017485
3. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is Cs-Cg alkyl, or C7-C10 arylalkyl, and R¹ and R¹are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently C1-C10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiCô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, C]-Cé alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, Al7, Al 8, Al 9, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

-151Y17485

R⁸ is hydrogen, Cj-Cô alkyl, CpCô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Côalkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cé alkylsulfonyl, CpCô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.
4. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cg alkyl, or C7-C10 arylalkyl, and

1 II 1 Ht

R and R are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R² is F, Br, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently Ci-Cæ alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiCf> alkoxycarbonyl, Ci-C₆ alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, C]-C₆dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

-15217485

Ύ 7’

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

O

R is hydrogen, Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.
5. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, Cj-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Cj-Cs alkyl, or C7-C10 arylalkyl, and R¹ and R¹ are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

•y

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, CJ-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR^l9R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently Cj-Cjo alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, Cj-Cjo alkoxy, or OH;

R³ and R⁴ are independently Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, Al 7, Al 8, Al9, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

-15317485

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

R⁸ is hydrogen, Ci-Ce alkyl, Ci-C₆ haloalkyl, C3-C6 alkenyl, C₃-Cô haloalkenyl, C₃-Cô alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cgalkoxycarbonyl, CpCô alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.
6. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cg alkyl, or C7-C10 arylalkyl, and R and R are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently C1-C10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Cj-Cé alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C₃-Cô haloalkenyl, C₃-Cô alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiCô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cè trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, or A36;

-15417485

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO₂;

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C₂C4 haloalkylamino, or phenyl;

Q

R is hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cé trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.
7. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cg alkyl, or C7-C10 arylalkyl, and R¹ and R¹ are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently Ci-Cæ alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CjCô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, C]-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently

-15517485 hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, A18, A19, or A20;

R⁵ is C4 alkyl, C1-C4 haloalkyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C4 alkylamino, or C₂C4 haloalkylamino;

R , R , and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

Q

R is hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C₃-Cô alkenyl, C₃-Cô haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.
8. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cs alkyl, or C7-C10 arylalkyl, and

R¹ and R* are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR^{8 * * * * * * * * 17}=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl;

R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently C1-C10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, C1-C10 alkoxy, or

OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C₃-Cô alkenyl,

C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-15617485

Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Cj-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Cj-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Cj-Cô alkoxy or Cj-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, A18, A19, or A20;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, Cj-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently C4 alkyl, Cj-C4 haloalkyl, halocyclopropyl, C3-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C4 alkylamino or C2-C4 haloalkylamino, or NO2;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Cj-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

Q

R is hydrogen, Cj-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Cô alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof. ⁹
9. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Cj-Cs alkyl, or C7-C10 arylalkyl, and R¹ and R¹ are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently Cj-Cjo alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, Cj-Cjo alkoxy, or OH;

-15717485

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Cj-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiC6 alkoxycarbonyl, Cj-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or C]-C6 alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is Al, A2, A3, A4, A5, A6, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A16, A17, orA18;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C4-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C]-C₃alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO₂;

R and R are independently C4 alkyl, C1-C4 haloalkyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 haloalkoxy, C1-C3 haloalkylthio, amino, C4 alkylamino, or C2-C4 haloalkylamino;

o

R is hydrogen, Ci-Cé alkyl, C]-C₆ haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-C₆ alkoxycarbonyl, C]-C₆alkylcarbamyl, C]-C₆ alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

or an N-oxide or agriculturally acceptable sait thereof.
10. The compound of claim 1 wherein

X is N or CY, wherein Y is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkoxy, C1-C3 alkylthio, or C1-C3 haloalkylthio;

R¹ is OR¹ or NR¹ R¹ , wherein R¹ is hydrogen, Ci-Cg alkyl, or C7-C10 arylalkyl, and

R¹ and R¹ are independently hydrogen, C1-C12 alkyl, C3-C12 alkenyl, or C3-C12 alkynyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR^{10 * * * * * * 17}=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl;

R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are

-15817485 independently Ci-Cio alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, Cj-Cio alkoxy, or OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiCô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Ci-Cô alkylsulfonyl, Cj-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, •j» A¹

R and R taken together with =C represent a 5- or 6-membered saturated ring;

A is A3, A6, Ail, A12, Al5, Al8, Al9, or A20;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or C2-C4 haloalkylamino, OH, CN, or NO2;

R and R are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

R⁸ is C3-C6 alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, Ci-Cô alkylcarbamyl, Cj-Cô alkylsulfonyl, or Ci-Cô trialkylsilyl;

or an N-oxide or agriculturally acceptable sait thereof.
11. The compound of any of daims 1-10, wherein R¹ is OR¹.
12. The compound of any of daims 1 or 3-11, wherein X is CF.
13. The compound of any of daims 1-5 or 7-12, wherein A is A15
14. The compound of any of daims 1-5 or 8-12, wherein R⁵ is F.

-15917485
15. A compound of the Formula (I):

(I) wherein

X is CF;

R¹ is OR¹, wherein R¹ is hydrogen, Cj-Cg alkyl, or C7-C10 arylalkyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, cyano, or a group of the formula -CR¹⁷=CR¹⁸-SiR¹⁹R²⁰R²¹, wherein R¹⁷ is hydrogen, F, or Cl; R¹⁸ is hydrogen, F, Cl, C1-C4 alkyl, or C1-C4 haloalkyl; and R¹⁹, R²⁰, and R²¹ are independently C1-C10 alkyl, C3-C6 cycloalkyl, phenyl, substituted phenyl, Ci-Qo alkoxy, or

OH;

R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, CiCô alkoxycarbonyl, C|-C₆ alkylcarbamyl, Ci-Cô alkylsulfonyl, Ci-Cô trialkylsilyl, Ci-Cô dialkylphosphonyl, or R³ and R⁴ taken together with N is a 5- or 6-membered saturated ring, or R³ and R⁴ taken together represent =CR³ (R⁴ ), wherein R³ and R⁴ are independently hydrogen, Ci-Cô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Cô alkoxy or Ci-Cô alkylamino, or, R³ and R⁴ taken together with =C represent a 5- or 6-membered saturated ring;

A is one of groups Al to A36

R₆ R6 R6 ^R6

Al

A2

A3

A4

-16017485

A21

A22

A23

A24

-16117485

A25

A26

A27

A28

A33

A34

A35

A36

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl,

C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2-C4 haloalkylamino, OH, or CN; R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino or

C2-C4 haloalkylamino, OH, CN, or NO2;

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy,Ci-C₃ alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, C2C4 haloalkylamino, or phenyl;

R⁸ is hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C₃-C₆ alkenyl, C₃-Cô haloalkenyl, C₃-C₆ alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Cj-Côalkoxycarbonyl, Cj-Cô alkylcarbamyl, C|-C₆ alkylsulfonyl, Ci-Cô trialkylsilyl, or phenyl;

-16217485 or an N-oxide or agriculturally acceptable sait thereof.
16. The compound of claim 15, wherein

R¹ is OR¹, wherein R¹ is hydrogen, CpCs alkyl, or C7-C10 arylalkyl;

R² is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4-alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, Ci-C4-alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, or C1-C4 haloalkylthio.

R³ and R⁴ are hydrogen, Ci-Cô alkyl, Ci-Cô haloalkyl, C3-C6 alkenyl, C3-C6 •J haloalkenyl, C3-C6 alkynyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, or R and

R⁴ taken together represent =CR³(R⁴), wherein R³ and R⁴ are independently hydrogen, CiCô alkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-C₆ alkoxy or Ci-Cé alkylamino;

A is Al, A2, A3, A7, A8, A9, A10, Ail, A12, A13, A14, A15, A21, A22, A23, A24,

A27, A28, A29, A30, A31, or A32;

R⁵ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, amino, C1-C4 alkylamino, or C2-C4 haloalkylamino;

R⁶, R⁶, and R⁶ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, halocyclopropyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C3 alkoxy, C1-C3 haloalkoxy, CN, orNCh;

R⁷and R⁷ are independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, cyclopropyl, amino or C1-C4 alkylamino;

R⁸ is hydrogen, C]-C₆ alkyl, C1-C4 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, formyl, C1-C3 alkylcarbonyl, C1-C3 haloalkylcarbonyl, Ci-Cô alkoxycarbonyl, or C|-C₆alkylcarbamyl.
17. The compound of claim 15 or 16, wherein R is halogen, C2-C4-alkenyl, C2-C4 haloalkenyl, or Ci-C4-alkoxy.
18. The compound of any of daims 15-17, wherein R² is Cl, methoxy, vinyl, or 1propenyl.
19. The compound of any of daims 15-18, wherein R³ and R⁴ are hydrogen.

-16317485
20. The compound of any of daims 15-19, wherein A is Al, A2, A3, A7, A8, A9, A10, A13, A14, orA15.
21. The compound of any of daims 15-20, wherein A is Al, A2, A3, Al3, Al4, or Al5.
22. The compound of any of daims 15-21, wherein A is Al5.
23. The compound of any of daims 15-22, wherein R⁵ is hydrogen or F.
24. The compound of any of daims 15-23 wherein R⁵ is F.
25. The compound of any of daims 15-24, wherein R⁶ is hydrogen or F.
26. The compound of any of daims 15-25, wherein R⁶ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, cyclopropyl, C2-C4 alkynyl, CN, or NO₂.
27. The compound of any of daims 15-26, wherein R⁶, R⁶, and R⁶ are ail hydrogen.
28. The compound of any of daims 15-27, wherein the compound is 4-amino-3-chloro-5fhioro-6-(7-fluoro-177-indol-6-yl) picolinic acid.
29. The compound of any of daims 15-27, wherein the compound is methyl 4-amino-3chloro-5-fluoro-6-(7-fluoro-177-indol-6-yl) picolinate.
30. A herbicidal composition comprising a compound of any of daims 1-29 and an agriculturally acceptable adjuvant or carrier.
31. The composition of claim 30, further comprising an additional pesticide.
32. The composition of claim 30 or 31, further comprising a herbicidal safener.
33. A method of controlling undesirable végétation which comprises applying to végétation or an area adjacent the végétation or applying to soil or water to prevent the

-16417485 emergence or growth of végétation a compound of any of claims 1-29 or a herbicidal composition of any of claims 30-32.